A N N U A L
R E P O R T
2 0 14MARCH 2015
TO OUR
SHAREHOLDERS
ALEX GORSKY
Chairman, Board of Directors
and Chief Executive Officer
I am often asked what led me to work in Perhaps there’s no better proof of that than the THERE IS
health care and why I chose to spend most success Johnson & Johnson achieved in 2014. NO COMPANY
of my career at Johnson & Johnson. From my We delivered solid financial results, with full-year BETTER
first job at Janssen, the flagship company of 2014 sales of $74.3 billion and adjusted net POSITIONED
our Pharmaceutical segment, to my current earnings of $17.1 billion†, while also continuing TO HELP MEET
role as the company’s Chairman and CEO to make investments to accelerate growth for THESE URGENT
25 years later, the answer always begins the long term. NEEDS THAN
with Our Credo. JOHNSON &
And while I am pleased with our performance, JOHNSON
A simple yet powerful document penned we know that we can never rest, because
by General Robert Wood Johnson, the son of providing sustainable high-quality health care
our founder and our company’s first Chairman, is one of our society’s greatest challenges.
Our Credo outlines the Company’s commitments
and responsibilities to the people and This is an unprecedented era in human history.
communities we touch every day with our The historic aging rate of the world’s population,
products and services. For more than 70 years along with a growing middle class around the
now, it has served as the moral compass of world, brings dramatically greater demand for
Johnson & Johnson – ensuring we never lose higher quality health care; and governments
sight of our strong values and the important and health systems must manage this with
needs of the many stakeholders we serve. increasingly strained resources.
That’s why I consider Our Credo to be one of the At Johnson & Johnson, Our Credo compels
most visionary statements of corporate purpose us to innovate in areas where there are unmet
ever written. medical needs, overcome barriers and advance
CHAIRMAN’S LETTER • Ihealth care in all corners of the world. For us, The world today requires the very best that
this involves preventing the spread of deadly Johnson & Johnson has to offer, and we are
infectious diseases, solving the twin challenges constantly striving to come up with ways we can
of over-nutrition and under-nutrition, leading innovate and lead. We have made very deliberate
breakthrough medical research and empowering choices about our portfolio and have focused our
citizens to take responsibility for managing their energies on capturing the greatest opportunities
own health and wellness. we have to advance patient care.
We are confident in the future of
There is no company better positioned
Johnson & Johnson for four reasons:
to help meet these urgent needs than
Johnson & Johnson. • O ur core businesses are strong and
positioned to continue expanding their
Given the progress we’ve made in our business leadership;
over the past several years, we’re evolving our • W e have an exciting and deep product
approach, placing an even greater emphasis on pipeline across the entire enterprise;
innovation and accelerating growth. Continued
• W e are changing the way we interact
commitment to excellence in execution is a non-
with our customers; and,
negotiable part of the process.
• W e are evolving our structure to be more
effective and efficient to drive growth.
To succeed, we have clear goals and priorities:
APPROXIMATELY We will grow our R&D pipeline. Over the In this interconnected global society in which
126,500 PEOPLE coming years our pharmaceutical pipeline is we live and do business, I have come to realize
WORKING poised to yield a consistent flow of new product through my travels around the world with
AT OUR 265 filings that will allow us to bring new medicines Johnson & Johnson that all health care is local
OPERATING and technologies to patients. We will continue and personal. With approximately 126,500
COMPANIES IN to build our pipeline in order to stay in the people working at our 265 operating companies
60 COUNTRIES forefront. in 60 countries across a broad range of medical
specialties and community health needs, we
We will lead in consumer health care markets. have unique insights and capabilities that can
We will aim to expand our leadership in targeted help address the most formidable challenges.
markets by holistically addressing critical-need I am very proud of our colleagues around the
states in over-the-counter medicines, as well as globe who are focused on doing all they can
oral care, baby and skin care markets. every single day to care for the world, one
person at a time.
We will strengthen our position in medical
devices. Our focus will be on accelerating growth As the largest and most diversified health
with innovative products and by transforming care company in the world, we have both the
our go-to-market models to better serve our opportunity and responsibility to help meet these
customers and patients. challenges with boldness, vision and a driving
II • CHAIRMAN’S LETTERsense of purpose. In 2014, we acknowledged those values come to life in ways that give our OUR CREDO IS
and embraced this responsibility in many ways, company an enduring competitive advantage. A CONSTANT
but perhaps most significantly in our efforts REMINDER OF
to address the Ebola epidemic. Through the I’ve always believed that working in health care THE WORK THAT
exceptional collaboration among the global is an honor and a privilege, and I can’t think of WE DO AND THE
health community, we substantially accelerated a better place to carry out the incredible work VALUES THAT WE
the production of our Ebola vaccine regimen we do than at Johnson & Johnson, thanks in no ARE COMMITTED
with the goal of bringing the vaccine, if approved, small part to the legacy of General Robert Wood TO UPHOLDING
to the families and frontline health care Johnson and Our Credo. TOGETHER
professionals most at risk as quickly as possible.
Thank you for your continued support and
Our Credo is a constant reminder of the work investment in Johnson & Johnson.
that we do and the values that we are committed
to upholding together; values that all of us strive Sincerely,
to make real with our energy, our passion, our
caring and our hard work every single day. When
joined with our four long-term drivers of growth:
creating value through innovation, expanding Alex Gorsky
global reach with local focus, maintaining a laser Chairman, Board of Directors
focus on excellence in execution, and leading and Chief Executive Officer
with purpose to make a difference in the world—
CHAIRMAN’S LETTER • IIIOUR CREDO IN ACTION: 2014 YEAR IN REVIEW
In Dar es Salaam, Tanzania, Johnson & Johnson partners with CCBRT and Kupona Foundation to provide support and rehabilitation to people
with disabilities resulting from childbirth injuries, such as obstetric fistula, and to remove barriers to medical care and treatment.
“The power of Our Credo is that it unites all shortage of at least one million health care professionals
the people of Johnson & Johnson around in the world’s poorest countries, and we have stepped in
to collaborate with multinational coalitions in more than
a common set of principles. As such, it is a
35 countries to develop a new generation of nurses, mid-
helpful framework for understanding our
wives, pharmacists and community health workers to fill
approach to driving growth and meeting the that gap. As part of our commitment to support nurses,
we also gave an educational grant to Nurse.com to make
needs of our stakeholders. I am therefore
continuing education resources about Ebola available to
pleased to highlight our key achievements
every nurse in the U.S. To date, more than 40,000 nurses
from 2014 .” have taken part in the virtual training.
– Alex Gorsky, Chairman, Board of Directors
and Chief Executive Officer We are also delivering new products that offer significant
advancements for our customers through our insight-
We believe our first responsibility is to the doctors, driven approach to innovation, and are continuously
nurses and patients, to mothers and fathers, and all adjusting our product and brand portfolios to meet and
others who use our products and services… exceed their expectations. Our strong pipelines are
In recognition of our first and most important responsibility, expected to yield; 20 key consumer product launches
Johnson & Johnson is supporting, training and protecting globally in 2015; 30 new major medical device product
health care workers who are on the front lines helping filings between 2014 and 2016; and 10 major new
people in the greatest need of care and services. The pharmaceutical filings and 25 line extensions between
World Health Organization estimates that there is a 2013 and 2017.
PHOTO
BY
MARK
TUSCHMAN,
2014
IV • OUR CREDO IN ACTIONWe are responsible to our employees, the men and Our four Johnson & Johnson Innovation Centers,
women who work with us throughout the world… which are located in major science and technology hubs
Caring for the world one person at a time unites and in London, Boston, La Jolla and Shanghai, have kept us
inspires the people of Johnson & Johnson. That includes at the forefront of new ideas and scientific breakthroughs.
our approximately 126,500 employees around the globe JLABS, our “no strings attached” incubators, is
who lead the way in managing their own health and stimulating a total innovation ecosystem by helping young
wellness. Our employee programs are at the forefront of companies with pioneering ideas get off the ground.
all industries, and we have decades of research that proves
a healthy company is a more productive and profitable Our final responsibility is to our shareholders…
company. In the U.S., our health and wellness programs When we operate according to these principles,
have helped our employees reduce their risk factors on the stockholders should realize a fair return…
key health measures to less than half that of the country’s It is gratifying that our shareholders have supported
general population. This includes areas such as smoking, us through the years as we have built our worldwide
high blood pressure, high cholesterol and inactivity. business and have extended our reach to improve the
lives of people everywhere.
Employee engagement at Johnson & Johnson is also at
an all-time high and continues to be measured at rates In 2014, our strong performance enabled us to meet
well above external benchmarks. We met our talent and our commitments to you, the shareholder.
engagement objectives for 2015, retained key talent,
strengthened the talent pipeline and improved employee
52 31
engagement and reputational standings, as measured
by Our Credo survey of all employees.
We are responsible to the communities in which we
consecutive years of consecutive years of
live and work and to the world community as well…
dividend increases of adjusted earnings
Our commitment to transforming the lives of patients increases‡
and communities includes our contributions of about
$1 billion in products and cash last year in support of
AAA
over 500 programs that address major health-related 1 of 3 industrial
issues in local communities in more than 50 countries companies to hold
a AAA credit rating
around the world.
We also made great progress toward our Healthy Future
2015 citizenship and sustainability goals, including efforts
in global health, the environment, and responsible and
transparent business practices.
70 24
We must experiment with new ideas…
Our research and development productivity is leading %
the industry, and our approach is designed to ensure
we continue to lead. Last year, we invested an industry-
of our sales come from brands and platforms
leading $8.5 billion, and also executed more than
the #1 or #2 global that generate over $1
100 strategic partnerships, licenses and acquisitions market share position billion in sales apiece
across our Pharmaceutical, Medical Devices and
Consumer segments. ‡Non-GAAP measure, excludes special items
OUR CREDO IN ACTION • V2014 BUSINESS HIGHLIGHTS
2014 was a strong year for Johnson & Johnson, as we delivered solid financial results
while continuing to make investments to accelerate growth for the long term. We have
built significant momentum in our Pharmaceutical business, are realizing the benefits
of innovation, scale and breadth in our Medical Devices business and are continuing our
market leadership with iconic brands in our Consumer business. We’ve achieved our
near-term priorities, exceeding our financial targets with full-year operational* sales growth
of 6.1 percent. Excluding the net impact of acquisitions and divestitures, on an operational
basis, worldwide sales increased 8.0 percent.†
PHARMACEUTICALS (golimumab) and REMICADE® (infliximab), biologics
Worldwide Pharmaceutical sales of $32.3 billion for approved for the treatment of a number of immune-
the full-year 2014 represented operational growth of mediated inflammatory diseases.
16.5 percent. With 14 new medicines launched since
2009, our Pharmaceutical segment is the fastest When it comes to innovation and ensuring we have
growing of the top 10 pharmaceutical businesses in continuous access to new ideas and products at their
the U.S., Europe and Japan**, and our medicines are earliest stages, we expect the best science to prevail
making a dramatic impact. regardless of whether that comes from sources inside
or outside of Johnson & Johnson. In 2014, we made
The strong sales results were driven by new products two significant acquisitions to add to our innovation
and the strength of our core products. New products portfolio: Alios BioPharma, Inc., a privately-held clinical
include OLYSIO®/SOVRIAD® (simeprevir), for stage biopharmaceutical company focused on developing
combination treatment of chronic hepatitis C in adult therapies for viral diseases; and Covagen AG, a privately-
patients; XARELTO® (rivaroxaban), an oral anticoagulant; held biopharmaceutical company specializing in the
ZYTIGA® (abiraterone acetate), an oral, once-daily development of multispecific protein therapeutics through
medication for use in combination with prednisone for the FynomAb® technology platform.
the treatment of metastatic, castration-resistant prostate
cancer; INVOKANA® (canagliflozin), for the treatment of MEDICAL DEVICES
adults with type 2 diabetes; and IMBRUVICA® (ibrutinib), Worldwide Medical Devices sales of $27.5 billion for the
an oral, once-daily therapy approved for use in treating full-year 2014 represented an operational decrease of
certain B-cell malignancies, or blood cancers. 1.6 percent. Excluding the net impact of acquisitions and
divestitures, on an operational basis, worldwide sales
Additional contributors to operational sales growth were increased 1.6 percent.†
STELARA® (ustekinumab), a biologic approved for the
treatment of moderate to severe plaque psoriasis and The Medical Devices business holds a strong leadership
psoriatic arthritis; INVEGA® SUSTENNA®/XEPLION® position in the industry, including 10 platforms with more
(paliperidone palmitate), a once-monthly, long-acting, than $1 billion in sales. We’ve launched over 50 major
injectable atypical antipsychotic for the treatment of new products since 2012, and have more than 30 major
schizophrenia in adults; SIMPONI®/SIMPONI ARIA® new filings planned by the end of 2016.
VI • 2014 BUSINESS HIGHLIGHTSPrimary contributors to operational growth were our broad During the year, we launched several new products
portfolio of Orthopaedic products; Biosense Webster’s including Women’s ROGAINE®, ZYRTEC® dissolve tabs
electrophysiology products in the Cardiovascular Care and several new formulations of LISTERINE®, and
business; and biosurgicals and international sales of re-launched brands such as TYLENOL® PM. Our
energy products in the Specialty Surgery business. insight-driven innovation in the Consumer business is
Sales results in the Vision Care and U.S. Diabetes Care focused on addressing key consumer need states, led
businesses were negatively impacted by competitive by our 12 megabrands, with 20 new product launches
pricing dynamics. planned for 2015.
Key approvals and launches during the year include CITIZENSHIP & SUSTAINABILITY
U.S. Food and Drug Administration (FDA) approval Managing our social, environmental and economic
for the Animas® Vibe™ insulin pump and Continuous impacts locally and globally is an important responsibility.
Glucose Monitoring system for the management of Our Citizenship & Sustainability strategic priorities focus
insulin-requiring diabetes in adults ages 18 and older; our efforts to advance global health, help to safeguard
the INCRAFT® AAA Stent Graft System was approved the planet, and lead a dynamic and growing business
and launched for treatment of abdominal aortic responsibly.
aneurysms (AAA) in Europe and Canada; the SABER™
PTA Dilatation Catheter for the treatment of patients We have continued to make progress toward our Healthy
with Peripheral Arterial Disease received FDA and Future 2015 goals, including leveraging our research and
European Commission approval; and the FDA approved development, and our ability to innovate and collaborate
the THERMOCOOL® SMARTTOUCH® Catheter for to find solutions for global health issues. In response to
treatment of patients suffering from drug-resistant the Ebola crisis, in collaboration with the U.S. National
paroxysmal atrial fibrillation. Institutes of Health and Bavarian Nordic A/S, we
committed to accelerate our vaccine program. With Stop
On June 30, 2014, the Company completed the TB Partnership’s Global Drug Facility and with USAID
divestiture of its Ortho-Clinical Diagnostics business we are expanding access to our multidrug-resistant
to The Carlyle Group for approximately $4 billion. tuberculosis compound, SIRTURO™. We have expanded
our collaboration with the International Partnership for
CONSUMER Microbicides for development and commercialization of
Worldwide Consumer sales of $14.5 billion for the full- dapivirine, for prevention of sexual transmission of HIV,
year 2014 represented an operational increase of 1.0 and we are working with Viiv Healthcare to develop a
percent. Excluding the net impact of acquisitions and two-drug single tablet regimen for maintenance treatment
divestitures, on an operational basis, worldwide sales of people living with HIV.
increased 2.8 percent.†
Our legacy of care for the environment and protection
Positive contributors to operational results were sales of natural resources continues. We are working to
of TYLENOL® and MOTRIN® analgesics and ZYRTEC® reduce our energy consumption while increasing the
allergy over-the-counter products; AVEENO® and proportion of energy we use from renewable sources,
NEUTROGENA® skin care products; and LISTERINE® thereby reducing our carbon dioxide emissions. We
oral care products. continue to look for ways to reduce water consumption
2014 BUSINESS HIGHLIGHTS • VII2014 BUSINESS HIGHLIGHTS
and waste production throughout our products’ lifecycles. health of women and children include our work in support
For example, we continue to integrate and expand of the Millennium Development Goals. In addition, in 2014
our EARTHWARDS® approach to drive continuous we expanded programs using mobile technology as a
sustainability improvements and innovation across way to disperse health information to new and expectant
our businesses. To date, more than 73 products have mothers in South Africa and India and announced a
gained EARTHWARDS® recognition, ahead of our global partnership with Save the Children that has
2015 goal. the potential to help improve the survival and healthy
development of millions of children under age 5 over
We remain committed to enhanced transparency and the next three years.
engagements with stakeholders that serve to improve the
health of patients and drive improved clinical outcomes. Our commitment to transforming the lives of patients
We announced an extended agreement with the Yale and communities includes our contributions of
Open Data Access (YODA) Project to provide access to approximately $1 billion in products and cash last year
clinical trial data for pharmaceutical and medical device in support of over 500 programs that address major
products, setting new industry standards by being the first health-related issues in local communities in more than
company to do so. Our ongoing efforts to improve the 50 countries around the world.
† Non-GAAP measure. See “Reconciliation of Non-GAAP Financial Measures” on pages 70 and 71 of this Annual Report.
* Operational measures exclude the impact of currency translation.
** IMS MIDAS data as of Q3 2014 (growth versus previous year (moving annual total) in local currency dollars)
NOTE REGARDING FORWARD-LOOKING STATEMENTS
The Chairman’s Letter and Business Highlights section contain forward-looking statements relating to, among other things, business
strategy, performance and expectations for product development. The reader is cautioned not to rely on these statements and should
review the section “Cautionary Factors That May Affect Future Results” on page 19 of this Annual Report for important information
about these statements, including the risks, uncertainties and other factors that could cause actual results to vary materially from the
assumptions, expectations, and projections expressed in any forward-looking statements. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information or future events or developments.
VIII • 2014 BUSINESS HIGHLIGHTSTable of Contents
MANAGEMENT’SDISCUSSIONANDANALYSIS OFRESULTS
OFOPERATIONSANDFINANCIALCONDITION
OrganizationandBusinessSegments 2
ResultsofOperations 3
AnalysisofSalesbyBusinessSegments 4
AnalysisofConsolidatedEarningsBeforeProvisionforTaxesonIncome 8
LiquidityandCapitalResources 11
OtherInformation 13
CautionaryFactorsThatMayAffectFutureResults 19
AUDITEDCONSOLIDATEDFINANCIALSTATEMENTS
ConsolidatedBalanceSheets 20
ConsolidatedStatementsofEarnings 21
ConsolidatedStatementsofComprehensiveIncome 22
ConsolidatedStatementsofEquity 23
ConsolidatedStatementsofCashFlows 24
NotestoConsolidatedFinancialStatements 25
ReportofIndependentRegisteredPublicAccountingFirm 66
Management’sReportonInternalControlOverFinancialReporting 67
SUPPORTINGSCHEDULES
SummaryofOperationsandStatisticalData2004–2014 68
ShareholderReturnPerformanceGraphs 69
ReconciliationofNon-GAAPFinancialMeasures 70
Johnson&Johnson2014AnnualReport • 1Management’s Discussion and Analysis of
Results of Operations and Financial Condition
Organization and Business Segments
DescriptionoftheCompanyandBusinessSegments
Johnson&Johnsonanditssubsidiaries(theCompany)haveapproximately126,500employeesworldwideengagedinthe
researchanddevelopment,manufactureandsaleofabroadrangeofproductsinthehealthcarefield.TheCompany
conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand
well-being.
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices(previously
referredtoasMedicalDevicesandDiagnostics).TheConsumersegmentincludesabroadrangeofproductsusedinthe
babycare,oralcare,skincare,over-the-counterpharmaceutical,women’shealthandwoundcaremarkets.These
productsaremarketedtothegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworld.The
Pharmaceuticalsegmentisfocusedonfivetherapeuticareas,includingimmunology,infectiousdiseases,neuroscience,
oncology,andcardiovascularandmetabolicdiseases.Productsinthissegmentaredistributeddirectlytoretailers,
wholesalers,hospitalsandhealthcareprofessionalsforprescriptionuse.TheMedicalDevicessegmentincludesabroad
rangeofproductsusedintheorthopaedic,surgicalcare,specialtysurgery,cardiovascularcare,diagnostics,diabetes
care,andvisioncaremarkets,whicharedistributedtowholesalers,hospitalsandretailers,andusedprincipallyinthe
professionalfieldsbyphysicians,nurses,hospitals,andclinics.
TheCompany’sstructureisbasedupontheprincipleofdecentralizedmanagement.TheExecutiveCommitteeof
Johnson&Johnsonistheprincipalmanagementgroupresponsibleforthestrategicoperationsandallocationofthe
resourcesoftheCompany.ThisCommitteeoverseesandcoordinatestheactivitiesoftheConsumer,Pharmaceuticaland
MedicalDevicesbusinesssegments.
Inallofitsproductlines,theCompanycompeteswithcompaniesbothlocallyandglobally,throughouttheworld.
Competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved.
Competitioninresearch,involvingthedevelopmentandtheimprovementofnewandexistingproductsandprocesses,is
particularlysignificant.ThedevelopmentofnewandinnovativeproductsisimportanttotheCompany’ssuccessinall
areasofitsbusiness.ThisalsoincludesprotectingtheCompany’sportfolioofintellectualproperty.Thecompetitive
environmentrequiressubstantialinvestmentsincontinuingresearch.Inaddition,thedevelopmentandmaintenanceof
customerdemandfortheCompany’sconsumerproductsinvolvessignificantexpendituresforadvertisingandpromotion.
Management’sObjectives
TheCompanymanageswithinastrategicframeworkwithOurCredoasthefoundation.TheCompanybelievesthatour
strategicoperatingprinciples:beingbroadlybasedinhumanhealthcare,managingthebusinessforthelongterm,a
decentralizedmanagementapproachandcommitmenttoourpeopleandvaluesarerequiredtosuccessfullymeetthe
demandsoftherapidlyevolvingmarketsinwhichwecompete.Tothisend,managementisfocusedonourgrowthdrivers:
creatingvaluethroughinnovation,expandingourglobalreachwithalocalfocus,excellenceinexecutionandleadingwith
purpose.
TheCompanyengagesinareasofhumanhealthcarewherethereisanopportunitytomakeameaningfuldifference,and
iscommittedtocreatingvaluebydevelopingbroadlyaccessible,highquality,innovativeproductsandservices.New
productsintroducedwithinthepastfiveyearsaccountedforapproximately25%of2014sales.In2014,$8.5billion,or
11.4%ofsales,wasinvestedinresearchanddevelopment,reflectingmanagement’scommitmenttodeliveringnewand
differentiatedproductsandservicestomeetevolvinghealthcareneedsandsustaintheCompany’slong-termgrowth.
Ourdiversebusinesseswithmorethan265operatingcompanieslocatedin60countriesarethekeydriversofthe
Company’ssuccess.MaintainingtheCompany’sdecentralizedmanagementapproach,whileatthesametimeleveraging
theextensiveresourcesoftheenterprise,uniquelypositionstheCompanytoinnovate,executeandreachmarketsglobally,
whilefocusingontheneedsandchallengesofthelocalmarkets.
2 • Johnson&Johnson2014AnnualReportInordertoremainaleaderinhealthcare,theCompanystrivestomaintainapurpose-drivenorganizationandiscommitted
todevelopingglobalbusinessleaderswhocanachievethesegrowthobjectives.Businessesaremanagedforthe
long-terminordertosustainmarketleadershippositionsandenablegrowth,whichprovidesanenduringsourceofvalue
toourshareholders.
OurCredounifiesallJohnson&Johnsonemployeesinachievingtheseobjectives,andprovidesacommonsetofvalues
thatserveasthefoundationoftheCompany’sresponsibilitiestoitscustomers,employees,communitiesandshareholders.
TheCompanybelievesthatthesebasicprinciplesandgrowthdrivers,alongwithitsoverallmissionofimprovingthequality
oflifeforpeopleacrosstheglobe,willenableJohnson&Johnsontocontinuetobealeaderinthehealthcareindustry.
Results of Operations
AnalysisofConsolidatedSales
In2014,worldwidesalesincreased4.2%to$74.3billion,comparedtoincreasesof6.1%in2013and3.4%in2012.
Thesesaleschangesconsistedofthefollowing:
Salesincrease/(decrease)dueto: 2014 2013 2012
Volume 6.3% 7.6 5.7
Price (0.2) 0.1 0.4
Currency (1.9) (1.6) (2.7)
Total 4.2% 6.1 3.4
In2014,salesoftheCompany’sHepatitisCproducts,OLYSIO®/SOVRIAD®(simeprevir)andINCIVO®(telaprevir),had
apositiveimpactof2.8%,andthedivestitureoftheOrtho-ClinicalDiagnosticsbusinesshadanegativeimpactof1.4%on
theworldwideoperationalgrowth.TheacquisitionofSynthes,Inc.,netoftherelateddivestiture,increasedworldwide
operationalgrowthby2.5%and3.1%in2013and2012,respectively.
SalesbyU.S.companieswere$34.8billionin2014,$31.9billionin2013and$29.8billionin2012.Thisrepresentsincreases
of9.0%in2014,7.0%in2013and3.2%in2012.Salesbyinternationalcompanieswere$39.5billionin2014,$39.4billion
in2013and$37.4billionin2012.Thisrepresentsincreasesof0.4%in2014,5.4%in2013and3.5%in2012.
Thefive-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere3.7%,2.4%and5.0%,
respectively.Theten-yearcompoundannualgrowthratesforworldwide,U.S.andinternationalsaleswere4.6%,2.3%and
7.3%,respectively.
SalesinEuropeachievedgrowthof1.9%ascomparedtotheprioryear,includingoperationalgrowthof2.6%partially
offsetbyanegativecurrencyimpactof0.7%.SalesintheWesternHemisphere(excludingtheU.S.)experiencedadecline
of3.5%ascomparedtotheprioryear,includingoperationalgrowthof5.2%offsetbyanegativecurrencyimpactof8.7%.
SalesintheAsia-Pacific,Africaregionachievedgrowthof0.4%ascomparedtotheprioryear,includingoperational
growthof4.4%andanegativecurrencyimpactof4.0%.
In2014,theCompanyhadonewholesalerdistributingproductsforallthreesegmentsthatrepresentedapproximately
11.0%ofthetotalconsolidatedrevenues.In2013and2012,theCompanydidnothaveacustomerthatrepresented
10%ormoreoftotalconsolidatedrevenues.
U.S.HealthCareReform
UndertheprovisionsofthePatientProtectionandAffordableCareActandtheHealthCareandEducationReconciliation
Actof2010,beginningin2013,theCompanybeganpayingataxdeductible2.3%excisetaximposedonthesaleof
certainmedicaldevices.Thefull-yearimpactoftheexcisetaxwasapproximately$180millionin2014and$200millionin
2013.
OnJuly28,2014,theInternalRevenueServiceissuedfinalregulationsfortheBrandedPrescriptionDrugFee,anannual
non-taxdeductiblefeeimposedonentitiesengagedinthebusinessofmanufacturingorimportingbrandedprescription
drugs(coveredentities)enactedbysection9008ofthePatientProtectionandAffordableCareAct.Thefinalregulations
acceleratedtheexpenserecognitioncriteriaforthefeeobligationbyoneyear,fromtheyearinwhichthefeeispaidtothe
yearinwhichthesalesusedtocalculatethefeeoccur.Thischangeimpactedcoveredentitiesandresultedintheneedfor
allentitiestorecordanadditionalexpensein2014forthefeethatwouldhaveotherwisebeenexpensedwhenpaidin
2015.TheCompanyaccruedanadditional$220millioninthefiscalthirdquarterof2014duetothischange.Thefee
associatedwiththisacceleratedexpensewillbepaid,asscheduledin2015andthereforehadnocashimpactin2014.
Johnson&Johnson2014AnnualReport • 3Analysis of Sales by Business Segments
ConsumerSegment
Consumersegmentsalesin2014were$14.5billion,adecreaseof1.4%from2013,whichincluded1.0%operational
growthoffsetbyanegativecurrencyimpactof2.4%.U.S.Consumersegmentsaleswere$5.1billion,adecreaseof
1.3%.Internationalsaleswere$9.4billion,adecreaseof1.4%,whichincluded2.3%operationalgrowthoffsetbya
negativecurrencyimpactof3.7%.
MajorConsumerFranchiseSales:
%Change
(DollarsinMillions) 2014 2013 2012 ’14vs.’13 ’13vs.’12
OTC $4,106 4,028 3,766 1.9% 7.0
SkinCare 3,758 3,704 3,618 1.5 2.4
BabyCare 2,239 2,295 2,254 (2.4) 1.8
OralCare 1,647 1,622 1,624 1.5 (0.1)
WoundCare/Other 1,444 1,480 1,560 (2.4) (5.1)
Women’sHealth 1,302 1,568 1,625 (17.0) (3.5)
TotalConsumerSales $14,496 14,697 14,447 (1.4)% 1.7
TheOver-the-Counter(OTC)franchiseachievedsalesof$4.1billion,anincreaseof1.9%from2013.StrongU.S.sales
growthof5.5%wasdrivenbyanalgesicsandupperrespiratoryproducts,primarilyduetocontinuedprogressinreturning
asupplyofproductstothemarketplace.
McNEIL-PPC,Inc.continuestooperateunderaconsentdecree,signedin2011withtheU.S.FoodandDrug
Administration(FDA),whichgovernscertainMcNeilConsumerHealthcaremanufacturingoperations(theConsent
Decree).TheConsentDecreerequiresMcNEIL-PPCtoremediatethefacilitiesitoperatesinLancaster,Pennsylvania,Fort
Washington,Pennsylvania,andLasPiedras,PuertoRico.TheFortWashingtonfacilitywasvoluntarilyshutdownin
April2010,however,manyproductspreviouslymadeinFortWashingtonhavebeentransferredtoothermanufacturing
sitesandsuccessfullyreintroducedtothemarket.TheLancasterandLasPiedrasfacilitiescontinuetomanufactureand
distributedrugswiththird-partyoversight.Third-partyoversightwillceaseoncetheFDAhasdeterminedthatthefacilities
appeartobeincompliancewithapplicablelaw.InFebruary2015,thethird-partyoverseersubmittedwrittencertification
totheFDAforallthreemanufacturingsites.ThetimelineforcompletionofanyFDAinspectioniswithintheFDA’s
discretion.
TheSkinCarefranchiseachievedsalesof$3.8billion,anincreaseof1.5%ascomparedtotheprioryear,primarilydueto
strongresultsfromtheAVEENO®,NEUTROGENA®,andDABAO™productlines.TheBabyCarefranchisesaleswere
$2.2billionin2014,adecreaseof2.4%from2013.SalesgrowthinLatinAmericaandAsiaPacificwasoffsetbythe
impactofnegativecurrencyinalltheregionsoutsidetheU.S.TheOralCarefranchisesaleswere$1.6billion,anincrease
of1.5%ascomparedtotheprioryear.ThegrowthwasdrivenbyincreasedsalesofLISTERINE®products,asaresultof
newproductlaunchesandsuccessfulmarketingcampaigns.TheWoundCare/Otherfranchisesaleswere$1.4billionin
2014,adecreaseof2.4%from2013,primarilyduetolowersalesofnutritionalsoutsidetheU.S.TheWomen’sHealth
franchisesaleswere$1.3billion,adecreaseof17.0%primarilyduetothedivestitureofwomen’ssanitaryprotection
productsintheU.S.,CanadaandCaribbean,whichwascompletedinthefiscalfourthquarterof2013.
Consumersegmentsalesin2013were$14.7billion,anincreaseof1.7%from2012,whichincluded2.8%operational
growthandanegativecurrencyimpactof1.1%.U.S.Consumersegmentsaleswere$5.2billion,anincreaseof2.3%.
Internationalsaleswere$9.5billion,anincreaseof1.4%,whichincluded3.1%operationalgrowthandanegative
currencyimpactof1.7%.
4 • Johnson&Johnson2014AnnualReportPharmaceutical Segment
ThePharmaceuticalsegmentachievedsalesof$32.3billionin2014,representinganincreaseof14.9%overtheprior
year,withstrongoperationalgrowthof16.5%andanegativecurrencyimpactof1.6%.U.S.saleswere$17.4billion,an
increaseof25.0%.Internationalsaleswere$14.9billion,anincreaseof5.0%,whichincluded8.3%operationalgrowth
andanegativecurrencyimpactof3.3%.In2013,Pharmaceuticalsegmentsalesincludedapositiveadjustmentto
previousestimatesforManagedMedicaidrebates.Thisnegativelyimpacted2014Pharmaceuticaloperationalsales
growthby0.8%ascomparedtotheprioryear.In2014,salesoftheCompany’sHepatitisCproducts,
OLYSIO®/SOVRIAD®(simeprevir)andINCIVO®(telaprevir),hadapositiveimpactof6.9%ontheoperationalgrowthof
thePharmaceuticalsegment.
MajorPharmaceutical TherapeuticAreaSales:*
%Change
(DollarsinMillions) 2014 2013 2012 ’14vs.’13 ’13vs.’12
TotalImmunology $10,193 9,190 7,874 10.9% 16.7
REMICADE® 6,868 6,673 6,139 2.9 8.7
SIMPONI®/SIMPONIARIA® 1,187 932 607 27.4 53.5
STELARA® 2,072 1,504 1,025 37.8 46.7
OtherImmunology 66 81 103 (18.5) (21.4)
TotalInfectiousDiseases 5,599 3,550 3,194 57.7 11.1
EDURANT® 365 236 102 54.7 **
INCIVO® 226 517 443 (56.3) 16.7
OLYSIO®/SOVRIAD® 2,302 23 – ** –
PREZISTA® 1,831 1,673 1,414 9.4 18.3
OtherInfectiousDiseases 875 1,101 1,235 (20.5) (10.9)
TotalNeuroscience 6,487 6,667 6,718 (2.7) (0.8)
CONCERTA®/methylphenidate 599 782 1,073 (23.4) (27.1)
INVEGA® 640 583 550 9.8 6.0
INVEGA®SUSTENNA®/XEPLION® 1,588 1,248 796 27.2 56.8
RISPERDAL®CONSTA® 1,190 1,318 1,425 (9.7) (7.5)
OtherNeuroscience 2,470 2,736 2,874 (9.7) (4.8)
TotalOncology 4,457 3,773 2,629 18.1 43.5
VELCADE® 1,618 1,660 1,500 (2.5) 10.7
ZYTIGA® 2,237 1,698 961 31.7 76.7
OtherOncology 602 415 168 45.1 **
TotalOther 5,577 4,945 4,936 12.8 0.2
PROCRIT®/EPREX® 1,238 1,364 1,462 (9.2) (6.7)
XARELTO® 1,522 864 239 76.2 **
Other 2,817 2,717 3,235 3.7 (16.0)
TotalPharmaceuticalSales $32,313 28,125 25,351 14.9% 10.9
* Prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
**Percentagegreaterthan100%
Immunologyproductsachievedsalesof$10.2billionin2014,representinganincreaseof10.9%ascomparedtotheprior
year.TheincreasedsalesofSTELARA®(ustekinumab)andSIMPONI®/SIMPONIARIA®(golimumab)wereprimarilydue
tomarketgrowthandmarketsharegains.REMICADE®(infliximab)growthwasprimarilyduetomarketgrowth.
ThepatentsforREMICADE®incertaincountriesinEurope(Germany,Spain,UnitedKingdom,Sweden,Austria,Belgium,
Switzerland,Denmark,France,Greece,Italy,LuxembourgandtheNetherlands)expireinFebruary2015.Lossofexclusivity
willlikelyresultinareductioninsalesasbiosimilarversionsareintroducedtothemarket.SeeNote21tothe
ConsolidatedFinancialStatementsforlegalmattersregardingtheREMICADE®patents.
Johnson&Johnson2014AnnualReport • 5Infectiousdiseaseproductsachievedsalesof$5.6billionin2014,representinganincreaseof57.7%ascomparedtothe
prioryear.MajorcontributorstothegrowthwerethelaunchofOLYSIO®/SOVRIAD®(simeprevir);PREZISTA®
(darunavir),duetomarketgrowth;andsalesofEDURANT®(rilpivirine).Thiswaspartiallyoffsetbylowersalesof
INCIVO®(telaprevir),duetocompetitivepressures,andlowersalesofvaccineproducts.Theapprovalofcompetitive
productstoOLYSIO®/SOVRIAD®(simeprevir)hadanegativeimpactinthefourthquarterof2014andisexpectedto
continuetohaveasignificantnegativeimpactonfuturesalesofOLYSIO®/SOVRIAD®(simeprevir).
Neuroscienceproductssaleswere$6.5billion,adeclineof2.7%ascomparedtotheprioryear.Strongsalesof
INVEGA®SUSTENNA®/XEPLION®(paliperidonepalmitate)andINVEGA®(paliperidonepalmitate)werepartiallyoffset
bylowersalesofRISPERDAL®CONSTA®.Additionally,adeclineinsalesofCONCERTA®/methylphenidateand
TOPAMAX®(topiramate)wereduetocontinuedgenericcompetition.
Oncologyproductsachievedsalesof$4.5billionin2014,representinganincreaseof18.1%ascomparedtotheprior
year.MajorcontributorstothegrowthwerestrongsalesofZYTIGA®(abirateroneacetate),aswellastherecentlaunchof
IMBRUVICA®(ibrutinib).SalesgrowthofVELCADE®(bortezomib)wasmorethanoffsetbynegativecurrency.
OtherPharmaceuticalsaleswere$5.6billion,anincreaseof12.8%ascomparedtotheprioryear.Strongsalesof
XARELTO®(rivaroxaban)andINVOKANA®/INVOKAMET™(canagliflozin)werepartiallyoffsetbylowersalesof
ACIPHEX®/PARIET®(rabeprazolesodium)andPROCRIT®/EPREX®(Epoetinalfa).
During2014,theCompanyreceivedseveralregulatoryapprovalsincluding:theU.S.FoodandDrugAdministration(FDA)
grantedapprovalofIMBRUVICA®(ibrutinib)capsules,whichisbeingjointlydevelopedandcommercializedby
Pharmacyclics,Inc.forthetreatmentofpatientswithchroniclymphocyticleukemia(CLL)whohavereceivedatleastone
priortherapy;theEuropeanCommission(EC)grantedconditionalapprovalforSIRTURO®(bedaquiline)intheEuropean
Union,foruseaspartofanappropriatecombinationregimenforpulmonarymulti-drugresistanttuberculosisinadult
patients;theFDAandtheECgrantedapprovalofSYLVANT®(siltuximab)forthetreatmentofpatientswithmulticentric
Castleman’sdiseasewhoarehumanimmunodeficiencyvirusnegativeandhumanherpesvirus-8negative;theECgranted
approvalforVOKANAMET®(canagliflozin/metforminHCl),afixed-dosetherapycombiningcanagliflozinandimmediate
releasemetforminhydrochlorideinasingletabletforthetreatmentofadultswithtype2diabetes;OLYSIO®(simeprevir)
forthetreatmentofadultpatientswithgenotype1or4chronichepatitisC;andforINVEGA®(paliperidoneER)toextend
itsadultindicationofschizophreniatoincludeadolescentsaged15yearsandolder;theFDAgrantedapprovalforathird
indicationforIMBRUVICA®(ibrutinib),forthetreatmentofpatientswithCLLwhohavethegeneticmutation17pdeletion
(del17p)andalsograntedIMBRUVICA®(ibrutinib)fullapprovalforthetreatmentofpatientswithCLLwhohavereceived
atleastonepriortherapy;FDAgrantedapprovalforINVOKAMET™(canagliflozin/metforminHCl)forthetreatmentof
adultswithtype2diabetes;TheECapprovedIMBRUVICA®(ibrutinib)forthetreatmentofadultpatientswithrelapsedor
refractorymantlecelllymphomaandadultpatientswithchroniclymphocyticleukemiawhohavereceivedatleastoneprior
therapy,orinfirst-lineinthepresenceof17pdeletionorTP53mutationinpatientsunsuitableforchemo-immunotherapy.
TheECalsoapprovedREZOLSTA®(darunavir/cobicistat)incombinationwithotherantiretroviralmedicinalproductsfor
thetreatmentofhumanimmunodeficiencyvirus-1infectioninadultsaged18yearsorolder.
TheCompanysubmittedseveralNewDrugApplications(NDAs)totheFDA,includinganNDAseekingapprovalfora
once-dailyfixed-doseantiretroviralcombinationtabletcontainingdarunavir,aproteaseinhibitordevelopedbyJanssen
R&DIrelandandmarketedasPREZISTA®intheU.S.,withcobicistat,aninvestigationalpharmacokineticenhanceror
boostingagent,developedbyGileadSciences,Inc.foruseincombinationwithotherhumanimmunodeficiencyvirus
medicines;anNDAforthree-monthatypicalantipsychoticpaliperidonepalmitateasatreatmentforschizophreniain
adults;andanNDAforYONDELIS®(trabectedin)forthetreatmentofpatientswithadvancedsofttissuesarcoma,
includingliposarcomaandleiomyosarcomasubtypes,whohavereceivedpriorchemotherapyincludingananthracycline.
Inaddition,asupplementalNewDrugApplication(sNDA)wasapprovedbytheFDAforOLYSIO®incombinationwiththe
nucleotideanalogNS5BpolymeraseinhibitorsofosbuvirdevelopedbyGileadSciences,Inc.forthetreatmentofchronic
hepatitisC.AdditionalsNDA’swerealsosubmittedtotheFDAforOLYSIO®forthetreatmentofadultpatientsin
genotype4chronichepatitisCandpatientsco-infectedwithHIV;once-monthlyatypicallong-actingantipsychotic
INVEGA®SUSTENNA®(paliperidonepalmitate)wasapprovedtotreatschizoaffectivedisorderaseithermonotherapyor
adjunctivetherapy;andaTypeIIvariationapplicationwassubmittedtotheEuropeanMedicinesAgency(EMA)foran
additionalindicationofIMBRUVICA®(ibrutinib)forthetreatmentofpatientswithWaldenström’smacroglobulinemia,a
raretypeofB-celllymphoma.
AMarketingAuthorizationApplicationwassubmittedtotheEuropeanMedicinesAgencytoexpandthelabelfor
VELCADE®(bortezomib)toincludeitsuse,incombinationwithrituximab,cyclophosphamide,doxorubicinandprednisone,
forthetreatmentofadultpatientswithpreviouslyuntreatedmantlecelllymphoma.
6 • Johnson&Johnson2014AnnualReportPharmaceuticalsegmentsalesin2013were$28.1billion,representinganincreaseof10.9%overtheprioryear,with
strongoperationalgrowthof12.0%andanegativecurrencyimpactof1.1%.U.S.saleswere$13.9billion,anincreaseof
12.3%.Internationalsaleswere$14.2billion,anincreaseof9.6%,whichincluded11.8%operationalgrowthanda
negativecurrencyimpactof2.2%.ThePharmaceuticalsegmentoperationalgrowthwasimpactedby0.8%in2013dueto
apositiveadjustmenttopreviousestimatesforManagedMedicaidrebates.
MedicalDevicesSegment
TheMedicalDevicessegmentsalesin2014were$27.5billion,adecreaseof3.4%from2013,whichincludedan
operationaldeclineof1.6%andanegativecurrencyimpactof1.8%.U.S.saleswere$12.3billion,adecreaseof4.3%as
comparedtotheprioryear.Internationalsaleswere$15.3billion,adeclineof2.7%ascomparedtotheprioryear,with
operationalgrowthof0.5%offsetbyanegativecurrencyimpactof3.2%.In2014,thedivestitureoftheOrtho-Clinical
Diagnosticsbusinesshadanegativeimpactof3.2%ontheoperationalgrowthoftheMedicalDevicessegment.
MajorMedicalDevicesFranchiseSales:*
%Change
(DollarsinMillions) 2014 2013 2012 ’14vs.’13 ’13vs.’12
Orthopaedics $9,675 9,509 7,799 1.7% 21.9
SurgicalCare 6,176 6,269 6,483 (1.5) (3.3)
SpecialtySurgery/Other 3,541 3,504 3,478 1.1 0.7
VisionCare 2,818 2,937 2,996 (4.1) (2.0)
CardiovascularCare 2,208 2,077 1,985 6.3 4.6
DiabetesCare 2,142 2,309 2,616 (7.2) (11.7)
Diagnostics 962 1,885 2,069 (49.0) (8.9)
TotalMedicalDevicesSales $27,522 28,490 27,426 (3.4)% 3.9
* PreviouslyreferredtoasMedicalDevicesandDiagnostics.Prioryearamountshavebeenreclassifiedtoconformtocurrentyear
presentation.InfectionPreventionisincludedinSpecialtySurgery/Other.
TheOrthopaedicsfranchiseachievedsalesof$9.7billionin2014,a1.7%increaseovertheprioryear.Growthwas
primarilydrivenbysalesoftrauma,sportsmedicine,kneeandhipproducts.Growthwasnegativelyimpactedbycontinued
pricingpressures.
TheSurgicalCarefranchisesaleswere$6.2billionin2014,adecreaseof1.5%fromtheprioryear.U.S.pricingpressure,
lowersalesofwomen’shealthandurologyproductsduetotheCompany’sdecisiontoexitfromcertainwomen’shealth
products,andtheimpactfromnegativecurrencywerepartiallyoffsetbyworldwidesalesgrowthofsuturesandthe
successoftheECHELONFLEX™poweredENDOPATH®StapleroutsidetheU.S.
TheSpecialtySurgery/Otherfranchisesaleswere$3.5billionin2014,a1.1%increaseovertheprioryear.Contributors
tothegrowthwerestrongsalesfrombiosurgicalproducts,salesofenergyproductsoutsidetheU.S.andMentorproducts
duetonewproductlaunchesandmarketgrowth.
TheVisionCarefranchisesaleswere$2.8billionin2014,adecreaseof4.1%fromtheprioryear.Thedeclinewas
primarilyduetoincreasedcompetitionandpricingpressuresintheU.S.andtheAsiaPacificregion,partiallyoffsetby
salesgrowthinEurope.
TheCardiovascularCarefranchiseachievedsalesof$2.2billion,a6.3%increaseovertheprioryear.Theincreasedsales
weredrivenbystronggrowthofBiosenseWebsterproductsinallregions.
TheDiabetesCarefranchisesaleswere$2.1billion,adecreaseof7.2%versustheprioryear.IntheU.S.,lowerprices
werepartiallyoffsetbyvolumegrowth.
TheDiagnosticsfranchisesaleswere$1.0billion,adeclineof49.0%versustheprioryear.Thedeclinewasduetothe
divestitureoftheOrtho-ClinicalDiagnosticsbusiness(theDiagnosticsfranchise)toTheCarlyleGrouponJune30,2014.
MedicalDevicessegmentsalesin2013were$28.5billion,representinganincreaseof3.9%overtheprioryear,with
operationalgrowthof6.1%andanegativecurrencyimpactof2.2%.U.S.saleswere$12.8billion,anincreaseof3.5%as
comparedtotheprioryear.Internationalsaleswere$15.7billion,anincreaseof4.2%overtheprioryear,withoperational
Johnson&Johnson2014AnnualReport • 7growthof8.3%andanegativecurrencyimpactof4.1%.TheacquisitionofSynthes,Inc.,netoftherelatedtrauma
businessdivestiture,increasedbothtotalsalesgrowthandoperationalgrowthfortheMedicalDevicessegmentby6.0%
and7.9%in2013and2012,respectively.
Analysis of Consolidated Earnings Before Provision for Taxes on
Income
Consolidatedearningsbeforeprovisionfortaxesonincomeincreasedto$20.6billionin2014ascomparedto$15.5
billionin2013,anincreaseof32.9%.Earningsbeforeprovisionfortaxesonincomewerefavorableduetostrongsales
volumegrowth,particularlysalesofOLYSIO®/SOVRIAD®(simeprevir),positivemixfromhighersalesofhighermargin
productsinthePharmaceuticalbusiness,divestituresoflowermarginbusinessesandcostreductioneffortsacrossmany
ofthebusinesses.Additionally,2014includedhighernetgainsondivestituresof$2.3billion,primarilythedivestitureof
theOrtho-ClinicalDiagnosticsbusiness,lowerlitigationexpenseof$1.0billion,lowerin-processresearchand
developmentcostsof$0.4billionandlowerexpensesof$0.1billionrelatedtotheDePuyASR™Hipprogramas
comparedtothefiscalyear2013.ThiswaspartiallyoffsetbytheinclusionofanadditionalyearoftheBranded
PrescriptionDrugFeeof$0.2billionand$0.1billionofhigherSynthesintegration/transactioncostsin2014.Thefiscal
year2013includedanetgainof$0.4billiononequityinvestmenttransactions,primarilythesaleofElanAmerican
DepositaryShares.
Consolidatedearningsbeforeprovisionfortaxesonincomeincreasedby$1.7billionto$15.5billionin2013as
comparedto$13.8billionin2012,anincreaseof12.3%.Earningsbeforeprovisionfortaxesonincomewerefavorable
duetoincreasedgrossprofitof$3.4billionresultingfromhighersalesofhighermarginproductsandcostcontainment
initiativesanda$0.4billionnetgainonequityinvestmenttransactions,primarilyfromthesaleofElanAmericanDepositary
Shares.Thiswaspartiallyoffsetbyhigherlitigationexpensesof$1.1billionandhigherexpensesof$0.1billionrelatedto
theDePuyASR™Hipprogramascomparedto2012.Thefiscalyear2012included$1.5billionofhigherwrite-downsof
intangibleassetsandin-processresearchanddevelopmentandhighercostsof$0.3billionrelatedtotheSynthes
acquisitionpartiallyoffsetbyhighergainsof$0.8billionrelatedtodivestitures.
Asapercenttosales,consolidatedearningsbeforeprovisionfortaxesonincomein2014was27.7%versus21.7%in
2013.
CostofProductsSoldandSelling,MarketingandAdministrativeExpenses:Costofproductssoldandselling,
marketingandadministrativeexpensesasapercenttosaleswereasfollows:
%ofSales 2014 2013 2012
Costofproductssold 30.6% 31.3 32.2
Percentpoint(decrease)/increaseovertheprioryear (0.7) (0.9) 0.9
Selling,marketingandadministrativeexpenses 29.5% 30.6 31.0
Percentpoint(decrease)/increaseovertheprioryear (1.1) (0.4) (1.3)
In2014,costofproductssoldasapercenttosalesdecreasedcomparedtotheprioryear.Thiswasprimarilytheresultof
positivemixfromhighersalesofhighermarginproductsinthePharmaceuticalbusiness,divestituresoflowermargin
businessesandcostimprovementsacrossmanyofthebusinesses.Thiswaspartiallyoffsetbypricingandtheimpactof
negativetransactionalcurrency.Inaddition,2013includedaninventorystep-upchargeof$0.1billionrelatedtothe
Synthesacquisition.Intangibleassetamortizationexpenseincludedincostofproductssoldforboth2014and2013was
$1.4billion.Therewasadecreaseinthepercenttosalesofselling,marketingandadministrativeexpensesin2014
comparedtotheprioryearprimarilyduetoleveragedcostsresultingfromgrowthinthePharmaceuticalbusiness,
particularlysalesofOLYSIO®/SOVRIAD®(simeprevir),andcostcontainmentinitiativesacrossmanyofthebusinesses.
ThiswaspartiallyoffsetbytheinclusionofanadditionalyearoftheBrandedPrescriptionDrugFeeof$220millioninthe
fiscalthirdquarterof2014.
In2013,costofproductssoldasapercenttosalesdecreasedcomparedtotheprioryear.Thiswasprimarilytheresultof
positivemixresultingfromhighersalesofhighermarginproducts,lowercostsassociatedwithstrongvolumegrowthinthe
Pharmaceuticalbusinessandcostreductioneffortsacrossmanyofthebusinesses.Thedecreasewaspartiallyoffsetby
incrementalintangibleassetamortizationexpenseprimarilyrelatedtoSynthes,theMedicalDeviceExcisetaxand
increasedamortizationexpenseasaresultoftheroyaltybuyoutagreementwithVertexforINCIVO®.Intangibleasset
amortizationexpensefor2013and2012was$1.4billionand$1.1billion,respectively.Additionally,2012included$0.2
8 • Johnson&Johnson2014AnnualReportbillionhigheramortizationoftheinventorystep-upchargerelatedtotheSynthes,Inc.acquisition.Therewasadecreasein
thepercenttosalesofselling,marketingandadministrativeexpensesin2013comparedtotheprioryearprimarilydueto
costcontainmentinitiativesacrossmanyofthebusinesses.
ResearchandDevelopmentExpense:Researchanddevelopmentexpensebysegmentofbusinesswasasfollows:
2014 2013 2012
(DollarsinMillions) Amount %ofSales* Amount %ofSales* Amount %ofSales*
Consumer $629 4.3% $590 4.0 622 4.3
Pharmaceutical 6,213 19.2 5,810 20.7 5,362 21.2
MedicalDevices 1,652 6.0 1,783 6.3 1,681 6.1
Totalresearchanddevelopmentexpense $8,494 11.4% 8,183 11.5 7,665 11.4
Percentincrease/(decrease)overtheprior
year 3.8% 6.8 1.6
* Asapercenttosegmentsales
ResearchanddevelopmentactivitiesrepresentasignificantpartoftheCompany’sbusiness.Theseexpendituresrelateto
theprocessesofdiscovering,testinganddevelopingnewproducts,improvingexistingproducts,aswellasensuring
productefficacyandregulatorycompliancepriortolaunch.TheCompanyremainscommittedtoinvestinginresearchand
developmentwiththeaimofdeliveringhighqualityandinnovativeproducts.In2014,worldwidecostsofresearchand
developmentactivitiesincreasedby3.8%comparedto2013.Thereductionasapercenttosaleswasprimarilydueto
strongsalesgrowthinthePharmaceuticalbusiness.ResearchspendinginthePharmaceuticalsegmentincreasedin
absolutedollarsto$6.2billionascomparedto$5.8billionprimarilyduetohigherlevelsofspendingtoadvancethe
Company’sPharmaceuticalpipeline.In2013,worldwidecostsofresearchanddevelopmentactivitiesincreasedby6.8%
comparedto2012.TheincreaseinthePharmaceuticalsegmentwasprimarilyduetohigherlevelsofspendingtoadvance
theCompany’sPharmaceuticalpipeline.
In-ProcessResearchandDevelopment(IPR&D):In2014,theCompanyrecordedchargesof$0.2billionforthe
impairmentofvariousIPR&DprojectsrelatedtoRespiVert,Crucell,MentorandSynthesforthedelayordiscontinuationof
certaindevelopmentprojects.In2013,theCompanyrecordedchargesof$0.6billionprimarilyfortheimpairmentof
variousIPR&DprojectsrelatedtoCrucell,CorImmunandAcclarentforthedelayordiscontinuationofcertaindevelopment
projects.In2012,theCompanyrecordedchargesof$1.2billion,whichincluded$0.7billionfortheimpairmentofthe
IPR&DrelatedtothediscontinuationofthePhaseIIIclinicaldevelopmentofbapineuzumabIVandthepartialimpairmentof
theIPR&DrelatedtotheCrucellvaccinebusinessintheamountof$0.4billion.Ofthe$0.7billionimpairmentofthe
IPR&DrelatedtothediscontinuationofthePhaseIIIclinicaldevelopmentofbapineuzumabIV,$0.3billionisattributableto
noncontrollinginterest.The2012chargesrelatetodevelopmentprojectswhichhavebeendiscontinuedordelayed.
Other(Income)Expense,Net:Other(income)expense,netincludesroyaltyincome;gainsandlossesrelatedtothe
saleandwrite-downofcertaininvestmentsinequitysecuritiesheldbyJohnson&JohnsonDevelopmentCorporation;
gainsorlossesondivestitures;currencygainsandlosses;andlitigationaccrualsandsettlements.Thechangeinother
(income)expense,netforthefiscalyear2014wasafavorablechangeof$2.6billionascomparedtotheprioryear.The
fiscalyear2014includedhighernetgainsondivestituresof$2.3billion,primarilythedivestitureoftheOrtho-Clinical
Diagnosticsbusiness,lowerlitigationexpenseof$1.0billionandlowercostsof$0.1billionrelatedtotheDePuyASR™
Hipprogramascomparedto2013.ThiswaspartiallyoffsetbyhigherSynthesintegration/transactioncostsof$0.2billion
andhigherintangibleassetwrite-downsof$0.1billionprimarilyrelatedtoINCIVO®(telaprevir)in2014.Additionally,the
fiscalyear2013includedahighernetgainof$0.5billionascomparedto2014onequityinvestmenttransactions,
primarilythesaleofElanAmericanDepositaryShares.
Thechangeinother(income)expense,netforthefiscalyear2013,wasanunfavorablechangeof$0.9billionas
comparedtotheprioryear.Thefiscalyear2013includedanetgainof$0.4billiononequityinvestmenttransactions,
primarilythesaleofElanAmericanDepositaryShares,offsetbyhigherlitigationexpensesof$1.1billion,higherexpenses
of$0.1billionrelatedtotheDePuyASR™Hipprogramandhighercurrencylossesof$0.1billion.Thefiscalyear2012
includedhigherwrite-downsofintangibleassetsof$0.8billion,primarilyrelatedtotheCrucellvaccinebusinessand
highercostsof$0.1billionrelatedtotheSynthesacquisition.Additionally,2012includedhighergainsof$0.8billion
relatedtodivestitures.
Interest(Income)Expense:Interestincomein2014wascomparabletotheprioryear.Ahigherbalanceincash,cash
equivalentsandmarketablesecuritieswasoffsetbylowerinterestrates.Cash,cashequivalentsandmarketablesecurities
Johnson&Johnson2014AnnualReport • 9totaled$33.1billionattheendof2014,andaveraged$31.1billionascomparedtothe$25.2billionaveragecash
balancein2013.Theincreaseintheyear-endcashbalancewasprimarilyduetocashgeneratedfromoperatingactivities.
Interestexpensein2014increasedby$51millionascomparedto2013duetoahigheraveragedebtbalance.The
averagedebtbalancewas$18.5billionin2014versus$17.2billionin2013.Thetotaldebtbalanceattheendof2014
was$18.8billionascomparedto$18.2billionattheendof2013.Thehigherdebtbalanceofapproximately$0.6billion
wasduetoincreasedborrowingsinNovember2014.TheCompanyincreasedborrowings,capitalizingonfavorableterms
inthecapitalmarkets.Theproceedsoftheborrowingswillbeusedforgeneralcorporatepurposes.
Interestincomein2013increasedby$10millionascomparedtotheprioryear.Cash,cashequivalentsandmarketable
securitiestotaled$29.2billionattheendof2013,andaveraged$25.2billionascomparedtothe$26.7billionaverage
cashbalancein2012.Theincreaseintheyearendcashbalancewasduetocashgeneratedfromoperatingactivities.
Interestexpensein2013decreasedby$50millionascomparedto2012duetoaloweraveragedebtbalance.The
averagedebtbalancewas$17.2billionin2013versus$17.9billionin2012.Thetotaldebtbalanceattheendof2013
was$18.2billionascomparedto$16.2billionattheendof2012.Thehigherdebtbalanceofapproximately$2.0billion
wasduetoincreasedborrowingsinDecember2013.TheCompanyincreasedborrowings,capitalizingonfavorableterms
inthecapitalmarkets.Theproceedsoftheborrowingswereusedforgeneralcorporatepurposes.
SegmentPre-TaxProfit
Pre-taxprofitsbysegmentofbusinesswereasfollows:
Percentof
SegmentSales
(DollarsinMillions) 2014 2013 2014 2013
Consumer $1,941 1,973 13.4% 13.4
Pharmaceutical 11,696 9,178 36.2 32.6
MedicalDevices 7,953 5,261 28.9 18.5
Total(1) 21,590 16,412 29.0 23.0
Less:Expensesnotallocatedtosegments(2) 1,027 941
Earningsbeforeprovisionfortaxesonincome $20,563 15,471 27.7% 21.7
(1) SeeNote18totheConsolidatedFinancialStatementsformoredetails.
(2) Amountsnotallocatedtosegmentsincludeinterest(income)expense,noncontrollinginterests,andgeneralcorporate(income)
expense.
ConsumerSegment:In2014,Consumersegmentpre-taxprofitasapercenttosaleswas13.4%,flattotheprioryear.
In2013,Consumersegmentpre-taxprofitasapercenttosaleswas13.4%versus11.7%in2012.Thefavorablepre-tax
profitin2013versus2012wasprimarilyduetoagainof$55milliononthesaleofintangibleandotherassetsaswellas
costcontainmentinitiatives.Includedin2012wereintangibleassetwrite-downsof$0.3billion.Inaddition,2012included
highergainsondivestituresof$0.1billion.
PharmaceuticalSegment:In2014,Pharmaceuticalsegmentpre-taxprofitasapercenttosaleswas36.2%versus
32.6%in2013.Thefavorablepre-taxprofitwasattributabletostrongsalesvolumegrowth,particularlysalesofOLYSIO®
/SOVRIAD®(simeprevir),positivesalesmixofhighermarginproductsandcostcontainmentinitiativesrealizedinselling,
marketingandadministrativeexpenses.Thiswaspartiallyoffsetby$0.2billionforanadditionalyearoftheBranded
PrescriptionDrugFeeanda$0.1billionintangibleassetwrite-downrelatedtoINCIVO®(telaprevir).Additionally,2013
includedanetgainof$0.4billiononequityinvestmenttransactions,primarilythesaleofElanAmericanDepositary
Shares,andapositiveadjustmentof$0.2billiontopreviousestimatesforManagedMedicaidrebates,partiallyoffsetby
higherwrite-downsof$0.4billionfortheimpairmentofIPR&Dascomparedto2014.In2013,Pharmaceuticalsegment
pre-taxprofitasapercenttosaleswas32.6%versus24.0%in2012.Thefavorablepre-taxprofitwasattributableto
positivesalesmixofhighermarginproducts,lowercostsassociatedwithstrongvolumegrowth,anetgainof$0.4billion
onequityinvestmenttransactions,primarilythesaleofElanAmericanDepositaryShares,apositiveadjustmentof$0.2
billiontopreviousestimatesforManagedMedicaidrebatesandcostcontainmentinitiatives.Thiswaspartiallyoffsetby
increasedamortizationexpenseasaresultoftheroyaltybuyoutagreementwithVertexforINCIVO®.Additionally,2012
includedhighernetlitigationexpenseof$0.4billionandhigherwrite-downsofintangibleassetsandin-processresearch
anddevelopmentof$0.9billion.Thiswaspartiallyoffsetbyhighergainsondivestituresof$0.3billion.
10 • Johnson&Johnson2014AnnualReportMedicalDevicesSegment:In2014,MedicalDevicessegmentpre-taxprofitasapercenttosaleswas28.9%versus
18.5%in2013.Thefavorablepre-taxprofitwasattributabletothenetgainof$1.9billiononthedivestitureofthe
Ortho-ClinicalDiagnosticsbusinessin2014andlowerlitigationexpenseof$1.1billionascomparedto2013.In2013,
MedicalDevicessegmentpre-taxprofitasapercenttosaleswas18.5%versus26.2%in2012.TheMedicalDevices
segmentpre-taxprofitwasunfavorablyimpactedbyhighercostsof$1.4billionforlitigationexpenseand$0.1billion
relatedtotheDePuyASR™HipprogramaswellastheMedicalDeviceExcisetaxascomparedto2012.Inaddition,2012
includedhighergainsof$0.4billionondivestiturespartiallyoffsetbyhigherwrite-downsofintangibleassetsand
in-processresearchanddevelopmentof$0.1billionandhighercostsof$0.1billionrelatedtotheSynthesacquisition.
ProvisionforTaxesonIncome:Theworldwideeffectiveincometaxratewas20.6%in2014,10.6%in2013and
23.7%in2012.Theincreaseinthe2014effectivetaxrate,ascomparedto2013,wasattributabletothefollowing:the
divestitureoftheOrtho-ClinicalDiagnosticsbusinessatanapproximate44%effectivetaxrate,litigationaccrualsatlow
taxrates,themixofearningsintohighertaxjurisdictions,primarilytheU.S.,theaccrualofanadditionalyearoftheBranded
PrescriptionDrugFee,whichisnottaxdeductible,andadditionalU.S.taxexpenserelatedtoaplannedincreasein
dividendsfromcurrentyearforeignearningsascomparedtotheprioryear.Theseincreasestothe2014effectivetaxrate
werepartiallyoffsetbyataxbenefitof$0.4billionassociatedwiththeConorMedsystemsdivestiture.
The2013effectivetaxratewasreducedbyataxbenefitassociatedwiththewrite-offofassetsfortaxpurposes
associatedwithScios,Inc.,andtheinclusionofboththe2013and2012benefitfromtheResearchandDevelopmenttax
creditandtheControlledForeignCorporationlook-throughprovisions,becausethoseprovisionswereenactedintolawin
January2013andwereretroactivetoJanuary1,2012.
The2014effectivetaxratewasalsoreducedastheCompanyadjusteditsunrecognizedtaxbenefitsasaresultof(i)the
federalappealscourt’sdecisioninOMJPharmaceuticals,Inc.’slitigationregardingcreditsunderformerSection936of
theInternalRevenueCode(seeNote21totheConsolidatedFinancialStatementsforadditionalinformation),and(ii)a
settlementofsubstantiallyallissuesrelatedtotheCompany’sU.S.InternalRevenueServiceauditoftaxyears2006-
2009.
NoncontrollingInterest:In2012,achargeof$0.7billionwasrecordedfortheimpairmentoftheIPR&Drelatedtothe
discontinuationofthePhaseIIIclinicaldevelopmentofbapineuzumabIV.Ofthe$0.7billionimpairment,$0.3billionwas
attributabletononcontrollinginterest.
Liquidity and Capital Resources
Liquidity&CashFlows
Cashandcashequivalentswere$14.5billionattheendof2014ascomparedwith$20.9billionattheendof2013.The
primarysourcesandusesofcashthatcontributedtothe$6.4billiondecreaseversustheprioryearwereapproximately
$18.5billionofcashgeneratedfromoperatingactivitiesoffsetby$12.3billionnetcashusedbyinvestingactivitiesand
$12.3billionnetcashusedbyfinancingactivities.SeeNote1totheConsolidatedFinancialStatementsforadditional
detailsoncash.Inaddition,theCompanyhad$18.6billioninmarketablesecuritiesattheendof2014and$8.3billionat
theendof2013.
Cashflowfromoperationsof$18.5billionwastheresultof$16.3billionofnetearningsand$5.2billionofnon-cash
chargesandotheradjustmentsfordepreciationandamortization,stock-basedcompensation,assetwrite-downs,
Venezuelaadjustmentsand$1.8billionrelatedtodeferredtaxes,accountspayableandaccruedliabilitiesandcurrentand
non-currentassets.Cashflowfromoperationswasreducedby$4.8billionrelatedtocurrentandnon-currentliabilities,
inventories,accountsreceivableandnetgainsonsaleofassets/businesses.
Investingactivitiesuseof$12.3billionwasprimarilyfornetpurchasesofinvestmentsinmarketablesecuritiesof$10.8
billion,additionstoproperty,plantandequipmentof$3.7billion,acquisitions,netofcashacquiredof$2.1billionand
other,primarilyintangiblesof$0.3billion,partiallyoffsetby$4.6billionofproceedsfromthedisposalofassets/
businesses.
Financingactivitiesuseof$12.3billionwasprimarilyfordividendstoshareholdersof$7.8billionand$7.1billionforthe
repurchaseofcommonstock.Financingactivitiesalsoincludedasourceof$0.8billionfromnetproceedsofshortand
long-termdebtand$1.8billionofnetproceedsfromstockoptionsexercisedandassociatedtaxbenefits.
OnJuly21,2014,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,authorizing
theCompanytopurchaseupto$5.0billionoftheCompany’ssharesofcommonstock.AsofDecember28,2014,$3.5
Johnson&Johnson2014AnnualReport • 11billionhasbeenrepurchasedundertheprogram.Sharerepurchaseswilltakeplaceontheopenmarketfromtimetotime
basedonmarketconditions.Therepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinued
atanytime.Anysharesacquiredwillbeavailableforgeneralcorporatepurposes.TheCompanyintendstofinancethe
sharerepurchaseprogramthroughavailablecash.
In2014,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.Foradditionaldetails
onborrowings,seeNote7totheConsolidatedFinancialStatements.
TheCompanyanticipatesthatoperatingcashflows,existingcreditfacilitiesandaccesstothecommercialpapermarkets
willprovidesufficientresourcestofundoperatingneedsin2015.
ConcentrationofCreditRisk
Globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge
numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimits.EconomicchallengesinItaly,
Spain,GreeceandPortugal(theSouthernEuropeanRegion)haveimpactedcertainpaymentpatterns,whichhave
historicallybeenlongerthanthoseexperiencedintheU.S.andotherinternationalmarkets.Thetotalnettradeaccounts
receivablebalanceintheSouthernEuropeanRegionwasapproximately$1.8billionasofDecember28,2014and$2.3
billionasofDecember29,2013.Approximately$1.1billionasofDecember28,2014andapproximately$1.3billionasof
December29,2013oftheSouthernEuropeanRegionnettradeaccountsreceivablebalancerelatedtotheCompany’s
Consumer,VisionCareandDiabetesCarebusinessesaswellascertainPharmaceuticalandMedicalDevicescustomers
whichareinlinewithhistoricalcollectionpatterns.
TheremainingbalanceofnettradeaccountsreceivableintheSouthernEuropeanRegionhasbeennegativelyimpacted
bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain
distributorsofthePharmaceuticalandMedicalDeviceslocalaffiliates.Thetotalnettradeaccountsreceivablebalancefor
thesecustomerswereapproximately$0.7billionatDecember28,2014and$1.0billionatDecember29,2013.The
Companycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentpremiums.Forcustomers
wherepaymentisexpectedoverperiodsoftimelongerthanoneyear,revenueandtradereceivableshavebeen
discountedovertheestimatedperiodoftimeforcollection.Allowancesfordoubtfulaccountshavebeenincreasedfor
thesecustomers,buthavebeenimmaterialtodate.TheCompanywillcontinuetoworkcloselywiththesecustomerson
paymentplans,monitortheeconomicsituationandtakeappropriateactionsasnecessary.
FinancingandMarketRisk
TheCompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows.
Accordingly,theCompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency
assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcosts.Gainsorlosses
onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactions.A10%appreciationoftheU.S.Dollar
fromtheDecember28,2014marketrateswouldincreasetheunrealizedvalueoftheCompany’sforwardcontractsby
$31million.Conversely,a10%depreciationoftheU.S.DollarfromtheDecember28,2014marketrateswoulddecrease
theunrealizedvalueoftheCompany’sforwardcontractsby$38million.Ineitherscenario,thegainorlossontheforward
contractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhavenoimpactonfuture
anticipatedearningsandcashflows.
TheCompanyhedgestheexposuretofluctuationsincurrencyexchangerates,andtheeffectoncertainassetsand
liabilitiesinforeigncurrency,byenteringintocurrencyswapcontracts.A1%changeinthespreadbetweenU.S.and
foreigninterestratesontheCompany’sinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe
unrealizedvalueoftheCompany’sswapcontractsbyapproximately$145million.Ineitherscenario,atmaturity,thegainor
lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransaction,andtherefore,wouldhaveno
impactonfutureanticipatedcashflows.
TheCompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposes.Further,theCompanyhasa
policyofonlyenteringintocontractswithpartiesthathaveatleastan“A”(orequivalent)creditrating.Thecounter-parties
tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone
counter-party.Managementbelievestheriskoflossisremote.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2014,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember17,2015.Interestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids
providedbybanks,theprimerateorLondonInterbankOfferedRates(LIBOR),plusapplicablemargins.Commitmentfees
undertheagreementarenotmaterial.
12 • Johnson&Johnson2014AnnualReportTotalborrowingsattheendof2014and2013were$18.8billionand$18.2billion,respectively.Theincreasein
borrowingsbetween2014and2013wasaresultoffinancingforgeneralcorporatepurposes.In2014,netcash(cash
andcurrentmarketablesecurities,netofdebt)was$14.3billioncomparedtonetcashof$11.0billionin2013.Totaldebt
represented21.2%oftotalcapital(shareholders’equityandtotaldebt)in2014and19.7%oftotalcapitalin2013.
Shareholders’equitypershareattheendof2014was$25.06comparedto$26.25atyear-end2013,adecreaseof
4.5%.
AsummaryofborrowingscanbefoundinNote7totheConsolidatedFinancialStatements.
ContractualObligationsandCommitments
TheCompany’scontractualobligationsareprimarilyforleases,debtandunfundedretirementplans.Therearenoother
significantobligations.Tosatisfytheseobligations,theCompanywillusecashfromoperations.Thefollowingtable
summarizestheCompany’scontractualobligationsandtheiraggregatematuritiesasofDecember28,2014(seeNotes7,
10and16totheConsolidatedFinancialStatementsforfurtherdetails):
Long-Term Intereston Unfunded
Debt Debt Retirement Operating
(DollarsinMillions) Obligations Obligations Plans Leases Total
2015 $7 603 74 200 884
2016 2,152 597 75 157 2,981
2017 1,722 557 78 111 2,468
2018 1,496 493 84 80 2,153
2019 1,713 448 89 66 2,316
After2019 8,039 4,679 531 77 13,326
Total $15,129 7,377 931 691 24,128
Fortaxmatters,seeNote8totheConsolidatedFinancialStatements.
Dividends
TheCompanyincreaseditsdividendin2014forthe52ndconsecutiveyear.Cashdividendspaidwere$2.76persharein
2014comparedwithdividendsof$2.59persharein2013,and$2.40persharein2012.Thedividendsweredistributed
asfollows:
2014 2013 2012
Firstquarter $0.66 0.61 0.57
Secondquarter 0.70 0.66 0.61
Thirdquarter 0.70 0.66 0.61
Fourthquarter 0.70 0.66 0.61
Total $2.76 2.59 2.40
OnJanuary5,2015,theBoardofDirectorsdeclaredaregularquarterlycashdividendof$0.70pershare,payableon
March10,2015,toshareholdersofrecordasofFebruary24,2015.TheCompanyexpectstocontinuethepracticeof
payingregularcashdividends.
Other Information
CriticalAccountingPoliciesandEstimates
Management’sdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedontheCompany’s
consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin
theU.S.(GAAP).Thepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand
Johnson&Johnson2014AnnualReport • 13assumptionsthataffecttheamountsreportedforrevenues,expenses,assets,liabilitiesandotherrelateddisclosures.
Actualresultsmayormaynotdifferfromtheseestimates.TheCompanybelievesthattheunderstandingofcertainkey
accountingpoliciesandestimatesareessentialinachievingmoreinsightintotheCompany’soperatingresultsand
financialcondition.Thesekeyaccountingpoliciesincluderevenuerecognition,incometaxes,legalandself-insurance
contingencies,valuationoflong-livedassets,assumptionsusedtodeterminetheamountsrecordedforpensionsandother
employeebenefitplansandaccountingforstockbasedawards.
RevenueRecognition:TheCompanyrecognizesrevenuefromproductsaleswhengoodsareshippedordelivered,and
titleandriskoflosspasstothecustomer.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,
productreturnsanddiscountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsales
arerecorded.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingpriceschargedbycompetitors.Rebates,whichincludetheMedicaidrebateprovision,
areestimatedbasedoncontractualterms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarket
conditionsinthevariousmarketsserved.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproducts
primarilythroughtheanalysisofwholesalerandotherthird-partysell-throughandmarketresearchdata,aswellas
internallygeneratedinformation.
Salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibitunusual
salesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas
partoftheaccountingforsalesreturnaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa
percenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescreditto
customersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewiththe
U.S.GAAPguidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsales
value.SalesreturnsintheConsumerandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Salesreturnsfor
certainfranchisesintheMedicalDevicessegmentaretypicallyresalablebutarenotmaterial.TheCompanyinfrequently
exchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhasbeen
approximately1.0%ofannualnettradesalesduringthefiscalreportingyears2014,2013and2012.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
yearincurred.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentiveprograms.The
redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.Volume-based
incentiveprogramsarebasedonestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsaresold.
TheCompanyalsoearnsservicerevenueforco-promotionofcertainproducts.Forallyearspresented,servicerevenues
werelessthan2%oftotalrevenuesandareincludedinsalestocustomers.Thesearrangementsareevaluatedto
determinetheappropriateamountstobedeferred.
Inaddition,theCompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities.
Amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered,
basedontherelativefairvalue.Upfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedoverthe
performanceperiod.SeeNote1totheConsolidatedFinancialStatementsforadditionaldisclosuresoncollaborations.
Reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebates,returnsandpromotionsarenot
anticipatedtohaveamaterialeffectonthefinancialstatements.TheCompanycurrentlydisclosestheimpactofchanges
toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact.
14 • Johnson&Johnson2014AnnualReportBelowaretablesthatshowtheprogressionofaccruedrebates,returns,promotions,reservefordoubtfulaccountsand
reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendedDecember28,2014andDecember29,2013.
ConsumerSegment
Balanceat Balanceat
Beginningof Payments/ Endof
(DollarsinMillions) Period Accruals Credits Period
2014
Accruedrebates(1) $137 619 (634) 122
Accruedreturns 80 102 (105) 77
Accruedpromotions 321 1,850 (1,930) 241
Subtotal $538 2,571 (2,669) 440
Reservefordoubtfulaccounts 25 5 (12) 18
Reserveforcashdiscounts 24 215 (217) 22
Total $587 2,791 (2,898) 480
2013
Accruedrebates(1) $132 524 (519) 137
Accruedreturns 108 94 (122) 80
Accruedpromotions 281 1,478 (1,438) 321
Subtotal $521 2,096 (2,079) 538
Reservefordoubtfulaccounts 38 8 (21) 25
Reserveforcashdiscounts 21 232 (229) 24
Total $580 2,336 (2,329) 587
(1) Includesreserveforcustomerrebatesof$37millionatDecember28,2014and$32millionatDecember29,2013,recordedasa
contraasset.
Pharmaceutical Segment
Balanceat Balanceat
Beginningof Payments/ Endof
(DollarsinMillions) Period Accruals Credits Period
2014
Accruedrebates(1) $1,985 7,652 (6,920) 2,717
Accruedreturns 372 83 (33) 422
Accruedpromotions 96 34 (96) 34
Subtotal $2,453 7,769 (7,049) 3,173
Reservefordoubtfulaccounts 95 4 (58) 41
Reserveforcashdiscounts 61 576 (586) 51
Total $2,609 8,349 (7,693) 3,265
2013
Accruedrebates(1) $1,767 5,774 (5,556) 1,985
Accruedreturns 397 30 (55) 372
Accruedpromotions 94 89 (87) 96
Subtotal $2,258 5,893 (5,698) 2,453
Reservefordoubtfulaccounts 191 26 (122) 95
Reserveforcashdiscounts 62 471 (472) 61
Total $2,511 6,390 (6,292) 2,609
(1) Includesreserveforcustomerrebatesof$297millionatDecember28,2014and$295millionatDecember29,2013,recordedasa
contraasset.
Johnson&Johnson2014AnnualReport • 15MedicalDevicesSegment
Balanceat Balanceat
Beginningof Payments/ Endof
(DollarsinMillions) Period Accruals Credits Period
2014
Accruedrebates(1) $801 4,663 (4,620) 844
Accruedreturns 180 395 (387) 188
Accruedpromotions 66 35 (48) 53
Subtotal $1,047 5,093 (5,055) 1,085
Reservefordoubtfulaccounts 213 62 (59) 216
Reserveforcashdiscounts 18 815 (817) 16
Total $1,278 5,970 (5,931) 1,317
2013
Accruedrebates(1) $567 4,261 (4,027) 801
Accruedreturns 205 356 (381) 180
Accruedpromotions 60 52 (46) 66
Subtotal $832 4,669 (4,454) 1,047
Reservefordoubtfulaccounts 237 19 (43) 213
Reserveforcashdiscounts 22 394 (398) 18
Total $1,091 5,082 (4,895) 1,278
(1) Includesreserveforcustomerrebatesof$354millionatDecember28,2014and$403millionatDecember29,2013,recordedasa
contraasset.
IncomeTaxes:Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe
resultsofanydifferencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.
TheCompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesin
taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAP,which
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
AtDecember28,2014andDecember29,2013,thecumulativeamountsofundistributedinternationalearningswere
approximately$53.4billionand$50.9billion,respectively.AtDecember28,2014andDecember29,2013,the
Company’sforeignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsof$14.3billionand$18.6
billion,respectively.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational
subsidiarieswheretheearningsareconsideredtobepermanentlyreinvested.TheCompanyintendstocontinueto
reinvesttheseearningsininternationaloperations.IftheCompanydecidedatalaterdatetorepatriatetheseearningsto
theU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectsontheseamounts.TheCompanydoesnot
determinethedeferredtaxliabilityassociatedwiththeseundistributedearnings,assuchdeterminationisnotpractical.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
LegalandSelfInsuranceContingencies:TheCompanyrecordsaccrualsforvariouscontingencies,includinglegal
proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusiness.Theaccrualsarebasedon
management’sjudgmentastotheprobabilityoflossesand,whereapplicable,actuariallydeterminedestimates.The
Companyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.Inadditiontoaccrualsintheself
insuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe
reasonablyestimated.Additionally,theCompanyrecordsinsurancereceivableamountsfromthird-partyinsurerswhen
recoveryisprobable.Asappropriate,reservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynot
becollectedfromthird-partyinsurers.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
16 • Johnson&Johnson2014AnnualReportLong-LivedandIntangibleAssets:TheCompanyassesseschangesineconomicconditionsandmakesassumptions
regardingestimatedfuturecashflowsinevaluatingthevalueoftheCompany’sproperty,plantandequipment,goodwill
andintangibleassets.Astheseassumptionsandestimatesmaychangeovertime,itmayormaynotbenecessaryforthe
Companytorecordimpairmentcharges.
EmployeeBenefitPlans:TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,
definedcontributionandterminationindemnityplans,whichcovermostemployeesworldwide.Theseplansarebasedon
assumptionsforthediscountrate,expectedreturnonplanassets,mortalityrates,expectedsalaryincreasesandhealth
carecosttrendrates.SeeNote10totheConsolidatedFinancialStatementsforfurtherdetailsontheseratesandthe
effectaratechangetothehealthcarecosttrendwouldhaveontheCompany’sresultsofoperations.
StockBasedCompensation:TheCompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity
instrumentstoemployeesfortheirservices.Basedonthetypeofequityinstrument,thefairvalueisestimatedonthedate
ofgrantusingeithertheBlack-ScholesoptionvaluationmodeloracombinationofboththeBlack-Scholesoption
valuationmodelandMonteCarlovaluationmodel,andisexpensedinthefinancialstatementsoverthevestingperiod.The
inputassumptionsusedindeterminingfairvaluearetheexpectedlife,expectedvolatility,risk-freerateandthedividend
yield.SeeNote17totheConsolidatedFinancialStatementsforadditionalinformation.
NewAccountingPronouncements
RefertoNote1totheConsolidatedFinancialStatementsforrecentlyadoptedaccountingpronouncementsandrecently
issuedaccountingpronouncementsnotyetadoptedasofDecember28,2014.
EconomicandMarketFactors
TheCompanyisawarethatitsproductsareusedinanenvironmentwhere,formorethanadecade,policymakers,
consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcare.Inresponsetotheseconcerns,
theCompanyhasalong-standingpolicyofpricingproductsresponsibly.Fortheperiod2004-2014,intheUnitedStates,
theweightedaveragecompoundannualgrowthrateoftheCompany’snetpriceincreasesforhealthcareproducts
(prescriptionandover-the-counterdrugs,hospitalandprofessionalproducts)wasbelowtheU.S.ConsumerPriceIndex
(CPI).
TheCompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallenges.The
Companycontinuestomonitorthesesituationsandtakeappropriateactions.Inflationratescontinuetohaveaneffecton
worldwideeconomiesand,consequently,onthewaycompaniesoperate.TheCompanyhasaccountedforoperationsin
Venezuelaashighlyinflationaryasthepriorthree-yearcumulativeinflationratesurpassed100%.Inthefaceofincreasing
costs,theCompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms,productivityimprovementsand
periodicpriceincreases.
TheVenezuelangovernmenthasestablishedorisintheprocessofestablishingalternativesystemsandofferingsof
variousforeigncurrencyexchanges.In2014,theCompanycontinuedtohaveaccesstoanofficialgovernmentrateof6.3
BolivaresFuertestooneU.S.dollartosettleimportsofvariousproductsintoVenezuela.Throughthefourthquarterof
2014,theCompanyhasprimarilyutilizedtheofficialgovernmentrateof6.3BolivaresFuertestooneU.S.dollarin
preparingitsfinancialstatements.Duringthesecondfiscalquarter,theCompanyappliedtosettleanoutstandingdividend
payableatoneofthealternativeforeignexchangerates.Asaresult,theCompanyhasappliedthisalternativeexchange
ratetotranslatecertaintransactions,asappropriate.AsofDecember28,2014,theCompany’sVenezuelansubsidiaries
representedlessthan0.5%oftheCompany’sconsolidatedassets,liabilities,revenuesandprofits;therefore,theeffectof
achangeintheexchangerateisnotexpectedtohaveamaterialadverseeffectontheCompany’s2015full-yearresults.
TheCompanyisexposedtofluctuationsincurrencyexchangerates.A1%changeinthevalueoftheU.S.Dollaras
comparedtoallforeigncurrenciesinwhichtheCompanyhadsales,incomeorexpensein2014wouldhaveincreasedor
decreasedthetranslationofforeignsalesbyapproximately$390millionandincomeby$100million.
TheCompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude
healthcarecostcontainmentandgovernmentlegislationrelatingtosales,promotionsandreimbursementofhealthcare
products.
Changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservices,includingdelaying
medicalprocedures,rationingprescriptionmedications,reducingthefrequencyofphysicianvisitsandforegoinghealth
careinsurancecoverage,asaresultofthecurrentglobaleconomicdownturn,maycontinuetoimpacttheCompany’s
businesses.
Johnson&Johnson2014AnnualReport • 17TheCompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrights.Firmshavefiled
AbbreviatedNewDrugApplicationsorBiosimilarBiologicalProductApplicationswiththeFDAorotherwisechallenged
thecoverageand/orvalidityoftheCompany’spatents,seekingtomarketgenericorbiosimilarformsofmanyofthe
Company’skeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproducts.Intheevent
theCompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuits,genericorbiosimilar
versionsoftheproductsatissuewillbeintroducedtothemarket,resultinginthepotentialforsubstantialmarketshareand
revenuelossesforthoseproducts,andwhichmayresultinanon-cashimpairmentchargeinanyassociatedintangible
asset.Forfurtherinformation,seethediscussionon“REMICADE®RelatedCases”and“LitigationAgainstFilersof
AbbreviatedNewDrugApplications”inNote21totheConsolidatedFinancialStatements.
LegalProceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercialandothermatters;governmentalinvestigations;andotherlegalproceedingsthatarise
fromtimetotimeintheordinarycourseofbusiness.
TheCompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount
ofthelosscanbereasonablyestimated.TheCompanyhasaccruedforcertainlitigationmattersandcontinuestomonitor
eachrelatedlegalissueandadjustaccrualsfornewinformationandfurtherdevelopmentsinaccordancewithAccounting
StandardsCodification(ASC)450-20-25.Fortheseandotherlitigationandregulatorymatterscurrentlydisclosedfor
whichalossisprobableorreasonablypossible,theCompanyisunabletodetermineanestimateofthepossiblelossor
rangeoflossbeyondtheamountsalreadyaccrued.Thesematterscanbeaffectedbyvariousfactors,includingwhether
damagessoughtintheproceedingsareunsubstantiatedorindeterminate;scientificandlegaldiscoveryhasnot
commencedorisnotcomplete;proceedingsareinearlystages;matterspresentlegaluncertainties;therearesignificant
factsindispute;ortherearenumerouspartiesinvolved.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutioninanyreportingperiodofone
ormoreofthesematters,eitheraloneorintheaggregate,mayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
SeeNote21totheConsolidatedFinancialStatementsforfurtherinformationregardinglegalproceedings.
CommonStockMarketPrices
TheCompany’sCommonStockislistedontheNewYorkStockExchangeunderthesymbolJNJ.AsofFebruary17,
2015,therewere162,062recordholdersofCommonStockoftheCompany.Thecompositemarketpricerangesfor
Johnson&JohnsonCommonStockduring2014and2013were:
2014 2013
High Low High Low
Firstquarter $98.47 86.09 81.59 69.18
Secondquarter 105.97 96.05 89.99 80.31
Thirdquarter 108.77 98.80 94.42 85.50
Fourthquarter 109.49 95.10 95.99 85.50
Year-endclose $105.06 92.35
18 • Johnson&Johnson2014AnnualReportCautionary Factors That May Affect Future Results
ThisAnnualReportcontainsforward-lookingstatements.Forward-lookingstatementsdonotrelatestrictlytohistoricalor
currentfactsandanticipateresultsbasedonmanagement’splansthataresubjecttouncertainty.Forward-looking
statementsmaybeidentifiedbytheuseofwordssuchas“plans,”“expects,”“will,”“anticipates,”“estimates”andother
wordsofsimilarmeaninginconjunctionwith,amongotherthings,discussionsoffutureoperations,financialperformance,
theCompany’sstrategyforgrowth,productdevelopment,regulatoryapproval,marketpositionandexpenditures.
Forward-lookingstatementsarebasedoncurrentexpectationsoffutureevents.TheCompanycannotguaranteethatany
forward-lookingstatementwillbeaccurate,althoughtheCompanybelievesthatithasbeenreasonableinitsexpectations
andassumptions.Investorsshouldrealizethatifunderlyingassumptionsproveinaccurateorthatknownorunknownrisks
oruncertaintiesmaterialize,actualresultscouldvarymateriallyfromtheCompany’sexpectationsandprojections.Investors
arethereforecautionednottoplaceunduerelianceonanyforward-lookingstatements.TheCompanydoesnotundertake
toupdateanyforward-lookingstatementsasaresultofnewinformationorfutureeventsordevelopments.
Risksanduncertaintiesinclude,butarenotlimitedto:economicfactors,suchasinterestrateandcurrencyexchangerate
fluctuations;competition,includingtechnologicaladvances,newproductsandpatentsattainedbycompetitors;
challengesinherentinnewproductdevelopment,includingobtainingregulatoryapprovals;challengestopatents;the
impactofpatentexpirations;uncertaintyofcommercialsuccessofnewandexistingproducts;significantadverselitigation
orgovernmentaction,includingrelatedtoproductliabilityclaims;impactofbusinesscombinationsanddivestitures;
significantchangesincustomerrelationshipsorchangesinbehaviorandspendingpatternsorfinancialdistressof
purchasersofhealthcareproductsandservices;changestolawsandregulationsandglobalhealthcarereforms;trends
towardhealthcarecostcontainment;increasedscrutinyofthehealthcareindustrybygovernmentagencies;financial
instabilityofinternationaleconomiesandsovereignrisk;manufacturingdifficultiesordelays;complexglobalsupplychains
withincreasingregulatoryrequirements;productefficacyorsafetyconcernsresultinginproductrecallsorregulatory
action;disruptionsduetonaturaldisasters;andthepotentialfailuretomeetobligationsincomplianceagreementswith
governmentbodies.
Adiscussionoftheseandotherfactorsthatcouldcauseactualresultstodiffermateriallyfromexpectationscanbefound
inthisAnnualReportonForm10-KforthefiscalyearendedDecember28,2014,includinginExhibit99.TheCompany
notesthesefactorsaspermittedbythePrivateSecuritiesLitigationReformActof1995.
Johnson&Johnson2014AnnualReport • 19JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AtDecember28,2014andDecember29,2013
(DollarsinMillionsExceptShareandPerShareAmounts)(Note1)
2014 2013
Assets
Currentassets
Cashandcashequivalents(Notes1and2) $14,523 20,927
Marketablesecurities(Notes1and2) 18,566 8,279
Accountsreceivabletrade,lessallowancesfordoubtfulaccounts$275(2013,$333) 10,985 11,713
Inventories(Notes1and3) 8,184 7,878
Deferredtaxesonincome(Note8) 3,567 3,607
Prepaidexpensesandotherreceivables 3,486 4,003
Totalcurrentassets 59,311 56,407
Property,plantandequipment,net(Notes1and4) 16,126 16,710
Intangibleassets,net(Notes1and5) 27,222 27,947
Goodwill(Notes1and5) 21,832 22,798
Deferredtaxesonincome(Note8) 3,396 3,872
Otherassets 3,232 4,949
Totalassets $131,119 132,683
LiabilitiesandShareholders’Equity
Currentliabilities
Loansandnotespayable(Note7) $3,638 4,852
Accountspayable 7,633 6,266
Accruedliabilities 6,553 7,685
Accruedrebates,returnsandpromotions 4,010 3,308
Accruedcompensationandemployeerelatedobligations 2,751 2,794
Accruedtaxesonincome 500 770
Totalcurrentliabilities 25,085 25,675
Long-termdebt(Note7) 15,122 13,328
Deferredtaxesonincome(Note8) 3,154 3,989
Employeerelatedobligations(Notes9and10) 9,972 7,784
Otherliabilities 8,034 7,854
Totalliabilities 61,367 58,630
Shareholders’equity
Preferredstock–withoutparvalue(authorizedandunissued2,000,000shares) – –
Commonstock–parvalue$1.00pershare(Note12)(authorized4,320,000,000shares;issued
3,119,843,000shares) 3,120 3,120
Accumulatedothercomprehensiveincome(Note13) (10,722) (2,860)
Retainedearnings 97,245 89,493
89,643 89,753
Less:commonstockheldintreasury,atcost(Note12)(336,620,000sharesand299,215,000shares) 19,891 15,700
Totalshareholders’equity 69,752 74,053
Totalliabilitiesandshareholders’equity $131,119 132,683
SeeNotestoConsolidatedFinancialStatements
20 • Johnson&Johnson2014AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(DollarsandSharesinMillionsExceptPerShareAmounts)(Note1)
2014 2013 2012
Salestocustomers $74,331 71,312 67,224
Costofproductssold 22,746 22,342 21,658
Grossprofit 51,585 48,970 45,566
Selling,marketingandadministrativeexpenses 21,954 21,830 20,869
Researchanddevelopmentexpense 8,494 8,183 7,665
In-processresearchanddevelopment 178 580 1,163
Interestincome (67) (74) (64)
Interestexpense,netofportioncapitalized(Note4) 533 482 532
Other(income)expense,net (70) 2,498 1,626
Earningsbeforeprovisionfortaxesonincome 20,563 15,471 13,775
Provisionfortaxesonincome(Note8) 4,240 1,640 3,261
Netearnings 16,323 13,831 10,514
Add:Netlossattributabletononcontrollinginterest – – 339
NetearningsattributabletoJohnson&Johnson $16,323 13,831 10,853
NetearningspershareattributabletoJohnson&Johnson(Notes1and15)
Basic $5.80 4.92 3.94
Diluted $5.70 4.81 3.86
Cashdividendspershare $2.76 2.59 2.40
Averagesharesoutstanding(Notes1and15)
Basic 2,815.2 2,809.2 2,753.3
Diluted 2,863.9 2,877.0 2,812.6
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2014AnnualReport • 21JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(DollarsinMillions)(Note1)
2014 2013 2012
Netearnings $16,323 13,831 10,514
Othercomprehensiveincome(loss),netoftax
Foreigncurrencytranslation (4,601) 94 1,230
Securities:
Unrealizedholdinggain(loss)arisingduringperiod 156 225 (248)
Reclassificationstoearnings (5) (314) (5)
Netchange 151 (89) (253)
Employeebenefitplans:
Priorservicecostamortizationduringperiod (18) 9 2
Priorservicecredit(cost)–currentyear 211 (27) (8)
Gainamortizationduringperiod 400 515 370
Gain(loss)–currentyear (4,098) 2,203 (1,643)
Effectofexchangerates 197 8 (52)
Netchange (3,308) 2,708 (1,331)
Derivatives&hedges:
Unrealizedgain(loss)arisingduringperiod 92 344 52
Reclassificationstoearnings (196) (107) 124
Netchange (104) 237 176
Othercomprehensiveincome(loss) (7,862) 2,950 (178)
Comprehensiveincome 8,461 16,781 10,336
Comprehensivelossattributabletononcontrollinginterest,netoftax – – 339
ComprehensiveincomeattributabletoJohnson&Johnson $8,461 16,781 10,675
Thetaxeffectsinothercomprehensiveincomeforthefiscalyearsended2014,2013and2012respectively:Securities;
$81million,$48millionand$136million,EmployeeBenefitPlans;$1,556million,$1,421millionand$653million,
Derivatives&Hedges;$56million,$128millionand$95million.
SeeNotestoConsolidatedFinancialStatements
22 • Johnson&Johnson2014AnnualReportJOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(DollarsinMillions)(Note1)
Accumulated
Other Treasury
Retained Comprehensive CommonStock Stock
Total Earnings Income IssuedAmount Amount
Balance,January1,2012 $57,080 81,251 (5,632) 3,120 (21,659)
NetearningsattributabletoJohnson&Johnson 10,853 10,853
Cashdividendspaid (6,614) (6,614)
Employeecompensationandstockoptionplans 3,269 19 3,250
Issuanceofcommonstockassociatedwiththe
acquisitionofSynthes,Inc. 13,335 483 12,852
Repurchaseofcommonstock(1) (12,919) (12,919)
Othercomprehensiveincome(loss),netoftax (178) (178)
Balance,December30,2012 64,826 85,992 (5,810) 3,120 (18,476)
NetearningsattributabletoJohnson&Johnson 13,831 13,831
Cashdividendspaid (7,286) (7,286)
Employeecompensationandstockoptionplans 3,285 (82) 3,367
Repurchaseofcommonstock (3,538) (2,947) (591)
Other (15) (15)
Othercomprehensiveincome(loss),netoftax 2,950 2,950
Balance,December29,2013 74,053 89,493 (2,860) 3,120 (15,700)
NetearningsattributabletoJohnson&Johnson 16,323 16,323
Cashdividendspaid (7,768) (7,768)
Employeecompensationandstockoptionplans 2,164 (769) 2,933
Repurchaseofcommonstock (7,124) (7,124)
Other (34) (34)
Othercomprehensiveincome(loss),netoftax (7,862) (7,862)
Balance,December28,2014 $69,752 97,245 (10,722) 3,120 (19,891)
(1) IncludesrepurchaseofcommonstockassociatedwiththeacquisitionofSynthes,Inc.
SeeNotestoConsolidatedFinancialStatements
Johnson&Johnson2014AnnualReport • 23JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(DollarsinMillions)(Note1)
2014 2013 2012
Cashflowsfromoperatingactivities
Netearnings $16,323 13,831 10,514
Adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities:
Depreciationandamortizationofpropertyandintangibles 3,895 4,104 3,666
Stockbasedcompensation 792 728 662
Noncontrollinginterest – – 339
Venezuelaadjustments 87 108 –
Assetwrite-downs 410 739 2,131
Netgainonsaleofassets/businesses (2,383) (113) (908)
Netgainonequityinvestmenttransactions – (417) –
Deferredtaxprovision 441 (607) (39)
Accountsreceivableallowances (28) (131) 92
Changesinassetsandliabilities,netofeffectsfromacquisitionsanddivestitures:
Increaseinaccountsreceivable (247) (632) (9)
Increaseininventories (1,120) (622) (1)
Increaseinaccountspayableandaccruedliabilities 955 1,821 2,768
Decrease/(Increase)inothercurrentandnon-currentassets 442 (1,693) (1,264)
(Decrease)/Increaseinothercurrentandnon-currentliabilities (1,096) 298 (2,555)
Netcashflowsfromoperatingactivities 18,471 17,414 15,396
Cashflowsfrominvestingactivities
Additionstoproperty,plantandequipment (3,714) (3,595) (2,934)
Proceedsfromthedisposalofassets/businesses,net 4,631 458 1,509
Acquisitions,netofcashacquired(Note20) (2,129) (835) (4,486)
Purchasesofinvestments (34,913) (18,923) (13,434)
Salesofinvestments 24,119 18,058 14,797
Other(primarilyintangibles) (299) (266) 38
Netcashusedbyinvestingactivities (12,305) (5,103) (4,510)
Cashflowsfromfinancingactivities
Dividendstoshareholders (7,768) (7,286) (6,614)
Repurchaseofcommonstock (7,124) (3,538) (12,919)
Proceedsfromshort-termdebt 1,863 1,411 3,268
Retirementofshort-termdebt (1,267) (1,397) (6,175)
Proceedsfromlong-termdebt 2,098 3,607 45
Retirementoflong-termdebt (1,844) (1,593) (804)
Proceedsfromtheexerciseofstockoptions/excesstaxbenefits 1,782 2,649 2,720
Other – 56 (83)
Netcashusedbyfinancingactivities (12,260) (6,091) (20,562)
Effectofexchangeratechangesoncashandcashequivalents (310) (204) 45
(Decrease)/Increaseincashandcashequivalents (6,404) 6,016 (9,631)
Cashandcashequivalents,beginningofyear(Note1) 20,927 14,911 24,542
Cashandcashequivalents,endofyear(Note1) $14,523 20,927 14,911
Supplementalcashflowdata
Cashpaidduringtheyearfor:
Interest $603 596 616
Interest,netofamountcapitalized 488 491 501
Incometaxes 3,536 3,155 2,507
Supplementalscheduleofnon-cashinvestingandfinancingactivities
IssuanceofcommonstockassociatedwiththeacquisitionofSynthes,Inc. – – 13,335
Treasurystockissuedforemployeecompensationandstockoptionplans,netofcashproceeds 1,170 743 615
Conversionofdebt 17 22 –
Acquisitions
Fairvalueofassetsacquired $2,167 1,028 19,025
Fairvalueofliabilitiesassumedandnoncontrollinginterests (38) (193) (1,204)
Netfairvalueofacquisitions $2,129 835 17,821
Less:IssuanceofcommonstockassociatedwiththeacquisitionofSynthes,Inc. – – 13,335
Netcashpaidforacquisitions $2,129 835 4,486
SeeNotestoConsolidatedFinancialStatements
24 • Johnson&Johnson2014AnnualReportNotes to Consolidated Financial Statements
1. SummaryofSignificantAccountingPolicies
PrinciplesofConsolidation
TheconsolidatedfinancialstatementsincludetheaccountsofJohnson&Johnsonanditssubsidiaries(theCompany).
Intercompanyaccountsandtransactionsareeliminated.
DescriptionoftheCompanyandBusinessSegments
TheCompanyhasapproximately126,500employeesworldwideengagedintheresearchanddevelopment,manufacture
andsaleofabroadrangeofproductsinthehealthcarefield.TheCompanyconductsbusinessinvirtuallyallcountriesof
theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwell-being.
TheCompanyisorganizedintothreebusinesssegments:Consumer,PharmaceuticalandMedicalDevices(previously
referredtoasMedicalDevicesandDiagnostics).TheConsumersegmentincludesabroadrangeofproductsusedinthe
babycare,oralcare,skincare,over-the-counterpharmaceutical,women’shealthandwoundcaremarkets.These
productsaremarketedtothegeneralpublicandsoldbothtoretailoutletsanddistributorsthroughouttheworld.The
Pharmaceuticalsegmentisfocusedonfivetherapeuticareas,includingimmunology,infectiousdiseases,neuroscience,
oncology,andcardiovascularandmetabolicdiseases.Productsinthissegmentaredistributeddirectlytoretailers,
wholesalers,hospitalsandhealthcareprofessionalsforprescriptionuse.TheMedicalDevicessegmentincludesabroad
rangeofproductsusedintheorthopaedic,surgicalcare,specialtysurgery,cardiovascularcare,diagnostics,diabetes
care,andvisioncaremarkets,whicharedistributedtowholesalers,hospitalsandretailers,andusedprincipallyinthe
professionalfieldsbyphysicians,nurses,hospitals,andclinics.
NewAccountingPronouncements
RecentlyAdoptedAccountingPronouncements
Duringthefiscalfirstquarterof2014,theCompanyadoptedtheFinancialAccountingStandardsBoard(FASB)guidance
clarifyingthereleaseofaccumulatedForeignCurrencyTranslationfromothercomprehensiveincome(OCI),intocurrent
yearNetEarnings.Theamendmentrequiresthatwhentheparentcompanyceasestohaveacontrollinginterestina
subsidiaryorabusinesswithinaforeignentitytheparentistoreleaseaccumulatedForeignCurrencyTranslationfrom
OCI.ThisupdatebecameeffectiveforallannualperiodsandinterimreportingperiodsbeginningafterDecember15,
2013.TheadoptionofthisstandarddidnothaveamaterialimpactontheCompany’sresultsofoperations,cashflowsor
financialposition.
Duringthefiscalfirstquarterof2014,theCompanyadoptedtheFASBguidanceonthepresentationofunrecognizedtax
benefitswhenvariousqualifyingtaxcreditsexist.Theamendmentrequiresthatunrecognizedtaxbenefitsbepresentedon
theConsolidatedBalanceSheetasareductiontodeferredtaxassetscreatedbynetoperatinglossesorothertaxcredits
frompriorperiodsthatoccurinthesametaxingjurisdiction.Totheextentthattheunrecognizedtaxbenefitexceedsthese
credits,itshallbepresentedasaliability.Thisupdatebecameeffectiveforallannualperiodsandinterimreportingperiods
beginningafterDecember15,2013.Theadoptionofthisstandarddidnothaveamaterialimpactonthepresentationof
theCompany’sfinancialposition.
Duringthefiscalsecondquarterof2014,theFASBissuedamendedguidanceontheuseandpresentationof
discontinuedoperationsinanentity’sfinancialstatements.Thenewguidancerestrictsthepresentationofdiscontinued
operationstobusinesscircumstanceswhenthedisposalofbusinessoperationsrepresentsastrategicshiftthathasorwill
haveamajoreffectonanentity’soperationsandfinancialresults.Examplesofastrategicshiftcouldinclude,butnotbe
limitedto,disposalofmajorgeographicsegments,amajorlineofbusinessorothermajorbusinesscomponentofan
entity.Thenewguidancealsoexpandstherequireddisclosuresforentitiesthathaveassetsheldforsalebutdonotmeet
thenewdefinitionofdiscontinuedoperations.ThisamendmentincludesearlyadoptionprovisionsallowingtheCompany
toimplementthisupdateimmediatelyforthefirstquarterof2014.TheCompanyelectedtoadoptthisstandardforthefirst
quarterof2014.ThebalancesandupdateddisclosuresrequiredbytheamendedguidanceareincludedinNote20inthe
NotestotheConsolidatedFinancialStatements.
Duringthefiscalsecondquarterof2014,theFASBissuedAccountingStandardsUpdate2014-12:Accountingfor
Share-BasedPaymentsWhentheTermsofanAwardProvideThataPerformanceTargetCouldBeAchievedafterthe
Johnson&Johnson2014AnnualReport • 25RequisiteServicePeriod.Thisstandardclarifiesthecurrentaccountingguidanceforentitiesthatissueshare-based
paymentawardsthatrequireaspecificperformancetargetbeachievedforemployeestobecomeeligibletovestinthe
awards,whichmayoccursubsequenttoarequiredserviceperiod.Currentaccountingguidancedoesnotexplicitly
addresshowtoaccountforthesetypesofawards.Thenewstandardprovidesexplicitguidanceandclarifiesthatthese
typesofperformancetargetsshouldbetreatedasperformanceconditions.Theaccountingforshare-basedawardswith
performanceconditionsisalreadyspecifiedincurrentaccountingguidance.Thisupdateisrequiredtobeadoptedbyall
publiccompaniesforallannualperiodsandinterimreportingperiodsbeginningafterDecember15,2015.Earlyadoption
ofthisstandardwaspermittedandtheCompanyhadelectedtoadoptthisstandardforthesecondquarterof2014.The
adoptionofthisstandarddidnothaveamaterialimpactontheCompany’sresultsofoperations,cashflowsorfinancial
position.
RecentlyIssuedAccountingStandards
NotAdoptedasofDecember28,2014
Duringthefiscalsecondquarterof2014,theFASBissuedAccountingStandardsUpdate2014-09:Revenuefrom
ContractswithCustomers.Thisstandardreplacessubstantiallyallcurrentrevenuerecognitionaccountingguidance.This
updateisrequiredtobeadoptedbyallpubliccompaniesforallannualperiodsandinterimreportingperiodsbeginning
afterDecember15,2016.Earlyadoptionofthisstandardisnotpermitted.TheCompanyiscurrentlyassessingtheimpact
ofthefutureadoptionofthisstandardonitsfinancialstatements.
Duringthefiscalsecondquarterof2014,theFASBissuedamendedguidanceAccountingStandardsUpdateNo.2014-
10:DevelopmentStageEntities:EliminationofCertainFinancialReportingRequirements,IncludinganAmendmentto
VariableInterestEntityGuidanceinTopic810,Consolidation.Thechangeinthecurrentguidancewillrequirethe
Companytodetermineifitshouldconsolidateoneoftheseentitiesbasedonthechangeintheconsolidationanalysis.
Thisupdatetotheconsolidationanalysiswillbecomeeffectiveforallannualperiodsandinterimreportingperiods
beginningafterDecember15,2015.Theadoptionofthisstandardisnotexpectedtohaveamaterialimpactonthe
presentationoftheCompany’sresultsofoperations,cashflowsorfinancialposition.
Duringthefiscalthirdquarterof2014,theFASBissuedAccountingStandardsUpdateNo.2014-15:Disclosureof
UncertaintiesaboutanEntity’sAbilitytoContinueasaGoingConcern.Thisstandardrequiresmanagementtoevaluate,
foreachannualandinterimreportingperiod,whetherthereareconditionsandevents,consideredintheaggregate,that
raisesubstantialdoubtaboutanentity’sabilitytocontinueasagoingconcernwithinoneyearafterthedatethefinancial
statementsareissuedorareavailabletobeissued.Ifsubstantialdoubtisraised,additionaldisclosuresaround
management’splantoalleviatethesedoubtsarerequired.Thisupdatewillbecomeeffectiveforallannualperiodsand
interimreportingperiodsbeginningafterDecember15,2016.Thisstandardisnotexpectedtohaveanyimpactoncurrent
disclosuresinthefinancialstatements.
CashEquivalents
TheCompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase
ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof
purchaseascurrentmarketablesecurities.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercial
institutionsthathaveatleastan“A”(orequivalent)creditrating.TheCompanyinvestsitscashprimarilyinreverse
repurchaseagreements(RRAs),governmentsecuritiesandobligations,corporatedebtsecuritiesandmoneymarket
funds.
RRAsarecollateralizedbydepositsintheformof‘GovernmentSecuritiesandObligations’foranamountnotlessthan
102%oftheirvalue.TheCompanydoesnotrecordanassetorliabilityastheCompanyisnotpermittedtosellor
repledgetheassociatedcollateral.TheCompanyhasapolicythatthecollateralhasatleastanA(orequivalent)credit
rating.TheCompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis
maintainedat102%ofthevalueoftheRRAsonadailybasis.RRAswithstatedmaturitiesofgreaterthanthreemonths
fromthedateofpurchaseareclassifiedasmarketablesecurities.
Investments
Short-termmarketablesecuritiesarecarriedatcost,whichapproximatesfairvalue.Investmentsclassifiedasavailable-for-
salearecarriedatestimatedfairvaluewithunrealizedgainsandlossesrecordedasacomponentofaccumulatedother
comprehensiveincome.Long-termdebtsecuritiesthattheCompanyhastheabilityandintenttoholduntilmaturityare
carriedatamortizedcost.Managementdeterminestheappropriateclassificationofitsinvestmentindebtandequity
26 • Johnson&Johnson2014AnnualReportsecuritiesatthetimeofpurchaseandre-evaluatessuchdeterminationateachbalancesheetdate.TheCompany
periodicallyreviewsitsinvestmentsinequitysecuritiesforimpairmentandadjuststheseinvestmentstotheirfairvalue
whenadeclineinmarketvalueisdeemedtobeotherthantemporary.Iflossesonthesesecuritiesareconsideredtobe
otherthantemporary,thelossisrecognizedinearnings.
Property,PlantandEquipmentandDepreciation
Property,plantandequipmentarestatedatcost.TheCompanyutilizesthestraight-linemethodofdepreciationoverthe
estimatedusefullivesoftheassets:
Buildingandbuildingequipment 20-30years
Landandleaseholdimprovements 10-20years
Machineryandequipment 2-13years
TheCompanycapitalizescertaincomputersoftwareanddevelopmentcosts,includedinmachineryandequipment,when
incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternaluse.Capitalizedsoftwarecostsare
amortizedovertheestimatedusefullivesofthesoftware,whichgenerallyrangefrom3to8years.
TheCompanyreviewslong-livedassetstoassessrecoverabilityusingundiscountedcashflows.Whencertaineventsor
changesinoperatingoreconomicconditionsoccur,animpairmentassessmentmaybeperformedontherecoverabilityof
thecarryingvalueoftheseassets.Iftheassetisdeterminedtobeimpaired,thelossismeasuredbasedonthedifference
betweentheasset’sfairvalueanditscarryingvalue.Ifquotedmarketpricesarenotavailable,theCompanywillestimate
fairvalueusingadiscountedvalueofestimatedfuturecashflows.
Revenue Recognition
TheCompanyrecognizesrevenuefromproductsaleswhenthegoodsareshippedordeliveredandtitleandriskofloss
passtothecustomer.Provisionsforcertainrebates,salesincentives,tradepromotions,coupons,productreturnsand
discountstocustomersareaccountedforasreductionsinsalesinthesameperiodtherelatedsalesarerecorded.
Productdiscountsgrantedarebasedonthetermsofarrangementswithdirect,indirectandothermarketparticipants,as
wellasmarketconditions,includingpriceschargedbycompetitors.Rebates,whichincludeMedicaid,areestimatedbased
oncontractualterms,historicalexperience,patientoutcomes,trendanalysisandprojectedmarketconditionsinthevarious
marketsserved.TheCompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughthe
analysisofwholesalerandotherthird-partysell-throughandmarketresearchdata,aswellasinternallygenerated
information.
Salesreturnsaregenerallyestimatedandrecordedbasedonhistoricalsalesandreturnsinformation.Productsthatexhibit
unusualsalesorreturnpatternsduetodating,competitionorothermarketingmattersarespecificallyinvestigatedand
analyzedaspartoftheaccountingforsalesreturnsaccruals.
Salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpiration,destructioninthefield,
orinspecificareas,productrecall.Thereturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarketasa
percenttogrosssales.InaccordancewiththeCompany’saccountingpolicies,theCompanygenerallyissuescreditto
customersforreturnedgoods.TheCompany’ssalesreturnsreservesareaccountedforinaccordancewithU.S.GAAP
guidanceforrevenuerecognitionwhenrightofreturnexists.Salesreturnsreservesarerecordedatfullsalesvalue.Sales
returnsintheConsumerandPharmaceuticalsegmentsarealmostexclusivelynotresalable.Salesreturnsforcertain
franchisesintheMedicalDevicessegmentaretypicallyresalablebutarenotmaterial.TheCompanyinfrequently
exchangesproductsfrominventoryforreturnedproducts.ThesalesreturnsreserveforthetotalCompanyhasbeen
approximately1.0%ofannualsalestocustomersduringthefiscalreportingyears2014,2013and2012.
Promotionalprograms,suchasproductlistingallowancesandcooperativeadvertisingarrangements,arerecordedinthe
yearincurred.Continuingpromotionalprogramsincludecouponsandvolume-basedsalesincentiveprograms.The
redemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue.Volume-based
incentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedasproductsare
sold.TheCompanyalsoearnsservicerevenueforco-promotionofcertainproductsandincludesitinsalestocustomers.
Thesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferred.
Johnson&Johnson2014AnnualReport • 27ShippingandHandling
Shippingandhandlingcostsincurredwere$1,068million,$1,128millionand$1,051millionin2014,2013and2012,
respectively,andareincludedinselling,marketingandadministrativeexpense.Theamountofrevenuereceivedfor
shippingandhandlingislessthan0.5%ofsalestocustomersforallperiodspresented.
Inventories
Inventoriesarestatedatthelowerofcostormarketdeterminedbythefirst-in,first-outmethod.
IntangibleAssetsandGoodwill
TheauthoritativeliteratureonU.S.GAAPrequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed
annuallyforimpairment.TheCompanycompletedtheannualimpairmenttestfor2014inthefiscalfourthquarter.Future
impairmenttestswillbeperformedannuallyinthefiscalfourthquarter,orsoonerifwarranted.Purchasedin-process
researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted,
atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleasset,orabandoned,atwhichpoint
theintangibleassetwillbewrittenofforpartiallyimpaired.
Intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullives,andarereviewedfor
impairmentwhenwarrantedbyeconomicconditions.SeeNote5forfurtherdetailsonIntangibleAssetsandGoodwill.
FinancialInstruments
AsrequiredbyU.S.GAAP,allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Fairvalueistheexit
pricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-basedmeasurement
determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.Theauthoritativeliterature
establishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue,withLevel1havingthehighest
priorityandLevel3havingthelowest.Changesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings
orothercomprehensiveincome,dependingonwhetherthederivativeisdesignatedaspartofahedgetransaction,andif
so,thetypeofhedgetransaction.
TheCompanydocumentsallrelationshipsbetweenhedgeditemsandderivatives.Theoverallriskmanagementstrategy
includesreasonsforundertakinghedgetransactionsandenteringintoderivatives.Theobjectivesofthisstrategyare:
(1)minimizeforeigncurrencyexposure’simpactontheCompany’sfinancialperformance;(2)protecttheCompany’scash
flowfromadversemovementsinforeignexchangerates;(3)ensuretheappropriatenessoffinancialinstruments;and
(4)managetheenterpriseriskassociatedwithfinancialinstitutions.SeeNote6foradditionalinformationonFinancial
Instruments.
ProductLiability
Accrualsforproductliabilityclaimsarerecorded,onanundiscountedbasis,whenitisprobablethataliabilityhasbeen
incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformation.Theaccrualsare
adjustedperiodicallyasadditionalinformationbecomesavailable.TheCompanyaccruesanestimateofthelegaldefense
costsneededtodefendeachmatter.Thisisreferredtoasdefensecostsinconnectionwithproductliabilitylitigation.In
certainmattersanindemnityamountisalsorecorded.Thisisreferredtoasproductliabilityaccrual.
Asaresultofcostandavailabilityfactors,effectiveNovember1,2005,theCompanyceasedpurchasingthird-party
productliabilityinsurance.TheCompanyhasselfinsurancethroughawholly-ownedcaptiveinsurancecompany.In
additiontoaccrualsintheselfinsuranceprogram,claimsthatexceedtheinsurancecoverageareaccruedwhenlossesare
probableandamountscanbereasonablyestimated.Basedontheavailabilityofpriorcoverage,receivablesforinsurance
recoveriesrelatedtoproductliabilityclaimsarerecordedonanundiscountedbasis,whenitisprobablethatarecoverywill
berealized.Asappropriate,reservesagainstthesereceivablesarerecordedforestimatedamountsthatmaynotbe
collectedfromthird-partyinsurers.
ConcentrationofCreditRisk
Globalconcentrationofcreditriskwithrespecttotradeaccountsreceivablescontinuestobelimitedduetothelarge
numberofcustomersgloballyandadherencetointernalcreditpoliciesandcreditlimits.EconomicchallengesinItaly,
Spain,GreeceandPortugal(theSouthernEuropeanRegion)haveimpactedcertainpaymentpatterns,whichhave
28 • Johnson&Johnson2014AnnualReporthistoricallybeenlongerthanthoseexperiencedintheU.S.andotherinternationalmarkets.Thetotalnettradeaccounts
receivablebalanceintheSouthernEuropeanRegionwasapproximately$1.8billionasofDecember28,2014and
approximately$2.3billionasofDecember29,2013.Approximately$1.1billionasofDecember28,2014and
approximately$1.3billionasofDecember29,2013oftheSouthernEuropeanRegionnettradeaccountsreceivable
balancerelatedtotheCompany’sConsumer,VisionCareandDiabetesCarebusinessesaswellascertain
PharmaceuticalandMedicalDevicescustomerswhichareinlinewithhistoricalcollectionpatterns.
TheremainingbalanceofnettradeaccountsreceivableintheSouthernEuropeanRegionhasbeennegativelyimpacted
bythetimingofpaymentsfromcertaingovernmentownedorsupportedhealthcarecustomersaswellascertain
distributorsofthePharmaceuticalandMedicalDeviceslocalaffiliates.Thetotalnettradeaccountsreceivablebalancefor
thesecustomerswereapproximately$0.7billionatDecember28,2014and$1.0billionatDecember29,2013.The
Companycontinuestoreceivepaymentsfromthesecustomersandinsomecaseslatepaymentpremiums.Forcustomers
wherepaymentisexpectedoverperiodsoftimelongerthanoneyear,revenueandtradereceivableshavebeen
discountedovertheestimatedperiodoftimeforcollection.Allowancesfordoubtfulaccountshavebeenincreasedfor
thesecustomers,buthavebeenimmaterialtodate.TheCompanywillcontinuetoworkcloselywiththesecustomerson
paymentplans,monitortheeconomicsituationandtakeappropriateactionsasnecessary.
ResearchandDevelopment
Researchanddevelopmentexpensesareexpensedasincurred.Upfrontandmilestonepaymentsmadetothirdpartiesin
connectionwithresearchanddevelopmentcollaborationsareexpensedasincurreduptothepointofregulatoryapproval.
Paymentsmadetothirdpartiessubsequenttoregulatoryapprovalarecapitalizedandamortizedovertheremaininguseful
lifeoftherelatedproduct.Amountscapitalizedforsuchpaymentsareincludedinotherintangibles,netofaccumulated
amortization.
TheCompanyentersintocollaborativearrangements,typicallywithotherpharmaceuticalorbiotechnologycompanies,to
developandcommercializedrugcandidatesorintellectualproperty.Thesearrangementstypicallyinvolvetwo(ormore)
partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe
commercialsuccessoftheactivities.Thesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties,
includingresearchanddevelopment,marketingandsellinganddistribution.Often,thesecollaborationsrequireupfront,
milestoneandroyaltyorprofitsharepayments,contingentupontheoccurrenceofcertainfutureeventslinkedtothe
successoftheassetindevelopment.Amountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare
generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract
developmentservicesisnotcentraltotheCompany’soperations.Ingeneral,theincomestatementpresentationforthese
collaborationsisasfollows:
Nature/TypeofCollaboration StatementofEarningsPresentation
Third-partysaleofproduct Salestocustomers
Royalties/milestonespaidtocollaborativepartner Costofproductssold
(post-regulatoryapproval)*
Royaltiesreceivedfromcollaborativepartner Otherincome(expense),net
Upfrontpayments&milestonespaidtocollaborativepartner Researchanddevelopmentexpense
(pre-regulatoryapproval)
Researchanddevelopmentpaymentstocollaborative Researchanddevelopmentexpense
partner
Researchanddevelopmentpaymentsreceivedfrom ReductionofResearchanddevelopmentexpense
collaborativepartner
* Milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldovertheusefullife.
Forallyearspresented,therewasnoindividualprojectthatrepresentedgreaterthan5%ofthetotalannualconsolidated
researchanddevelopmentexpense.
Advertising
Costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinselling,marketingand
administrativeexpenses.Advertisingexpensesworldwide,whichcomprisedtelevision,radio,printmediaandInternet
advertising,were$2.6billion,$2.5billionand$2.3billionin2014,2013and2012,respectively.
Johnson&Johnson2014AnnualReport • 29IncomeTaxes
Incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany
differencebetweenU.S.GAAPaccountingandtaxreporting,recordedasdeferredtaxassetsorliabilities.TheCompany
estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandrates.Futurechangesintaxlawsand
ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture.
TheCompanyhasunrecognizedtaxbenefitsforuncertaintaxpositions.TheCompanyfollowsU.S.GAAPwhich
prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof
ataxpositiontakenorexpectedtobetakeninataxreturn.Managementbelievesthatchangesintheseestimateswould
nothaveamaterialeffectontheCompany’sresultsofoperations,cashflowsorfinancialposition.
AtDecember28,2014andDecember29,2013,thecumulativeamountsofundistributedinternationalearningswere
approximately$53.4billionand$50.9billion,respectively.AtDecember28,2014andDecember29,2013,the
Company’sforeignsubsidiariesheldbalancesofcashandcashequivalentsintheamountsof$14.3billionand$18.6
billion,respectively.TheCompanyhasnotprovideddeferredtaxesontheundistributedearningsfromcertaininternational
subsidiarieswheretheearningsareconsideredtobepermanentlyreinvested.TheCompanyintendstocontinueto
reinvesttheseearningsininternationaloperations.IftheCompanydecidedatalaterdatetorepatriatetheseearningsto
theU.S.,theCompanywouldberequiredtoprovideforthenettaxeffectsontheseamounts.TheCompanydoesnot
determinethedeferredtaxliabilityassociatedwiththeseundistributedearnings,assuchdeterminationisnotpractical.
SeeNote8totheConsolidatedFinancialStatementsforfurtherinformationregardingincometaxes.
NetEarningsPerShare
Basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage
numberofcommonsharesoutstandingfortheperiod.Dilutedearningspersharereflectsthepotentialdilutionthatcould
occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod.
UseofEstimates
Thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe
U.S.requiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreported.Estimatesareusedwhen
accountingforsalesdiscounts,rebates,allowancesandincentives,productliabilities,incometaxes,depreciation,
amortization,employeebenefits,contingenciesandintangibleassetandliabilityvaluations.Actualresultsmayormaynot
differfromthoseestimates.
TheCompanyfollowstheprovisionsofU.S.GAAPwhenrecordinglitigationrelatedcontingencies.Aliabilityisrecorded
whenalossisprobableandcanbereasonablyestimated.Thebestestimateofalosswithinarangeisaccrued;however,
ifnoestimateintherangeisbetterthananyother,theminimumamountisaccrued.
AnnualClosingDate
TheCompanyfollowstheconceptofafiscalyear,whichendsontheSundaynearesttotheendofthemonthof
December.Normallyeachfiscalyearconsistsof52weeks,buteveryfiveorsixyearsthefiscalyearconsistsof53weeks,
aswasthecasein2009,andisthecaseagainin2015.
Reclassification
Certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation.
30 • Johnson&Johnson2014AnnualReport2. Cash,CashEquivalentsandCurrentMarketableSecurities
Attheendof2014and2013,cash,cashequivalentsandcurrentmarketablesecuritieswerecomprisedof:
(DollarsinMillions) 2014 2013
Cash $2,336 2,789
Governmentsecuritiesandobligations 20,610 7,632
Reverserepurchaseagreements 6,735 15,006
Corporatedebtsecurities 1,343 1,467
Moneymarketfunds 1,352 1,886
Timedeposits 713 426
Totalcash,cashequivalentsandcurrentmarketablesecurities $33,089 29,206
TheestimatedfairvalueapproximatedcostasofDecember28,2014andDecember29,2013.
AsofDecember28,2014,currentmarketablesecuritiesconsistedof$17,682million,and$884millionofgovernment
securitiesandobligationsandcorporatedebtsecurities,respectively,withnoreverserepurchaseagreements.
AsofDecember29,2013,currentmarketablesecuritiesconsistedof$6,160million,$1,100millionand$1,019millionof
governmentsecuritiesandobligations,reverserepurchaseagreementsandcorporatedebtsecurities,respectively.
Fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker
pricesandsignificantotherobservableinputs.
TheCompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhigh-quality
moneymarketinstruments.TheCompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat
leastan“A”(orequivalent)creditrating.
3. Inventories
Attheendof2014and2013,inventorieswerecomprisedof:
(DollarsinMillions) 2014 2013
Rawmaterialsandsupplies $1,214 1,224
Goodsinprocess 2,461 2,612
Finishedgoods 4,509 4,042
Totalinventories $8,184 7,878
4. Property,PlantandEquipment
Attheendof2014and2013,property,plantandequipmentatcostandaccumulateddepreciationwere:
(DollarsinMillions) 2014 2013
Landandlandimprovements $833 885
Buildingsandbuildingequipment 10,046 10,423
Machineryandequipment 22,206 22,527
Constructioninprogress 3,600 3,298
Totalproperty,plantandequipment,gross $36,685 37,133
Lessaccumulateddepreciation 20,559 20,423
Totalproperty,plantandequipment,net $16,126 16,710
TheCompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipment.Interestexpense
capitalizedin2014,2013and2012was$115million,$105millionand$115million,respectively.
Johnson&Johnson2014AnnualReport • 31Depreciationexpense,includingtheamortizationofcapitalizedinterestin2014,2013and2012,was$2.5billion,$2.7
billionand$2.5billion,respectively.
Uponretirementorotherdisposalofproperty,plantandequipment,thecostsandrelatedamountsofaccumulated
depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccounts,respectively.The
difference,ifany,betweenthenetassetvalueandtheproceedsarerecordedinearnings.
5. IntangibleAssetsandGoodwill
Attheendof2014and2013,thegrossandnetamountsofintangibleassetswere:
(DollarsinMillions) 2014 2013
Intangibleassetswithdefinitelives:
Patentsandtrademarks–gross $9,074 9,164
Lessaccumulatedamortization 4,700 4,146
Patentsandtrademarks–net $4,374 5,018
Customerrelationshipsandotherintangibles–gross $17,970 19,027
Lessaccumulatedamortization 5,227 4,872
Customerrelationshipsandotherintangibles–net $12,743 14,155
Intangibleassetswithindefinitelives:
Trademarks $7,263 7,619
Purchasedin-processresearchanddevelopment 2,842 1,155
Totalintangibleassetswithindefinitelives $10,105 8,774
Totalintangibleassets–net $27,222 27,947
GoodwillasofDecember28,2014andDecember29,2013,asallocatedbysegmentofbusiness,wasasfollows:
(DollarsinMillions) Consumer Pharmaceutical MedDevices Total
GoodwillatDecember30,2012 $8,519 1,792 12,113 22,424
Goodwill,relatedtoacquisitions 83 246 9 338
Goodwill,relatedtodivestitures (71) – – (71)
Currencytranslation/other – 30 77 107
GoodwillatDecember29,2013 $8,531 2,068 12,199 22,798
Goodwill,relatedtoacquisitions 13 665 – 678
Goodwill,relatedtodivestitures (138) – (603) (741)
Currencytranslation/other (731) (107) (65) (903)
GoodwillatDecember28,2014 $7,675 2,626 11,531 21,832
Theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible
assetsare17yearsand24years,respectively.Theamortizationexpenseofamortizableassetsincludedincostof
productssoldwas$1,398million,$1,363millionand$1,146millionbeforetax,forthefiscalyearsendedDecember28,
2014,December29,2013andDecember30,2012,respectively.Theestimatedamortizationexpenseforthefive
succeedingyearsapproximates$1,300millionbeforetax,peryear.
SeeNote20totheConsolidatedFinancialStatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures.
6. FairValueMeasurements
TheCompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflows,primarily
relatedtotheforeignexchangeratechangesoffutureintercompanyproductandthird-partypurchasesofmaterials
denominatedinaforeigncurrency.TheCompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk
primarilyrelatedtoborrowings.Bothtypesofderivativesaredesignatedascashflowhedges.
32 • Johnson&Johnson2014AnnualReportAdditionally,theCompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate
borrowings.Thesederivativesaretreatedasfairvaluehedges.TheCompanymayuseforwardforeignexchangecontracts
designatedasnetinvestmenthedges.Additionally,theCompanyusesforwardforeignexchangecontractstooffsetits
exposuretocertainforeigncurrencyassetsandliabilities.Theseforwardforeignexchangecontractsarenotdesignatedas
hedgesandtherefore,changesinthefairvaluesofthesederivativesarerecognizedinearnings,therebyoffsettingthe
currentearningseffectoftherelatedforeigncurrencyassetsandliabilities.
TheCompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposes,orthatcontaincredit
riskrelatedcontingentfeaturesorrequirementstopostcollateral.Onanongoingbasis,theCompanymonitors
counterpartycreditratings.TheCompanyconsiderscreditnon-performancerisktobelow,becausetheCompanyenters
intoagreementswithcommercialinstitutionsthathaveatleastan“A”(orequivalent)creditrating.AsofDecember28,
2014,theCompanyhadnotionalamountsoutstandingforforwardforeignexchangecontracts,crosscurrencyinterest
rateswapsandinterestrateswapsof$29.6billion,$2.4billionand$2.2billion,respectively.
Allderivativeinstrumentsarerecordedonthebalancesheetatfairvalue.Changesinthefairvalueofderivativesare
recordedeachperiodincurrentearningsorothercomprehensiveincome,dependingonwhetherthederivativeis
designatedaspartofahedgetransaction,andifso,thetypeofhedgetransaction.
Thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontract.Atinception,allderivatives
areexpectedtobehighlyeffective.Changesinthefairvalueofaderivativethatisdesignatedasacashflowhedgeandis
highlyeffectivearerecordedinaccumulatedothercomprehensiveincomeuntiltheunderlyingtransactionaffectsearnings,
andarethenreclassifiedtoearningsinthesameaccountasthehedgedtransaction.Gainsandlossesassociatedwith
interestrateswapsarerecordedtointerestexpenseintheperiodinwhichtheyoccur.Gainsandlossesonnetinvestment
hedgesareaccountedforthroughthecurrencytranslationaccountandareinsignificant.Onanongoingbasis,the
Companyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesofhedgeditems.Ifand
whenaderivativeisnolongerexpectedtobehighlyeffective,hedgeaccountingisdiscontinued.Hedgeineffectiveness,if
any,isincludedincurrentperiodearningsinOther(income)expense,netforforwardforeignexchangecontractsand
crosscurrencyinterestrateswaps.Forinterestrateswapsdesignatedasfairvaluehedges,hedgeineffectiveness,ifany,
isincludedincurrentperiodearningswithininterestexpense.Forthecurrentreportingperiod,hedgeineffectiveness
associatedwithinterestrateswapsarenotmaterial.
AsofDecember28,2014,thebalanceofdeferrednetgainsonderivativesincludedinaccumulatedothercomprehensive
incomewas$141millionafter-tax.Foradditionalinformation,seetheConsolidatedStatementsofComprehensiveIncome
andNote13.TheCompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill
bereclassifiedintoearningsoverthenext12monthsasaresultoftransactionsthatareexpectedtooccuroverthat
period.ThemaximumlengthoftimeoverwhichtheCompanyishedgingtransactionexposureis18months,excluding
interestratecontracts.Theamountultimatelyrealizedinearningsmaydifferasforeignexchangerateschange.Realized
gainsandlossesareultimatelydeterminedbyactualexchangeratesatmaturityofthederivative.
Thefollowingtableisasummaryoftheactivityrelatedtoderivativesdesignatedascashflowhedgesforthefiscalyears
endedDecember28,2014andDecember29,2013:
Gain/(Loss) Gain/(Loss)
Gain/(Loss) ReclassifiedFrom RecognizedIn
RecognizedIn AccumulatedOCI Other
(DollarsinMillions) AccumulatedOCI(1) IntoIncome(1) Income/Expense(2)
CashFlowHedgesbyIncomeStatementCaption 2014 2013 2014 2013 2014 2013
Salestocustomers(3) $(106) 45 (3) 49 (5) 2
Costofproductssold(3) 58 271 204 69 2 23
Researchanddevelopmentexpense(3) 39 24 7 16 – (4)
Interest(income)/Interestexpense,net(4) 21 17 (15) (10) – –
Other(income)expense,net(3) 80 (13) 3 (17) – (4)
Total $92 344 196 107 (3) 17
Allamountsshowninthetableabovearenetoftax.
(1) Effectiveportion
(2) Ineffectiveportion
(3) Forwardforeignexchangecontracts
(4) Crosscurrencyinterestrateswaps
Johnson&Johnson2014AnnualReport • 33ForthefiscalyearsendedDecember28,2014andDecember29,2013,againof$5millionandagainof$32million,
respectively,wasrecognizedinOther(income)expense,net,relatingtoforwardforeignexchangecontractsnot
designatedashedginginstruments.
Fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliability.Fairvalueisamarket-based
measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliability.The
authoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedbelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Thefairvalueofaderivativefinancialinstrument(i.e.,forwardforeignexchangecontracts,interestratecontracts)isthe
aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand
subsequentlyconvertedtotheU.S.Dollaratthecurrentspotforeignexchangerate.TheCompanydoesnotbelievethat
fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor
maturity,orthatthechangesinfairvaluewillhaveamaterialeffectontheCompany’sresultsofoperations,cashflowsor
financialposition.TheCompanyalsoholdsequityinvestmentswhichareclassifiedasLevel1becausetheyaretradedin
anactiveexchangemarket.TheCompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwould
requirerevisedvaluationsunderthisstandardthatarerecognizedatfairvalue.
Thefollowingthreelevelsofinputsareusedtomeasurefairvalue:
Level1—Quotedpricesinactivemarketsforidenticalassetsandliabilities.
Level2—Significantotherobservableinputs.
Level3—Significantunobservableinputs.
TheCompany’ssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofDecember28,2014and
December29,2013wereasfollows:
2014 2013
(DollarsinMillions) Level1 Level2 Level3 Total Total(1)
Derivativesdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts $ – 996 – 996 537
Interestratecontracts(2) – 31 – 31 169
Total – 1,027 – 1,027 706
Liabilities:
Forwardforeignexchangecontracts – 751 – 751 133
Interestratecontracts(3)(4) – 8 – 8 26
Total – 759 – 759 159
Derivativesnotdesignatedashedginginstruments:
Assets:
Forwardforeignexchangecontracts – 29 – 29 25
Liabilities:
Forwardforeignexchangecontracts – 51 – 51 29
Otherinvestments(5) $679 – – 679 333
(1) 2013assetsandliabilitiesareallclassifiedasLevel2withtheexceptionofOtherinvestmentsof$333million,whichareclassifiedas
Level1.
(2) Includes$29millionand$169millionofnon-currentassetsforthefiscalyearsendingDecember28,2014andDecember29,2013,
respectively.
(3) Includes$8millionand$19millionofnon-currentliabilitiesforthefiscalyearsendingDecember28,2014andDecember29,2013,
respectively.
(4) Includescrosscurrencyinterestrateswapsandinterestrateswaps.
(5) Classifiedasnon-currentotherassets.
SeeNotes2and7forfinancialassetsandliabilitiesheldatcarryingamountontheConsolidatedBalanceSheet.
34 • Johnson&Johnson2014AnnualReport7. Borrowings
Thecomponentsoflong-termdebtareasfollows:
Effective Effective
(DollarsinMillions) 2014 Rate% 2013 Rate%
3monthLIBOR+0.09%FRNdue2014 $ – –% 750 0.33
1.20%Notesdue2014 – – 999 1.24
2.15%Notesdue2016 898 2.22 898 2.22
3monthLIBOR+0.07%FRNdue2016 800 0.31 800 0.31
0.70%Notesdue2016 398 0.74 397 0.74
5.55%Debenturesdue2017 1,000 5.55 1,000 5.55
1.125%Notesdue2017 697 1.15 – –
5.15%Debenturesdue2018 898 5.15 898 5.15
1.65%Notesdue2018 597 1.70 589 1.70
4.75%Notesdue2019(1BEuro1.2199)(2)/(1BEuro1.3683)(3) 1,216(2) 5.83 1,363(3) 5.83
1.875%Notesdue2019 497 1.93 – –
3%ZeroCouponConvertibleSubordinatedDebenturesdue2020 158 3.00 179 3.00
2.95%Debenturesdue2020 543 3.15 542 3.15
3.55%Notesdue2021 446 3.67 446 3.67
2.45%Notesdue2021 349 2.48 – –
6.73%Debenturesdue2023 250 6.73 250 6.73
3.375%Notesdue2023 812(5) 3.17 550 3.38
5.50%Notesdue2024(500MMGBP1.5542)(2)/(500MMGBP1.6414)(3) 772(2) 6.75 816(3) 6.75
6.95%Notesdue2029 297 7.14 296 7.14
4.95%Debenturesdue2033 500 4.95 500 4.95
4.375%Notesdue2033 865(5) 4.23 646 4.42
5.95%Notesdue2037 995 5.99 995 5.99
5.85%Debenturesdue2038 700 5.86 700 5.86
4.50%Debenturesdue2040 539 4.63 539 4.63
4.85%Notesdue2041 298 4.89 298 4.89
4.50%Notesdue2043 499 4.52 499 4.52
Other 105 – 147 –
Subtotal 15,129(4) 4.08%(1) 15,097(4) 4.00(1)
Lesscurrentportion 7 1,769
Totallong-termdebt $15,122 13,328
(1) Weightedaverageeffectiverate.
(2) TranslationrateatDecember28,2014.
(3) TranslationrateatDecember29,2013.
(4) Theexcessofthefairvalueoverthecarryingvalueofdebtwas$2.2billionin2014and$1.4billionin2013.
(5) Includesthereopeningoftheseissues.
Fairvalueofthenon-currentdebtwasestimatedusingmarketprices,whichwerecorroboratedbyquotedbrokerprices
andsignificantotherobservableinputs.
TheCompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwide.InSeptember2014,the
Companysecuredanew364-dayCreditFacility.TotalcreditavailabletotheCompanyapproximates$10billion,which
expiresonSeptember17,2015.Interestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbids
providedbybanks,theprimerateorLondonInterbankOfferedRates(LIBOR),plusapplicablemargins.Commitmentfees
undertheagreementsarenotmaterial.
Johnson&Johnson2014AnnualReport • 35Throughout2014,theCompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarket.Short-term
borrowingsandthecurrentportionoflong-termdebtamountedtoapproximately$3.6billionattheendof2014,ofwhich
$3.1billionwasborrowedundertheCommercialPaperProgram.Theremainderprincipallyrepresentslocalborrowingby
internationalsubsidiaries.
TheCompanyhasashelfregistrationwiththeU.S.SecuritiesandExchangeCommissionthatenablestheCompanyto
issuedebtsecuritiesandwarrantstopurchasedebtsecuritiesonatimelybasis.TheCompanyissuedbondsinNovember
2014foratotalof$2.0billionforgeneralcorporatepurposes.Thisincludedthereopeningofthe2023and2033bonds
issuedinDecember2013.
Aggregatematuritiesoflong-termobligationscommencingin2015are:
(DollarsinMillions)
After
2015 2016 2017 2018 2019 2019
$7 2,152 1,722 1,496 1,713 8,039
8. IncomeTaxes
Theprovisionfortaxesonincomeconsistsof:
(DollarsinMillions) 2014 2013 2012
Currentlypayable:
U.S.taxes $2,625 594 2,023
Internationaltaxes 1,174 1,653 1,277
Totalcurrentlypayable 3,799 2,247 3,300
Deferred:
U.S.taxes (258) (251) (120)
Internationaltaxes 699 (356) 81
Totaldeferred 441 (607) (39)
Provisionfortaxesonincome $4,240 1,640 3,261
AcomparisonofincometaxexpenseattheU.S.statutoryrateof35%in2014,2013and2012,totheCompany’s
effectivetaxrateisasfollows:
(DollarsinMillions) 2014 2013 2012
U.S. $8,001 4,261 4,664
International 12,562 11,210 9,111
Earningsbeforetaxesonincome: $20,563 15,471 13,775
Taxrates:
U.S.statutoryrate 35.0% 35.0 35.0
InternationaloperationsexcludingIreland (7.0) (10.6) (9.8)
IrelandandPuertoRicooperations (6.9) (9.0) (3.9)
Researchandorphandrugtaxcredits (0.3) (0.8) –
U.S.stateandlocal 1.0 0.4 1.3
U.S.manufacturingdeduction (0.6) (0.8) (0.9)
U.S.taxoninternationalincome 1.4 1.7 1.1
U.S.taxbenefitonasset/businessdisposals (1.9) (5.1) –
Allother (0.1) (0.2) 0.9
Effectivetaxrate 20.6% 10.6 23.7
36 • Johnson&Johnson2014AnnualReportTheincreaseinthe2014effectivetaxrate,ascomparedto2013,wasattributabletothefollowing:thedivestitureofthe
Ortho-ClinicalDiagnosticsbusinessatanapproximate44%effectivetaxrate,litigationaccrualsatlowtaxrates,themixof
earningsintohighertaxjurisdictions,primarilytheU.S.,theaccrualofanadditionalyearoftheBrandedPrescriptionDrug
Fee,whichisnottaxdeductible,andadditionalU.S.taxexpenserelatedtoaplannedincreaseindividendsfromcurrent
yearforeignearningsascomparedtotheprioryear.Theseincreasestothe2014effectivetaxratewerepartiallyoffsetby
ataxbenefitof$0.4billionassociatedwiththeConorMedsystemsdivestiture.
The2013effectivetaxratewasreducedbyataxbenefitassociatedwiththewrite-offofassetsfortaxpurposes
associatedwithScios,Inc.,andtheinclusionofboththe2013and2012benefitfromtheResearchandDevelopmenttax
creditandtheControlledForeignCorporationlook-throughprovisions,becausethoseprovisionswereenactedintolawin
January2013andwereretroactivetoJanuary1,2012.
The2014effectivetaxratewasalsoreducedastheCompanyadjusteditsunrecognizedtaxbenefitsasaresultof(i)the
federalappealscourt’sdecisioninOMJPharmaceuticals,Inc.’slitigationregardingcreditsunderformerSection936of
theInternalRevenueCode(seeNote21totheConsolidatedFinancialStatementsforadditionalinformation),and(ii)a
settlementofsubstantiallyallissuesrelatedtotheCompany’sU.S.InternalRevenueServiceauditoftaxyears2006-
2009.TheimpactofthesettlementisreflectedintheU.S.taxoninternationalincomeandtheAllotherlineitemswithin
theabovereconciliation.
Theitemsnotedabovereflectthekeydriversoftheratereconciliation.
TheCompanyhassubsidiariesoperatinginPuertoRicoundervarioustaxincentives.
Temporarydifferencesandcarryforwardsfor2014and2013wereasfollows:
2014 2013
DeferredTax DeferredTax
(DollarsinMillions) Asset Liability Asset Liability
Employeerelatedobligations $3,426 1,908
Stockbasedcompensation 799 1,121
Depreciation (564) (772)
Non-deductibleintangibles (6,671) (6,250)
InternationalR&Dcapitalizedfortax 1,433 1,656
Reserves&liabilities 1,497 1,587
Incomereportedfortaxpurposes 1,067 1,043
Netoperatinglosscarryforwardinternational 949 1,090
Miscellaneousinternational 1,128(1) (305) 1,508(1) (361)
MiscellaneousU.S. 996 927
Totaldeferredincometaxes $11,295 (7,540) 10,840 (7,383)
(1) The$1,128millionin2014wasnetofavaluationallowancerelatedtoBelgiumof$172million.The$1,508millionin2013wasnet
ofavaluationallowancerelatedtoBelgiumof$187million.
Thedifferencebetweenthenetdeferredtaxonincomeperthebalancesheetandthenetdeferredtaxaboveisincludedin
taxesonincomeonthebalancesheet.TheCompanyhaswholly-ownedinternationalsubsidiariesthathavecumulativenet
losses.TheCompanybelievesthatitismorelikelythannotthatthesesubsidiarieswillrealizefuturetaxableincome
sufficienttoutilizethesedeferredtaxassets.
Thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits:
(DollarsinMillions) 2014 2013 2012
Beginningofyear $2,729 3,054 2,699
Increasesrelatedtocurrentyeartaxpositions 281 643 538
Increasesrelatedtopriorperiodtaxpositions 295 80 57
Decreasesrelatedtopriorperiodtaxpositions (288) (574) (41)
Settlements (477) (418) (120)
Lapseofstatuteoflimitations (75) (56) (79)
Endofyear $2,465 2,729 3,054
Johnson&Johnson2014AnnualReport • 37Theunrecognizedtaxbenefitsof$2.5billionatDecember28,2014,ifrecognized,wouldaffecttheCompany’sannual
effectivetaxrate.TheCompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits
inprogresswithanumberoftaxauthorities.TheIRShascompleteditsauditforthetaxyearsthrough2009;however,
therearealimitednumberofissuesremainingopenforpriortaxyearsgoingbackto1999.Inothermajorjurisdictions
wheretheCompanyconductsbusiness,theyearsremainopengenerallybacktotheyear2004.TheCompanybelievesit
ispossiblethatauditsmaybecompletedbytaxauthoritiesinsomejurisdictionsoverthenexttwelvemonths.However,the
Companyisnotabletoprovideareasonablyreliableestimateofthetimingofanyotherfuturetaxpaymentsrelatingto
uncertaintaxpositions.
TheCompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslong-termliabilities.
Interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpense.TheCompany
recognizedaftertaxinterestexpenseof$12million,$40millionand$41millionin2014,2013and2012,respectively.
Thetotalamountofaccruedinterestwas$298millionand$412millionin2014and2013,respectively.
9. EmployeeRelatedObligations
Attheendof2014and2013,employeerelatedobligationsrecordedontheConsolidatedBalanceSheetswere:
(DollarsinMillions) 2014 2013
Pensionbenefits $4,547 2,950
Postretirementbenefits 3,161 2,655
Postemploymentbenefits 2,062 1,872
Deferredcompensation 599 693
Totalemployeeobligations 10,369 8,170
Lesscurrentbenefitspayable 397 386
Employeerelatedobligations–non-current $9,972 7,784
Prepaidemployeerelatedobligationsof$233millionand$2,363millionfor2014and2013,respectively,areincludedin
otherassetsontheConsolidatedBalanceSheets.
10. PensionsandOtherBenefitPlans
TheCompanysponsorsvariousretirementandpensionplans,includingdefinedbenefit,definedcontributionand
terminationindemnityplans,whichcovermostemployeesworldwide.TheCompanyalsoprovidespost-retirement
benefits,primarilyhealthcare,toalleligibleU.S.retiredemployeesandtheirdependents.
Manyinternationalemployeesarecoveredbygovernment-sponsoredprogramsandthecosttotheCompanyisnot
significant.
RetirementplanbenefitsforemployeeshiredbeforeJanuary1,2015areprimarilybasedontheemployee’scompensation
duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofservice.In2014,theCompanyannounced
thattheU.S.DefinedBenefitplanwasamendedtoadoptanewbenefitformula,effectiveforemployeeshiredonorafter
January1,2015.Thebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof
service.Internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrustees,annuitiesarepurchased
undergroupcontracts,orreservesareprovided.
TheCompanydoesnotfundretireehealthcarebenefitsinadvanceandhastherighttomodifytheseplansinthefuture.
TheCompanyusesthedateofitsconsolidatedfinancialstatements(December28,2014andDecember29,2013,
respectively)asthemeasurementdateforallU.S.andinternationalretirementandotherbenefitplans.
38 • Johnson&Johnson2014AnnualReportNetperiodicbenefitcostsfortheCompany’sdefinedbenefitretirementplansandotherbenefitplansfor2014,2013and
2012includethefollowingcomponents:
RetirementPlans OtherBenefitPlans
(DollarsinMillions) 2014 2013 2012 2014 2013 2012
Servicecost $882 906 722 211 196 175
Interestcost 1,018 908 878 197 151 165
Expectedreturnonplanassets (1,607) (1,447) (1,236) (7) (6) (4)
Amortizationofpriorservicecost(credit) 6 6 6 (34) (2) (3)
Amortizationofnettransitionobligation 1 1 1 – – –
Recognizedactuariallosses 460 681 494 136 111 76
Curtailmentsandsettlements (17) – – – 2 –
Netperiodicbenefitcost $743 1,055 865 503 452 409
AmountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearfortheCompany’sdefinedbenefit
retirementplansandotherpost-retirementplans:
(DollarsinMillions)
Amortizationofnettransitionobligation –
Amortizationofnetactuariallosses 944
Amortizationofpriorservicecredit 33
UnrecognizedgainsandlossesfortheU.S.pensionplansareamortizedovertheaverageremainingfutureserviceforeach
plan.Forplanswithnoactiveemployees,theyareamortizedovertheaveragelifeexpectancy.Theamortizationofgains
andlossesfortheotherU.S.benefitplansisdeterminedbyusinga10%corridorofthegreaterofthemarketvalueof
assetsortheprojectedbenefitobligation.Totalunamortizedgainsandlossesinexcessofthecorridorareamortizedover
theaverageremainingfutureservice.
Priorservicecosts/benefitsfortheU.S.pensionplansareamortizedovertheremainingfutureserviceofplanparticipants
atthetimeoftheplanamendment.Priorservicecost/benefitfortheotherU.S.benefitplansisamortizedovertheaverage
remainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment.
Theweighted-averageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalue
ofprojectedbenefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear.
RetirementPlans OtherBenefitPlans
2014 2013 2012 2014 2013 2012
WorldwideBenefitPlans
Discountrate 3.78% 4.78% 4.25% 4.31% 5.25% 4.55%
Expectedlong-termrateofreturnonplanassets 8.53% 8.46% 8.45%
Rateofincreaseincompensationlevels 4.05% 4.08% 4.08% 4.11% 4.29% 4.28%
TheCompany’sdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighquality,long-term
fixedincomeinstruments.Theresultingdiscountratesareconsistentwiththedurationofplanliabilities.
TheexpectedratesofreturnonplanassetassumptionsrepresenttheCompany’sassessmentoflong-termreturnson
diversifiedinvestmentportfoliosglobally.Theassessmentisdeterminedusingprojectionsfromexternalfinancialsources,
long-termhistoricalaverages,actualreturnsbyassetclassandthevariousassetclassallocationsbymarket.
FormeasurementofU.S.retirementbenefitobligations,themortalityassumptionwasupdatedtoanewlyestablished
2014mortalitytableresultinginanincreasetotheprojectedbenefitobligation.
Thefollowingtabledisplaystheassumedhealthcarecosttrendrates,forallindividuals:
HealthCarePlans 2014 2013
Healthcarecosttrendrateassumedfornextyear 6.00% 6.50%
Ratetowhichthecosttrendrateisassumedtodecline(ultimatetrend) 4.50% 4.50%
Yeartheratereachestheultimatetrendrate 2032 2032
Johnson&Johnson2014AnnualReport • 39Aone-percentage-pointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect:
One-Percentage- One-Percentage-
(DollarsinMillions) PointIncrease PointDecrease
HealthCarePlans
Totalinterestandservicecost $45 $(34)
Post-retirementbenefitobligation 560 (444)
Thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyear-end
2014and2013fortheCompany’sdefinedbenefitretirementplansandotherpost-retirementplans:
OtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2014 2013 2014 2013
ChangeinBenefitObligation
Projectedbenefitobligation–beginningofyear $21,488 21,829 4,407 4,159
Servicecost 882 906 211 196
Interestcost 1,018 908 197 151
Planparticipantcontributions 59 54 – –
Amendments (60) 35 (254) 7
Actuarial(gains)losses 5,395 (1,432) 1,030 296
Divestitures&acquisitions (121) 8 – –
Curtailments,settlements&restructuring (53) (15) – (11)
Benefitspaidfromplan (813) (751) (493) (373)
Effectofexchangerates (906) (54) (17) (18)
Projectedbenefitobligation–endofyear $26,889 21,488 5,081 4,407
ChangeinPlanAssets
Planassetsatfairvalue–beginningofyear $20,901 17,536 87 122
Actualreturnonplanassets 2,078 3,573 8 15
Companycontributions 1,176 565 477 323
Planparticipantcontributions 59 54 – –
Settlements (40) (4) – –
Divestitures&acquisitions (109) 9 – –
Benefitspaidfromplanassets (813) (751) (493) (373)
Effectofexchangerates (677) (81) – –
Planassetsatfairvalue–endofyear $22,575 20,901 79 87
Fundedstatus–endofyear $(4,314) (587) (5,002) (4,320)
AmountsRecognizedintheCompany’sBalanceSheetconsistofthefollowing:
Non-currentassets $233 2,363 – –
Currentliabilities (74) (71) (309) (302)
Non-currentliabilities (4,473) (2,879) (4,693) (4,018)
Totalrecognizedintheconsolidatedbalancesheet–endofyear $(4,314) (587) (5,002) (4,320)
AmountsRecognizedinAccumulatedOtherComprehensiveIncomeconsistof
thefollowing:
Netactuarialloss $7,547 3,344 2,611 1,732
Priorservicecost(credit) (33) 26 (225) (6)
Unrecognizednettransitionobligation 1 2 – –
Totalbeforetaxeffects $7,515 3,372 2,386 1,726
AccumulatedBenefitObligations–endofyear $23,816 19,203
40 • Johnson&Johnson2014AnnualReportOtherBenefit
RetirementPlans Plans
(DollarsinMillions) 2014 2013 2014 2013
ChangesinPlanAssetsandBenefitObligationsRecognizedinOther
ComprehensiveIncome
Netperiodicbenefitcost $743 1,055 503 452
Netactuarial(gain)loss 4,942 (3,559) 1,015 248
Amortizationofnetactuarialloss (460) (681) (136) (111)
Priorservicecost(credit) (60) 34 (253) 8
Amortizationofpriorservice(cost)credit (6) (13) 34 –
Effectofexchangerates (273) (6) – (6)
Totalrecognizedinothercomprehensiveincome,beforetax $4,143 (4,225) 660 139
Totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome $4,886 (3,170) 1,163 591
TheCompanyplanstocontinuetofunditsU.S.QualifiedPlanstocomplywiththePensionProtectionActof2006.
InternationalPlansarefundedinaccordancewithlocalregulations.Additionaldiscretionarycontributionsaremadewhen
deemedappropriatetomeetthelong-termobligationsoftheplans.Forcertainplans,fundingisnotacommonpractice,as
fundingprovidesnoeconomicbenefit.Consequently,theCompanyhasseveralpensionplansthatarenotfunded.
In2014,theCompanycontributed$561millionand$615milliontoitsU.S.andinternationalpensionplans,respectively.
ThefollowingtabledisplaysthefundedstatusoftheCompany’sU.S.Qualified&Non-Qualifiedpensionplansand
internationalfundedandunfundedpensionplansatDecember28,2014andDecember29,2013,respectively:
U.S.Plans InternationalPlans
QualifiedPlans Non-QualifiedPlans FundedPlans UnfundedPlans
(DollarsinMillions) 2014 2013 2014 2013 2014 2013 2014 2013
PlanAssets $15,201 13,990 – – 7,374 6,911 – –
ProjectedBenefitObligation 15,571 11,921 1,683 1,296 9,203 7,797 432 474
AccumulatedBenefitObligation 13,875 10,745 1,363 1,065 8,205 6,974 373 419
Over(Under)FundedStatus
ProjectedBenefitObligation $(370) 2,069 (1,683) (1,296) (1,829) (886) (432) (474)
AccumulatedBenefitObligation 1,326 3,245 (1,363) (1,065) (831) (63) (373) (419)
Planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligation,projected
benefitobligationandplanassetsof$8.2billion,$9.4billionand$5.3billion,respectively,attheendof2014,and$5.4
billion,$5.8billionand$3.3billion,respectively,attheendof2013.
ThefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromtheCompany’sretirementandotherbenefitplans:
(DollarsinMillions) 2015 2016 2017 2018 2019 2020-2024
Projectedfuturebenefitpayments
Retirementplans $793 813 868 907 963 5,858
Otherbenefitplans $316 309 306 303 300 1,475
Thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplans.Theseamounts
donotincludeanydiscretionarycontributionsthattheCompanymayelecttomakeinthefuture.
(DollarsinMillions) 2015 2016 2017 2018 2019 2020-2024
Projectedfuturecontributions $74 75 78 84 89 531
Eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand
investmentofthepensionplans.Indetermininginvestmentpolicies,strategiesandgoals,eachcommitteeorboard
considersfactorsincluding,localpensionrulesandregulations;localtaxregulations;availabilityofinvestmentvehicles
(separateaccounts,commingledaccounts,insurancefunds,etc.);fundedstatusoftheplans;ratioofactivestoretirees;
Johnson&Johnson2014AnnualReport • 41durationofliabilities;andotherrelevantfactorsincluding:diversification,liquidityoflocalmarketsandliquidityofbase
currency.AmajorityoftheCompany’spensionfundsareopentonewentrantsandareexpectedtobeon-goingplans.
Permittedinvestmentsareprimarilyliquidand/orlisted,withlittlerelianceonilliquidandnon-traditionalinvestmentssuch
ashedgefunds.
TheCompany’sretirementplanassetallocationattheendof2014and2013andtargetallocationsfor2015areas
follows:
Percentof Target
PlanAssets Allocation
2014 2013 2015
WorldwideRetirementPlans
Equitysecurities 77% 76% 73%
Debtsecurities 23 24 27
Totalplanassets 100% 100% 100%
DeterminationofFairValueofPlanAssets
ThePlanhasanestablishedandwell-documentedprocessfordeterminingfairvalues.Fairvalueisbaseduponquoted
marketprices,whereavailable.Iflistedpricesorquotesarenotavailable,fairvalueisbaseduponmodelsthatprimarily
use,asinputs,market-basedorindependentlysourcedmarketparameters,includingyieldcurves,interestrates,volatilities,
equityordebtprices,foreignexchangeratesandcreditcurves.
WhilethePlanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipants,theuseof
differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent
estimateoffairvalueatthereportingdate.
ValuationHierarchy
Theauthoritativeliteratureestablishesathree-levelhierarchytoprioritizetheinputsusedinmeasuringfairvalue.Thelevels
withinthehierarchyaredescribedinthetablebelowwithLevel1havingthehighestpriorityandLevel3havingthelowest.
Afinancialinstrument’scategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis
significanttothefairvaluemeasurement.
Followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue.
• Short-terminvestments–Cashandquotedshort-terminstrumentsarevaluedattheclosingpriceortheamountheld
ondepositbythecustodianbank.OtherinvestmentsarethroughinvestmentvehiclesvaluedusingtheNetAssetValue
(NAV)providedbytheadministratorofthefund.TheNAVisbasedonthevalueoftheunderlyingassetsownedbythe
fund,minusitsliabilities,andthendividedbythenumberofsharesoutstanding.TheNAVisaquotedpriceinamarket
thatisnotactiveandclassifiedasLevel2.
• Governmentandagencysecurities–Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon
themajormarketonwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,
theinvestmentsareclassifiedwithinLevel1ofthevaluationhierarchy.Ifquotedmarketpricesarenotavailableforthe
specificsecurity,thenfairvaluesareestimatedbyusingpricingmodels,quotedpricesofsecuritieswithsimilar
characteristicsordiscountedcashflows.Whenquotedmarketpricesforasecurityarenotavailableinanactivemarket,
theyareclassifiedasLevel2.
• Debtinstruments–Alimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket
onwhichtheindividualsecuritiesaretraded.Wherequotedpricesareavailableinanactivemarket,theinvestmentsare
classifiedasLevel1.Ifquotedmarketpricesarenotavailableforthespecificsecurity,thenfairvaluesareestimatedby
usingpricingmodels,quotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified
asLevel2.Level3debtinstrumentsarepricedbasedonunobservableinputs.
• Equitysecurities–Commonstocksarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual
securitiesaretraded.SubstantiallyallcommonstockisclassifiedwithinLevel1ofthevaluationhierarchy.
• Commingledfunds–TheseinvestmentvehiclesarevaluedusingtheNAVprovidedbythefundadministrator.TheNAV
isbasedonthevalueoftheunderlyingassetsownedbythefund,minusitsliabilities,andthendividedbythenumberof
sharesoutstanding.AssetsintheLevel2categoryhaveaquotedmarketpriceinamarketthatisnotactive.
42 • Johnson&Johnson2014AnnualReport• Insurancecontracts–Theinstrumentsareissuedbyinsurancecompanies.Thefairvalueisbasedonnegotiatedvalue
andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe
issuer.Theunderlyinginvestmentsaregovernment,asset-backedandfixedincomesecurities.Ingeneral,insurance
contractsareclassifiedasLevel3astherearenoquotedpricesnorotherobservableinputsforpricing.
• Otherassets–Otherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestments,aswellas
commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebt.Otherassetsthatareexchange
listedandactivelytradedareclassifiedasLevel1,whileinactivelytradedassetsareclassifiedasLevel2.Mostlimited
partnershipsrepresentinvestmentsinprivateequityandsimilarfundsthatarevaluedbythegeneralpartners.Certainof
theselimitedpartnerships,aswellasanyotherassetsvaluedusingunobservableinputs,areclassifiedasLevel3.
ThefollowingtablesetsforththeRetirementPlans’investmentsmeasuredatfairvalueasofDecember28,2014and
December29,2013:
QuotedPrices Significant
inActive Other Significant
Marketsfor Observable Unobservable
IdenticalAssets Inputs Inputs
(Level1) (Level2) (Level3) TotalAssets
(DollarsinMillions) 2014 2013 2014 2013 2014 2013 2014 2013
Short-terminvestmentfunds $168 304 551 561 – – 719 865
Governmentandagencysecurities – – 1,934 1,965 – – 1,934 1,965
Debtinstruments – – 1,143 1,215 1 1 1,144 1,216
Equitysecurities 11,204 10,526 21 23 – 4 11,225 10,553
Commingledfunds – – 7,205 5,846 46 44 7,251 5,890
Insurancecontracts – – – 2 24 23 24 25
Otherassets 1 4 214 314 63 69 278 387
Investmentsatfairvalue $11,373 10,834 11,068 9,926 134 141 22,575 20,901
TheCompany’sOtherBenefitPlansareunfundedexceptforU.S.commingledfunds(Level2)of$79millionand$76
millionatDecember28,2014andDecember29,2013,respectively,and$0millionand$11millionofU.S.short-term-
investmentfunds(Level2)atDecember28,2014andDecember29,2013,respectively.
ThefairvalueofJohnson&JohnsonCommonStockdirectlyheldinplanassetswas$778million(3.4%oftotalplan
assets)atDecember28,2014and$671million(3.2%oftotalplanassets)atDecember29,2013.
Level3GainsandLosses
ThetablebelowsetsforthasummaryofchangesinthefairvalueofthePlan’sLevel3assetsfortheyearsended
December28,2014andDecember29,2013:
Debt Equity Commingled Insurance Other Total
(DollarsinMillions) Instruments Securities Funds Contracts Assets Level3
BalanceDecember30,2012 $3 4 50 24 69 150
Realizedgains(losses) – – – – (5) (5)
Unrealizedgains(losses) – (1) – (1) – (2)
Purchases,sales,issuancesandsettlements,net (2) 1 (6) – 5 (2)
BalanceDecember29,2013 1 4 44 23 69 141
Realizedgains(losses) – – – – (5) (5)
Unrealizedgains(losses) – – 2 – – 2
Purchases,sales,issuancesandsettlements,net – – (2) 3 (1) –
Transfersin/outandexchangeratechanges – (4) 2 (2) – (4)
BalanceDecember28,2014 $1 – 46 24 63 134
Johnson&Johnson2014AnnualReport • 4311. SavingsPlan
TheCompanyhasvoluntary401(k)savingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible
employees.TheCompanymatchesapercentageofeachemployee’scontributionsconsistentwiththeprovisionsofthe
planforwhichhe/sheiseligible.TotalCompanymatchingcontributionstotheplanswere$172million,$164millionand
$160millionin2014,2013and2012,respectively.
12. CapitalandTreasuryStock
Changesintreasurystockwere:
TreasuryStock
(AmountsinMillionsExceptTreasuryStockSharesinThousands) Shares Amount
BalanceatJanuary1,2012 395,480 $21,659
Employeecompensationandstockoptionplans (55,170) (3,250)
IssuanceofcommonstockassociatedwiththeacquisitionofSynthes,Inc. (203,740) (12,852)
Repurchaseofcommonstock(1) 204,784 12,919
BalanceatDecember30,2012 341,354 18,476
Employeecompensationandstockoptionplans (48,555) (3,367)
Repurchaseofcommonstock 6,416 591
BalanceatDecember29,2013 299,215 15,700
Employeecompensationandstockoptionplans (32,302) (2,933)
Repurchaseofcommonstock 69,707 7,124
BalanceatDecember28,2014 336,620 $19,891
(1) IncludesrepurchaseofcommonstockassociatedwiththeacquisitionofSynthes,Inc.
Aggregatesharesofcommonstockissuedwereapproximately3,119,843,000sharesattheendof2014,2013and
2012.
Cashdividendspaidwere$2.76persharein2014,comparedwithdividendsof$2.59persharein2013,and$2.40per
sharein2012.
OnJuly21,2014,theCompanyannouncedthatitsBoardofDirectorsapprovedasharerepurchaseprogram,authorizing
theCompanytopurchaseupto$5.0billionoftheCompany’ssharesofcommonstock.AsofDecember28,2014,$3.5
billionhasbeenrepurchasedundertheprogram.Sharerepurchaseswilltakeplaceontheopenmarketfromtimetotime
basedonmarketconditions.Therepurchaseprogramhasnotimelimitandmaybesuspendedforperiodsordiscontinued
atanytime.Anysharesacquiredwillbeavailableforgeneralcorporatepurposes.TheCompanyintendstofinancethe
sharerepurchaseprogramthroughavailablecash.
13. AccumulatedOtherComprehensiveIncome
Componentsofothercomprehensiveincome(loss)consistofthefollowing:
Gain/ Total
Gain/ (Loss) Accumulated
Foreign (Loss) Employee On Other
Currency On Benefit Derivatives Comprehensive
(DollarsinMillions) Translation Securities Plans &Hedges Income(Loss)
January1,2012 $(1,526) 448 (4,386) (168) (5,632)
Net2012changes 1,230 (253) (1,331) 176 (178)
December30,2012 (296) 195 (5,717) 8 (5,810)
Net2013changes 94 (89) 2,708 237 2,950
December29,2013 (202) 106 (3,009) 245 (2,860)
Net2014changes (4,601) 151 (3,308) (104) (7,862)
December28,2014 $(4,803) 257 (6,317) 141 (10,722)
44 • Johnson&Johnson2014AnnualReportAmountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpact.Foreigncurrency
translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiaries.For
additionaldetailsoncomprehensiveincomeseetheConsolidatedStatementsofComprehensiveIncome.
DetailsonreclassificationsoutofAccumulatedOtherComprehensiveIncome:
Gain/(Loss)onSecurities–reclassificationsreleasedtoOther(income)expense,net.
EmployeeBenefitPlans–reclassificationsareincludedinnetperiodicbenefitcost.SeeNote10foradditional
details.
Gain/(Loss)onDerivatives&Hedges–reclassificationstoearningsarerecordedinthesameaccountasthe
hedgedtransaction.SeeNote6foradditionaldetails.
14. InternationalCurrencyTranslation
Fortranslationofitssubsidiariesoperatinginnon-U.S.Dollarcurrencies,theCompanyhasdeterminedthatthelocal
currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomies,which
aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationof100%ormoreduringthepastthreeyears,
orwhereasubstantialportionofitscashflowsarenotinthelocalcurrency.
Inconsolidatinginternationalsubsidiaries,balancesheetcurrencyeffectsarerecordedasacomponentofaccumulated
othercomprehensiveincome.Thisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand
liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalrates,exceptforthoselocatedinhighlyinflationary
economies.Thetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperating
results.
Arollforwardofthechangesduring2014,2013and2012forforeigncurrencytranslationadjustmentsisincludedin
Note13.
NetcurrencytransactiongainsandlossesincludedinOther(income)expensewerelossesof$156million,$186million
and$58millionin2014,2013and2012,respectively.
15. EarningsPerShare
Thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended
December28,2014,December29,2013andDecember30,2012:
(InMillionsExceptPerShareAmounts) 2014 2013 2012
BasicnetearningspershareattributabletoJohnson&Johnson $5.80 4.92 3.94
Averagesharesoutstanding–basic 2,815.2 2,809.2 2,753.3
Potentialsharesexercisableunderstockoptionplans 142.6 148.5 164.6
Less:sharesrepurchasedundertreasurystockmethod (96.5) (103.3) (128.2)
Convertibledebtshares 2.6 3.0 3.6
Acceleratedsharerepurchaseprogram – 19.6 19.3
Adjustedaveragesharesoutstanding–diluted 2,863.9 2,877.0 2,812.6
DilutednetearningspershareattributabletoJohnson&Johnson $5.70 4.81 3.86
Thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelated
reductionininterestexpenseof$3millionafter-taxfor2014and$4millionforyears2013and2012.
Thedilutedearningspersharecalculationfor2014and2013includedallsharesrelatedtostockoptions,astheexercise
priceofalloptionswaslessthantheaveragemarketvalueoftheCompany’sstock.Dilutednetearningspersharefor
2012excluded0.2millionsharesrelatedtostockoptions,astheexercisepriceoftheseoptionswasgreaterthantheir
averagemarketvalue,whichwouldresultinananti-dilutiveeffectondilutedearningspershare.
ThedilutedearningspersharecalculationforthefiscalyearsendedDecember29,2013andDecember30,2012
includedthedilutiveeffectof19.6millionsharesand19.3millionshares,respectively,relatedtotheacceleratedshare
repurchaseprogram,associatedwiththeacquisitionofSynthes,Inc.SeeNote20totheConsolidatedFinancial
Statementsforadditionaldetails.
Johnson&Johnson2014AnnualReport • 4516. RentalExpenseandLeaseCommitments
Rentalsofspace,vehicles,manufacturingequipmentandofficeanddataprocessingequipmentunderoperatingleases
wereapproximately$341million,$363millionand$375millionin2014,2013and2012,respectively.
Theapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnon-cancelable
leasetermsinexcessofoneyearatDecember28,2014are:
(DollarsinMillions)
After
2015 2016 2017 2018 2019 2019 Total
$200 157 111 80 66 77 691
Commitmentsundercapitalleasesarenotsignificant.
17. CommonStock,StockOptionPlansandStockCompensationAgreements
AtDecember28,2014,theCompanyhad3stock-basedcompensationplans.Thesharesoutstandingareforcontracts
undertheCompany’s2000StockOptionPlan,the2005Long-TermIncentivePlanandthe2012Long-TermIncentive
Plan.The2005Long-TermIncentivePlanexpiredApril26,2012.Alloptionsandrestrictedsharesgrantedsubsequentto
thatdatewereunderthe2012Long-TermIncentivePlan.Underthe2012Long-TermIncentivePlan,theCompanymay
issueupto650millionsharesofcommonstock,plusanysharescanceled,expired,forfeited,ornotissuedfromthe2005
Long-TermIncentivePlansubsequenttoApril26,2012.Sharesavailableforfuturegrantsunderthe2012Long-Term
IncentivePlanwere530millionattheendof2014.
Thecompensationcostthathasbeenchargedagainstincomefortheseplanswas$792million,$728millionand$662
millionfor2014,2013and2012,respectively.Thetotalincometaxbenefitrecognizedintheincomestatementfor
share-basedcompensationcostswas$259million,$243millionand$220millionfor2014,2013and2012,
respectively.Thetotalunrecognizedcompensationcostwas$722million,$636millionand$565millionfor2014,2013
and2012,respectively.Theweightedaverageperiodforthiscosttoberecognizedwas1.18years,1.26yearsand1.02
yearsfor2014,2013,and2012,respectively.Share-basedcompensationcostscapitalizedaspartofinventorywere
insignificantinallperiods.
TheCompanysettlesemployeebenefitequityissuanceswithtreasuryshares.Treasurysharesarereplenishedthroughout
theyearforthenumberofsharesusedtosettleemployeebenefitequityissuances.
StockOptions
Stockoptionsexpire10yearsfromthedateofgrantandvestoverserviceperiodsthatrangefrom6monthsto4years.All
optionsaregrantedattheaverageofthehighandlowpricesoftheCompany’sCommonStockontheNewYorkStock
Exchangeonthedateofgrant.
ThefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheBlack-Scholesoptionvaluationmodel
thatusestheassumptionsnotedinthefollowingtable.Expectedvolatilityrepresentsablendedrateof4-yeardaily
historicalaveragevolatilityrate,anda5-weekaverageimpliedvolatilityratebasedonat-the-moneytradedJohnson&
Johnsonoptionswithalifeof2years.Historicaldataisusedtodeterminetheexpectedlifeoftheoption.Therisk-freerate
wasbasedontheU.S.Treasuryyieldcurveineffectatthetimeofgrant.
Theaveragefairvalueofoptionsgrantedwas$8.42,$4.88and$6.39,in2014,2013and2012,respectively.Thefair
valuewasestimatedbasedontheweightedaverageassumptionsof:
2014 2013 2012
Risk-freerate 1.87% 1.01% 1.06%
Expectedvolatility 14.60% 14.04% 18.38%
Expectedlife(inyears) 6.0 6.0 6.0
Dividendyield 3.10% 3.40% 3.60%
46 • Johnson&Johnson2014AnnualReportAsummaryofoptionactivityunderthePlanasofDecember28,2014,December29,2013andDecember30,2012,and
changesduringtheyearsendingonthosedatesispresentedbelow:
Aggregate
Intrinsic
Weighted Value
Outstanding Average (Dollarsin
(SharesinThousands) Shares ExercisePrice Millions)
SharesatJanuary1,2012 179,459 $60.10 $1,004
Optionsgranted 8,661 65.36
Optionsexercised (49,388) 56.73
Optionscanceled/forfeited (4,381) 62.97
SharesatDecember30,2012 134,351 61.58 1,061
Optionsgranted 29,010 72.54
Optionsexercised (41,357) 59.99
Optionscanceled/forfeited (2,448) 65.89
SharesatDecember29,2013 119,556 64.70 3,306
Optionsgranted 24,356 90.44
Optionsexercised (25,319) 62.31
Optionscanceled/forfeited (2,881) 75.48
SharesatDecember28,2014 115,712 $70.37 $4,014
Thetotalintrinsicvalueofoptionsexercisedwas$954million,$941millionand$547millionin2014,2013and2012,
respectively.
ThefollowingtablesummarizesstockoptionsoutstandingandexercisableatDecember28,2014:
(SharesinThousands) Outstanding Exercisable
Average Average
Average Exercise Exercise
ExercisePriceRange Options Life(1) Price Options Price
$52.13-$58.33 10,182 4.1 $58.32 10,182 $58.32
$58.34-$62.20 24,179 3.1 $60.68 23,653 $60.64
$62.62-$65.62 25,630 4.4 $64.60 18,346 $64.30
$65.80-$72.54 32,252 6.6 $71.43 5,661 $66.20
$90.44-$100.48 23,469 9.1 $90.44 4 $90.44
115,712 5.7 $70.37 57,846 $61.94
(1) Averagecontractualliferemaininginyears.
StockoptionsoutstandingatDecember29,2013andDecember30,2012were119,556andanaveragelifeof5.1years
and134,351andanaveragelifeof4.3years,respectively.StockoptionsexercisableatDecember29,2013and
December30,2012were75,210atanaveragepriceof$62.01and104,860atanaveragepriceof$61.15,respectively.
RestrictedShareUnitsandPerformance ShareUnits
TheCompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrom6monthsto3years.The
Companyalsograntsperformanceshareunits,whicharepaidinsharesofJohnson&JohnsonCommonStockafterthe
endofathree-yearperformanceperiod.Whetheranyperformanceshareunitsvest,andtheamountthatdoesvest,istied
tothecompletionofserviceperiodsthatrangefrom6monthsto3yearsandtheachievement,overathree-yearperiod,of
threeequally-weightedgoalsthatdirectlyalignwithorhelpdrivelong-termtotalshareholderreturn:sales,adjusted
operationalearningspershare,andrelativetotalshareholderreturn.Thenumberofsharesactuallyearnedattheendof
thethree-yearperiodwillvary,basedonlyonactualperformance,from0%to200%ofthetargetnumberofperformance
shareunitsgranted.
Johnson&Johnson2014AnnualReport • 47AsummaryoftherestrictedshareunitsandperformanceshareunitsactivityunderthePlansasofDecember28,2014is
presentedbelow:
Outstanding Outstanding
Restricted Performance
(SharesinThousands) ShareUnits ShareUnits
SharesatJanuary1,2012 31,026
Granted 12,197 327
Issued (9,278) –
Canceled/forfeited (2,111) (42)
SharesatDecember30,2012 31,834 285
Granted 10,582 1,290
Issued (10,078) –
Canceled/forfeited (1,721) (40)
SharesatDecember29,2013 30,617 1,535
Granted 8,487 1,113
Issued (9,685) (19)
Canceled/forfeited (1,726) (98)
SharesatDecember28,2014 27,693 2,531
Theaveragefairvalueoftherestrictedshareunitsgrantedwas$83.01,$65.90and$58.93in2014,2013and2012,
respectively,usingthefairmarketvalueatthedateofgrant.Thefairvalueofrestrictedshareunitswasdiscountedfor
dividends,whicharenotpaidontherestrictedshareunitsduringthevestingperiod.Thefairvalueofrestrictedshareunits
issuedwas$541.0million,$569.2millionand$483.2millionin2014,2013and2012,respectively.
Theweightedaveragefairvalueoftheperformanceshareunitsgrantedwas$85.94,$73.42and$55.01in2014,2013
and2012,calculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthedateof
grant.
Thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof
grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividends,whicharenotpaidonthe
performanceshareunitsduringthevestingperiod.Thefairvaluefortherelativetotalshareholderreturngoalofeach
performanceshareunitwasestimatedonthedateofgrantusingtheMonteCarlovaluationmodel.Thefairvalueof
performanceshareunitsissuedin2014was$1.4millionduetoacceleratedvestinginaccordancewiththeplan
document.Noperformanceshareunitsvestedin2013and2012.
18. SegmentsofBusinessandGeographicAreas
SalestoCustomers
(DollarsinMillions) 2014 2013 2012
Consumer–
UnitedStates $5,096 5,162 5,046
International 9,400 9,535 9,401
Total 14,496 14,697 14,447
Pharmaceutical–
UnitedStates 17,432 13,948 12,421
International 14,881 14,177 12,930
Total 32,313 28,125 25,351
MedicalDevices–
UnitedStates 12,254 12,800 12,363
International 15,268 15,690 15,063
Total 27,522 28,490 27,426
Worldwidetotal $74,331 71,312 67,224
48 • Johnson&Johnson2014AnnualReportPre-TaxProfit IdentifiableAssets
(DollarsinMillions) 2014(3) 2013(4) 2012(5) 2014 2013 2012
Consumer $1,941 1,973 1,693 $21,813 23,711 24,131
Pharmaceutical 11,696 9,178 6,075 25,803 23,783 23,219
MedicalDevices 7,953 5,261 7,187 41,445 44,585 42,926
Total 21,590 16,412 14,955 89,061 92,079 90,276
Less:Expensenotallocatedtosegments(1) 1,027 941 1,180
Generalcorporate(2) 42,058 40,604 31,071
Worldwidetotal $20,563 15,471 13,775 $131,119 132,683 121,347
AdditionstoProperty, Depreciationand
Plant&Equipment Amortization
(DollarsinMillions) 2014 2013 2012 2014 2013 2012
Consumer $581 533 468 $577 539 575
Pharmaceutical 977 856 737 1,053 1,075 1,010
MedicalDevices 1,807 1,724 1,230 1,974 2,224 1,857
Segmentstotal 3,365 3,113 2,435 3,604 3,838 3,442
Generalcorporate 349 482 499 291 266 224
Worldwidetotal $3,714 3,595 2,934 $3,895 4,104 3,666
SalestoCustomers Long-LivedAssets(6)
(DollarsinMillions) 2014 2013 2012 2014 2013 2012
UnitedStates $34,782 31,910 29,830 $36,835 35,880 35,115
Europe 18,947 18,599 16,945 21,559 24,868 25,261
WesternHemisphereexcludingU.S. 7,160 7,421 7,207 3,210 3,281 3,636
Asia-Pacific,Africa 13,442 13,382 13,242 2,438 2,434 2,362
Segmentstotal 74,331 71,312 67,224 64,042 66,463 66,374
Generalcorporate 1,138 992 899
Othernonlong-livedassets 65,939 65,228 54,074
Worldwidetotal $74,331 71,312 67,224 $131,119 132,683 121,347
SeeNote1foradescriptionofthesegmentsinwhichtheCompanyoperates.
Exportsalesarenotsignificant.In2014,theCompanyhadonewholesalerdistributingproductsforallthreesegmentsthatrepresented
approximately11.0%ofthetotalconsolidatedrevenues.In2013and2012,theCompanydidnothaveacustomerthatrepresented
10.0%oftotalrevenues.
(1) Amountsnotallocatedtosegmentsincludeinterest(income)expense,noncontrollinginterestsandgeneralcorporate(income)
expense.Includescurrencyrelatedexpenseof$0.2billionassociatedwiththeacquisitionofSynthes,Inc.in2012.
(2) Generalcorporateincludescash,cashequivalentsandmarketablesecurities.
(3) Includesnetlitigationexpenseof$1,253millioncomprisedof$907million,$259millionand$87millionintheMedicalDevices,
PharmaceuticalandConsumersegments,respectively.Includes$178millionofin-processresearchanddevelopmentexpense,
comprisedof$147millionand$31millioninthePharmaceuticalandMedicalDevicessegments,respectively.TheMedicalDevices
segmentincludesanetgainof$1,899millionfromthedivestitureoftheOrtho-ClinicalDiagnosticsbusiness,Synthesintegration
costsof$754millionand$126millionexpenseforthecostassociatedwiththeDePuyASR™Hipprogram.Includesanadditional
yearoftheBrandedPrescriptionDrugFeeof$220millioninthePharmaceuticalsegment.
(4) Includes$2,276millionofnetlitigationexpensecomprisedof$1,975millionand$301millionintheMedicalDevicesand
Pharmaceuticalsegments,respectively.Includes$683millionofSynthesintegration/transactioncostsintheMedicalDevices
segment.Includes$580millionofin-processresearchanddevelopmentexpense,comprisedof$514millionand$66millioninthe
PharmaceuticalandMedicalDevicessegments,respectively.TheMedicalDevicessegmentalsoincludes$251millionexpensefor
thecostassociatedwiththeDePuyASRTMHipprogram.Includes$98millionofincomerelatedtootheradjustmentscomprisedof
$55millionand$43millionintheConsumerandPharmaceuticalsegments,respectively.
(5) Includes$1,218millionofnetlitigationexpensecomprisedof$658millionand$560millioninthePharmaceuticalandMedical
Devicessegments,respectively.Includes$1,163millionofin-processresearchanddevelopmentexpense,comprisedof$1,111
millionand$52millioninthePharmaceuticalandMedicalDevicessegments,respectively.Includes$795millionofSynthes
integration/transactioncostsintheMedicalDevicessegment.Includes$909millionofassetwrite-downsandotheradjustments,
comprisedof$499million,$264millionand$146millioninthePharmaceutical,ConsumerandMedicalDevicessegments,
respectively.TheMedicalDevicessegmentalsoincludes$110millionexpenseforthecostassociatedwiththeDePuyASR™Hip
program.
(6) Long-livedassetsincludeproperty,plantandequipment,netfor2014,2013and2012of$16,126,$16,710and$16,097,
respectively,andintangibleassetsandgoodwill,netfor2014,2013and2012of$49,054,$50,745and$51,176,respectively.
Johnson&Johnson2014AnnualReport • 4919. SelectedQuarterlyFinancialData(unaudited)
Selectedunauditedquarterlyfinancialdatafortheyears2014and2013aresummarizedbelow:
2014 2013
(DollarsinMillionsExceptPerShare First Second Third Fourth First Second Third Fourth
Data) Quarter(1) Quarter(2) Quarter(3) Quarter(4) Quarter(5) Quarter(6) Quarter(7) Quarter(8)
Segmentsalestocustomers
Consumer $3,557 3,744 3,589 3,606 3,675 3,658 3,611 3,753
Pharmaceutical 7,498 8,509 8,307 7,999 6,768 7,025 7,036 7,296
MedicalDevices 7,060 7,242 6,571 6,649 7,062 7,194 6,928 7,306
Totalsales 18,115 19,495 18,467 18,254 17,505 17,877 17,575 18,355
Grossprofit 12,660 13,456 13,068 12,401 11,951 12,388 12,231 12,400
Earningsbeforeprovisionfortaxeson
income 5,424 5,626 6,810 2,703 4,261 4,793 3,667 2,750
NetearningsattributabletoJohnson&
Johnson 4,727 4,326 4,749 2,521 3,497 3,833 2,982 3,519
Basicnetearningspershareattributable
toJohnson&Johnson $1.67 1.53 1.69 0.90 1.25 1.36 1.06 1.25
Dilutednetearningspershare
attributabletoJohnson&Johnson $1.64 1.51 1.66 0.89 1.22 1.33 1.04 1.23
(1) Thefirstquarterof2014includesSynthesintegrationcostsof$84millionafter-tax($118millionbefore-tax)anda$398milliontax
benefitassociatedwithConorMedsystems.
(2) Thesecondquarterof2014includeslitigationexpenseof$342millionafter-tax($276millionbefore-tax)andSynthesintegration
costsof$104millionafter-tax($144millionbefore-tax).
(3) Thethirdquarterof2014includesanadditionalyearoftheBrandedPrescriptionDrugFeeof$220millionafterandbeforetax,
litigationexpenseof$231millionafter-tax($285millionbefore-tax),Synthesintegrationcostsof$130millionafter-tax($167million
before-tax)and$111millionafter-tax($126millionbefore-tax)forcostsassociatedwiththeDePuyASR™Hipprogram.Additionally,
thefiscalthirdquarterof2014includesanetgainof$1.1billionafter-tax($1.9billionbefore-tax)forthedivestitureoftheOrtho-
ClinicalDiagnosticsbusiness.
(4) Thefourthquarterof2014includeslitigationexpense,primarilyrelatedtoproductliabilityandpatentlitigationof$652millionafter-
tax($692millionbefore-tax),Synthesintegrationcostsof$237millionafter-tax($325millionbefore-tax)and$115millionafter-tax
($156millionbefore-tax)fromimpairmentofin-processresearchanddevelopment.
(5) Thefirstquarterof2013includesSynthesintegration/transactioncostsof$183millionafter-tax($258millionbefore-tax)andnet
litigationexpenseof$391millionafter-tax($529millionbefore-tax).
(6) Thesecondquarterof2013includesnetlitigationexpenseof$308millionafter-tax($375millionbefore-tax)andSynthes
integration/transactioncostsof$87millionafter-tax($122millionbefore-tax).
(7) Thethirdquarterof2013includesnetlitigationexpenseof$720millionafter-tax($872millionbefore-tax),Synthesintegration/
transactioncostsof$103millionafter-tax($122millionbefore-tax)and$126millionafter-tax($178millionbefore-tax)from
impairmentofin-processresearchanddevelopment.
(8) Thefourthquarterof2013includesnetlitigationexpenseof$227millionafter-tax($506millionbefore-tax),Synthesintegration/
transactioncosts$110millionafter-tax($181millionbefore-tax),$294millionafter-tax($338millionbefore-tax)fromimpairmentof
in-processresearchanddevelopmentand$118millionafter-tax($134millionbefore-tax)forcostsassociatedwiththeDePuyASR™
Hipprogramanda$707milliontaxbenefitassociatedwithSciosInc.
20. BusinessCombinationsandDivestitures
Certainbusinesseswereacquiredfor$2,129millionincashand$38millionofliabilitiesassumedduring2014.These
acquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeenincluded
inthefinancialstatementsfromtheirrespectivedatesofacquisition.
The2014acquisitionsincluded:CovagenAG,aprivately-held,biopharmaceuticalcompanyspecializinginthe
developmentofmultispecificproteintherapeuticsthroughtheFynomAb®technologyplatform;AliosBioPharma,Inc.,a
privately-held,clinicalstagebiopharmaceuticalcompanyfocusedondevelopingtherapiesforviraldiseases;andthe
ORSL™electrolyteready-to-drinkbrandfromJagdaleIndustriesLtd.Theexcessofpurchasepriceovertheestimatedfair
valueoftangibleassetsacquiredamountedto$2,069millionandhasbeenassignedtoidentifiableintangibleassets,
50 • Johnson&Johnson2014AnnualReportwithanyresidualrecordedtogoodwill.Ofthisamount,approximately$1,913millionhasbeenidentifiedasthevalueof
IPR&DassociatedwiththeacquisitionsofCovagenAGandAliosBioPharma,Inc.ThevalueoftheIPR&Dwascalculated
usingcashflowprojectionsdiscountedfortheinherentriskintheprojects.
TheIPR&DrelatedtotheacquisitionofAliosBioPharma,Inc.(Alios)of$1,688millionisassociatedwithAlios’lead
compoundAL-8176,anorallyadministeredantiviraltherapyfortreatmentofinfantswithrespiratorysyncytialvirus(RSV).
Aprobabilityofsuccessfactorof60.0%wasusedtoreflectinherentclinicalandregulatoryrisk.Thediscountrateapplied
was11.4%.TheIPR&DrelatedtotheacquisitionofCovagenAGof$225millionisassociatedwithCovagen’slead
compoundCOVA-322,currentlyinPhase1bstudyforpsoriasisandholdingpotentialasatreatmentforabroadrangeof
inflammatorydiseasesincludingrheumatoidarthritis.Aprobabilityofsuccessfactorof26%wasusedtoreflectinherent
clinicalandregulatoryrisk.Thediscountrateappliedwas12.5%.
Certainbusinesseswereacquiredfor$835millionincashand$193millionofliabilitiesassumedduring2013.These
acquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshavebeenincluded
inthefinancialstatementsfromtheirrespectivedatesofacquisition.
Theassumedliabilitiesprimarilyrepresentthefairvalueofthecontingentconsiderationwhichmaybepayablerelatedto
theacquisitionofAragonPharmaceuticals,Inc.Aspertermsoftheagreement,additionalpaymentsofupto$350million
maybepaidinthefuturebasedonreachingpredeterminedmilestones.
The2013acquisitionsincluded:FlexibleStentingSolutions,Inc.,aleadingdeveloperofinnovativeflexibleperipheral
arterial,venousandbiliarystents;ShanghaiElskerMother&BabyCo.,Ltd,ababycarecompanyinChinaandAragon
Pharmaceuticals,Inc.,aprivately-held,pharmaceuticaldiscoveryanddevelopmentcompanyfocusedondrugstotreat
hormonally-drivencancers.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$941millionandhas
beenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.Ofthisamount,approximately$831
millionhasbeenidentifiedasthevalueofIPR&DassociatedwiththeacquisitionsofAragonPharmaceuticals,Inc.and
FlexibleStentingSolutions,Inc.
TheIPR&DrelatedtotheacquisitionofAragonPharmaceuticals,Inc.of$810millionisassociatedwithAragon’s
androgenreceptorantagonistprogramfortreatmentofhormonally-drivencancers.ThevalueoftheIPR&Dwascalculated
usingcashflowprojectionsdiscountedfortheinherentriskinsuchprojects.Probabilityofsuccessfactorsrangingfrom
37%-52.0%wereusedtoreflectinherentclinicalandregulatoryrisk.Thediscountrateappliedwas15.5%.TheIPR&D
relatedtotheacquisitionofFlexibleStentingSolutions,Inc.of$21millionisassociatedwiththeapprovalforperipheral
vascularindications,includingthesuperficialfemoralarteryindication.Aprobabilityofsuccessfactorof100%wasused
andadiscountraterangingbetween16.5%-17.5%wasapplied.
Certainbusinesseswereacquiredfor$17,821millionincashandstockand$1,204millionofliabilitiesassumedduring
2012.Theseacquisitionswereaccountedforusingtheacquisitionmethodand,accordingly,resultsofoperationshave
beenincludedinthefinancialstatementsfromtheirrespectivedatesofacquisition.
The2012acquisitionsincluded:Synthes,Inc.,aglobaldeveloperandmanufactureroforthopaedicsdevices;Guangzhou
BiosealBiotechCo.,Ltd.,adeveloperofbiologiccombinationsaddressingmoderatetoseverehemostasis;Angiotech
Pharmaceuticals,Inc.,intellectualpropertyandknowhowrelatedtotheQuillTMKnotlessTissue-ClosureDevice;
CorImmunGmbH,adeveloperofaphaseIItreatmentforCHF;CalibraMedical,Inc.,adeveloperofaunique,wearable
three-dayinsulinpatchforconvenientanddiscreetmealtimedosingforpeoplewithdiabeteswhotakemultipledaily
injectionsofinsulin;SpectrumVisionLLC,afullservicedistributorofcontactlensesservingRussiawithfacilitiesinthe
UkraineandKazakhstan;andmarketingauthorizations,trademarks,andpatentsextendingZYRTEC®relatedmarketrights
inAustraliaandCanada.
Theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedto$15,785millionand
hasbeenassignedtoidentifiableintangibleassets,withanyresidualrecordedtogoodwill.Ofthisamount,approximately
$208millionhasbeenidentifiedasthevalueofIPR&DassociatedwiththeacquisitionsofCorImmunGmbHandSynthes,
Inc.
TheIPR&DrelatedtotheacquisitionofSynthes,Inc.of$63millionisassociatedwithorthopaedicdevices,andtheIPR&D
associatedwithCorImmunof$145millionisrelatedtoaCHFtreatment.TheseIPR&Dvalueswerecalculatedusingthe
cashflowprojectionsdiscountedfortheriskinherentinsuchprojects.Synthes,Inc.hadaprobabilityofsuccessfactorof
100%,discountedusinga14%rate.CorImmunhadaprobabilityofsuccessfactorof38%,discountedusinga25%rate.
During2013,theCompanyrecordedachargeof$0.2billionfortheimpairmentofthein-processresearchand
developmentassociatedwithCorImmun.
Johnson&Johnson2014AnnualReport • 51Duringthefiscalsecondquarterof2012,theCompanycompletedtheacquisitionofSynthes,Inc.,aglobaldeveloperand
manufactureroforthopaedicsdevices,forapurchasepriceof$20.2billionincashandstock.Thenetacquisitioncostof
thetransactionwas$17.5billionbasedoncashonhandatclosingof$2.7billion.
Underthetermsoftheagreement,eachshareofSynthes,Inc.commonstockwasexchangedforCHF55.65incashand
1.717sharesofJohnson&Johnsoncommonstock,basedonthecalculatedexchangeratio.Theexchangeratiowas
calculatedonJune12,2012andbasedontherelevantexchangerateandclosingpriceofJohnson&Johnsoncommon
stockonthatdate,thetotalfairvalueofconsiderationtransferredwas$19.7billion.Whentheacquisitionwascompleted
onJune14,2012,basedontherelevantexchangerateandclosingpriceofJohnson&Johnsoncommonstockonthat
date,thetotalfairvalueoftheconsiderationtransferredwas$20.2billion.JanssenPharmaceutical,acompanyorganized
underthelawsofIrelandandawholly-ownedsubsidiaryofJohnson&Johnson,usedcashonhandtosatisfythecash
portionofthemergerconsideration.
ThestockportionofthemergerconsiderationconsistedofsharesofJohnson&Johnsoncommonstockpurchasedby
JanssenPharmaceuticalfromtwobanks,pursuanttotwoacceleratedsharerepurchase(ASR)agreementsdatedJune12,
2012.OnJune13,2012,JanssenPharmaceuticalpurchasedanaggregateofapproximately203.7millionsharesof
Johnson&Johnsoncommonstockataninitialpurchasepriceof$12.9billionundertheASRagreements,withallofthe
sharesdeliveredtoJanssenPharmaceuticalonJune13,2012.Duringthefiscalthirdquarterof2013,theCompany
settledtheremainingliabilitiesundertheASRagreementsfor$2.9billionincashwhichwasrecordedasareductionto
equity.
Inaddition,whiletheCompanybelievesthatthetransactionsundereachASRagreementandaseriesofrelatedinternal
transactionswereconsummatedinataxefficientmannerinaccordancewithapplicablelaw,itispossiblethattheInternal
RevenueServicecouldassertoneormorecontrarypositionstochallengethetransactionsfromataxperspective.If
challenged,anamountuptothetotalpurchasepricefortheSynthessharescouldbetreatedassubjecttoapplicableU.S.
taxatapproximatelythestatutoryratetotheCompany,plusinterest.
ThefollowingtablesummarizestheconsiderationtransferredtoacquireSynthes,Inc.valuedontheacquisitiondateof
June14,2012:
(DollarsinMillions)
Cash(multiply55.65CHFbysharesofSynthescommonstockoutstandingbytheexchangerate)(A) $6,902
CommonStock(multiply1.717bysharesofSynthescommonstockoutstandingbyJ&Jstockprice)(B) $13,335
Totalfairvalueofconsiderationtransferred $20,237
(A) Synthescommonstockoutstandingof118.7millionsharesasoftheacquisitiondateandCHF/USDexchangerateof.95674
(B) Johnson&JohnsonclosingstockpriceontheNewYorkStockExchangeasofacquisitiondateof$65.45pershare.
TheCompanycontinuestoexecutetheintegrationplanstocombinebusinesses,salesorganizations,systemsand
locationsasaresultofwhichtheCompanyhasandwillcontinuetoincurintegrationcosts.
TheoperatingresultsofSyntheswerereportedintheCompany’sfinancialstatementsbeginningonJune14,2012.Total
salesandnetearningsforSynthesforthefiscalyearendedDecember30,2012were$2,159millionand$324million,
respectively.
ThefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendedDecember30,2012,asifSynthes,
Inc.hadbeenacquiredasofthebeginningoftheperiodpresented.Theproformaresultsincludetheeffectofdivestitures
andcertainpurchaseaccountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseon
theacquiredtangibleandintangibleassets.However,proformaresultsdonotincludeanyanticipatedcostsavingsor
othereffectsoftheintegrationofSynthes,Inc.Accordingly,suchamountsarenotnecessarilyindicativeoftheresultsifthe
acquisitionhadoccurredonthedatesindicatedorwhichmayoccurinthefuture.
UnauditedProforma
consolidatedresults
(DollarsinMillionsExceptPerShareAmounts) 2012
NetSales $68,894
NetEarningsattributabletoJohnson&Johnson $11,564
DilutedNetEarningspershareattributabletoJohnson&Johnson $4.11
52 • Johnson&Johnson2014AnnualReportTheCompanyrecordedacquisitionrelatedcostsbeforetaxof$754million,$683millionand$1,028millionin2014,
2013and2012,respectively,whichwererecordedinOther(income)expenseandCostofproductssold.
InconnectionwiththeSynthesacquisition,DePuyOrthopaedics,Inc.agreedtodivestcertainrightsandassetsrelatedto
itstraumabusinesstoBiomet,Inc.andcompletedtheinitialclosingforthistransactioninthefiscalsecondquarterof
2012,includingthosecountriesthatrepresentedthemajorityofsales.AsofDecember30,2012,thetransactionhad
closedworldwide.
WiththeexceptionoftheSynthes,Inc.acquisition,supplementalproformainformationfor2014,2013and2012in
accordancewithU.S.GAAPstandardsrelatedtobusinesscombinations,andgoodwillandotherintangibleassets,isnot
provided,astheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectontheCompany’sresultsof
operations,cashflowsorfinancialposition.
During2014,theCompanydivestituresincluded:TheOrtho-ClinicalDiagnosticsbusinesstoTheCarlyleGroup;theK-Y®
brandtoReckittBenckiserGroupPLCintheU.S.andcertainothermarkets;andtheBENECOL®brandtoRaisioplc.In
2014,thegainsonthedivestituresofbusinesseswereapproximately$2.4billion.TheCompanycompletedthedivestiture
ofitsOrtho-ClinicalDiagnosticsbusinesstoTheCarlyleGroupforapproximately$4.0billionandtheCompanyrecorded
apre-taxnetgainofapproximately$1.9billion.Ortho-ClinicalDiagnostics’resultsareincludedintheCompany’sMedical
Devicessegmentpre-taxprofit.AsofDecember28,2014,theassetsclassifiedasheldforsalerelatingtotheOrtho-
ClinicalDiagnosticscompaniesincountriesthathavenotcompletelyclosedduetolocalregulatoryrequirementswere
$41millionofinventory,classifiedasprepaidexpensesandotherontheConsolidatedBalanceSheetand$117millionof
property,plantandequipment,classifiedasotherassetsontheConsolidatedBalanceSheet.
During2013,theCompanydivestituresincluded:women’ssanitaryprotectionproductsintheU.S.,Canadaandthe
CaribbeantoEnergizerHoldings,Inc.;Rolaids®toChattem,Inc.;DORIBAX®rightstoShionogi;andthesaleofcertain
consumerbrandsandcertainpharmaceuticalproducts.In2013,thegainsonthedivestituresofbusinesseswere$0.1
billion.During2012,theCompanydivestituresincluded:BYSTOLIC®(nebivolol)IPrightstoForestLaboratories,Inc.;the
traumabusinessofDePuyOrthopaedics,Inc.toBiomet,Inc.;theTherakosbusinesstoanaffiliateofGoresCapital
PartnersIII,L.P.;thesaleofcertainconsumerbrands;andtheRhoGAM®business.In2012,thegainsonthedivestitures
ofbusinesseswere$0.9billion.
InJanuary2015,adefinitiveagreementwasannouncedtodivesttheU.S.licenserightstoNUCYNTA®(tapentadol),
NUCYNTA®ER(tapentadolextended-releasetablets),andNUCYNTA®(tapentadol)oralsolutionforapproximately$1.05
billion.Thetransactionisexpectedtocloseinthefiscalsecondquarterof2015,subjecttocustomaryclosingconditions
andcompletionoffinancing.
21. LegalProceedings
Johnson&Johnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability,
intellectualproperty,commercialandothermatters;governmentalinvestigations;andotherlegalproceedingsthatarise
fromtimetotimeintheordinarycourseoftheirbusiness.
TheCompanyrecordsaccrualsforsuchcontingencieswhenitisprobablethataliabilitywillbeincurredandtheamount
ofthelosscanbereasonablyestimated.AsofDecember28,2014,theCompanyhasdeterminedthattheliabilities
associatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated.TheCompanyhasaccruedfor
thesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsasmightbewarrantedbasedon
newinformationandfurtherdevelopmentsinaccordancewithASC450-20-25.Fortheseandotherlitigationand
regulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossible,theCompanyisunableto
determineanestimateofthepossiblelossorrangeoflossbeyondtheamountsalreadyaccrued.Thesematterscanbe
affectedbyvariousfactors,includingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminate;
scientificandlegaldiscoveryhasnotcommencedorisnotcomplete;proceedingsareinearlystages;matterspresent
legaluncertainties;therearesignificantfactsindispute;ortherearenumerouspartiesinvolved.Amountsaccruedforlegal
contingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyon
estimatesandassumptions.
IntheCompany’sopinion,basedonitsexaminationofthesematters,itsexperiencetodateanddiscussionswithcounsel,
theultimateoutcomeoflegalproceedings,netofliabilitiesaccruedintheCompany’sbalancesheet,isnotexpectedto
haveamaterialadverseeffectontheCompany’sfinancialposition.However,theresolutioninanyreportingperiodofone
ormoreofthesematters,eitheraloneorintheaggregate,mayhaveamaterialadverseeffectontheCompany’sresultsof
operationsandcashflowsforthatperiod.
Johnson&Johnson2014AnnualReport • 53PRODUCTLIABILITY
CertainsubsidiariesofJohnson&Johnsonareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolvingmultiple
products.Claimantsinthesecasesseeksubstantialcompensatoryand,whereavailable,punitivedamages.Whilethese
subsidiariesbelievetheyhavesubstantialdefenses,itisnotfeasibletopredicttheultimateoutcomeoflitigation.The
CompanyhasestablishedproductliabilityaccrualsincompliancewithASC450-20basedoncurrentlyavailable
information,whichinsomecasesmaybelimited.Inaddition,productliabilityaccrualscanrepresentprojectedproduct
liabilityforthousandsofclaimsaroundtheworld,eachindifferentlitigationenvironmentsandwithdifferentfactpatterns.
Changestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable.
ThemostsignificantofthesecasesincludetheDePuyASR™XLAcetabularSystemandDePuyASR™HipResurfacing
System,thePINNACLE®AcetabularCupSystem,pelvicmeshesandRISPERDAL®.AsofDecember28,2014,inthe
U.S.therewereapproximately11,200plaintiffswithdirectclaimsinpendinglawsuitsregardinginjuriesallegedlydueto
theASR™XLAcetabularSystemandDePuyASR™HipResurfacingSystem,7,300withrespecttothePINNACLE®
AcetabularCupSystem,36,600withrespecttopelvicmeshes,and1,200withrespecttoRISPERDAL®.
InAugust2010,DePuyOrthopaedics,Inc.(DePuy)announcedaworldwidevoluntaryrecallofitsASR™XLAcetabular
SystemandDePuyASR™HipResurfacingSystemusedinhipreplacementsurgery.Claimsforpersonalinjuryhavebeen
madeagainstDePuyandJohnson&Johnson.Thenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuits
aresettledordismissedandadditionallawsuitsarefiled.CasesfiledinFederalcourtsintheUnitedStateshavebeen
organizedasamulti-districtlitigationintheUnitedStatesDistrictCourtfortheNorthernDistrictofOhio.Litigationhas
alsobeenfiledincountriesoutsideoftheUnitedStates,primarilyintheUnitedKingdom,CanadaandAustralia.In
November2013,DePuyreachedanagreementwithaCourt-appointedcommitteeoflawyersrepresentingASR™Hip
SystemplaintiffstoestablishaprogramtosettleclaimswitheligibleASRHippatientsintheUnitedStateswhohad
surgerytoreplacetheirASRHips,knownasrevisionsurgery,asofAugust31,2013.Thissettlementcovered
approximately8,000patients.InFebruary2015,DePuyreachedanadditionalagreement,subjecttofinaldocumentation,
whichwouldeffectivelyextendtheexistingsettlementprogramtoASRHippatientswhohadrevisionsurgeriesafter
August31,2013andpriortoFebruary1,2015.Thissecondagreementisestimatedtocoverapproximately1,400
additionalpatients.Theestimatedcostoftheseagreementsiscoveredbyexistingaccruals.Thissettlementprogramis
expectedtobringtoaclosesignificantASRHiplitigationactivityintheU.S.However,manylawsuitsintheU.S.will
remain,andthesettlementprogramdoesnotaddresslitigationoutsideoftheU.S.TheCompanycontinuestoreceive
informationwithrespecttopotentialcostsassociatedwiththisrecallonaworldwidebasis.TheCompanyhasestablished
accrualsforthecostsassociatedwiththeDePuyASR™Hipprogramandrelatedproductliabilitylitigation.Updatesto
theseaccrualsmayberequiredinthefutureasadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavealsobeenmadeagainstDePuyandJohnson&JohnsonrelatingtoDePuy’sPINNACLE®
AcetabularCupSystemusedinhipreplacementsurgery.Thenumberofpendingproductliabilitylawsuitscontinuesto
increase,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof
cases.CasesfiledinFederalcourtsintheUnitedStateshavebeenorganizedasamulti-districtlitigationintheUnited
StatesDistrictCourtfortheNorthernDistrictofTexas.LitigationhasalsobeenfiledincountriesoutsideoftheUnited
States,primarilyintheUnitedKingdom.TheCompanyhasestablishedanaccrualtocoverdefensecostsinconnection
withproductliabilitylitigationassociatedwithDePuy’sPINNACLE®AcetabularCupSystem.Changestothisaccrualmay
berequiredinthefutureasadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavebeenmadeagainstEthicon,Inc.(Ethicon)andJohnson&JohnsonarisingoutofEthicon’s
pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapse.Thenumberofpendingproduct
liabilitylawsuitscontinuestoincrease,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcosts
andtheanticipatednumberofcases.CasesfiledinFederalcourtsintheUnitedStateshavebeenorganizedasamulti-
districtlitigationintheUnitedStatesDistrictCourtfortheSouthernDistrictofWestVirginia.Inaddition,classactionsand
individualpersonalinjurycasesorclaimshavebeencommencedinAustralia,Belgium,Canada,England,Israel,Italy,the
Netherlands,ScotlandandVenezuela,seekingdamagesforallegedinjuryresultingfromEthicon’spelvicmeshdevices.
TheCompanyhasestablishedanaccrualwithrespecttoproductliabilitylitigationassociatedwithEthicon’spelvicmesh
products.Changestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable.
ClaimsforpersonalinjuryhavebeenmadeagainstJanssenPharmaceuticals,Inc.andJohnson&Johnsonarisingoutoftheuse
ofRISPERDAL®,indicatedforthetreatmentofschizophrenia,acutemanicormixedepisodesassociatedwithbipolarIdisorder
andirritabilityassociatedwithautism,andrelatedcompounds.Thenumberofpendingproductliabilitylawsuitscontinuesto
increase,andtheCompanycontinuestoreceiveinformationwithrespecttopotentialcostsandtheanticipatednumberof
cases.TheCompanyhasestablishedanaccrualtocoverdefensecostsinconnectionwithproductliabilitylitigationassociated
withRISPERDAL®.Changestothisaccrualmayberequiredinthefutureasadditionalinformationbecomesavailable.
54 • Johnson&Johnson2014AnnualReportINTELLECTUALPROPERTY
CertainsubsidiariesofJohnson&Johnsonaresubject,fromtimetotime,tolegalproceedingsandclaimsrelatedto
patent,trademarkandotherintellectualpropertymattersarisingoutoftheirbusinesses.Manyofthesemattersinvolve
challengestothecoverageand/orvalidityofthepatentsonvariousproducts.Althoughthesesubsidiariesbelievethatthey
havesubstantialdefensestothesechallengeswithrespecttoallmaterialpatents,therecanbenoassuranceastothe
outcomeofthesematters,andalossinanyofthesecasescouldpotentiallyadverselyaffecttheabilityofthese
subsidiariestoselltheirproducts,orrequirethepaymentofpastdamagesandfutureroyalties.Themostsignificantof
thesemattersaredescribedbelow.
MedicalDevices
InJanuary2010,TycoHealthcareGroup,LP(Tyco)andU.S.SurgicalCorporation(nowCovidienplc)filedalawsuit
againstEthiconEndo-Surgery,Inc.(EES)intheUnitedStatesDistrictCourtfortheDistrictofConnecticutallegingthat
EES’sHARMONIC®shearsinfringedthreeTycopatents.ThecasewastriedinJuly2012,andinMarch2013,theCourt
ruledthatsomeofEES’sHARMONIC®shearsinfringedTyco’spatentsandorderedEEStopaydamagesof
approximately$176million,butdeclinedtoorderinjunctiverelief.EESappealedandinDecember2014,theUnited
StatesCourtofAppealsfortheFederalCircuitreversedtheDistrictCourt’srulingandfoundalltheassertedclaims
invalid.InJanuary2015,Tycofiledamotionforrehearing.InJuly2014,Covidienfiledanotherpatentinfringementlawsuit
againstEESintheUnitedStatesDistrictCourtfortheDistrictofConnecticutseekingdamagesandapreliminary
injunction,allegingthatEES’snewestversionofitsharmonicscalpels,theHARMONICACE®+7Shearsandthe
HARMONICACE®+Shears,infringedthethreeTycopatentsassertedinthepreviouscase.Covidienbroughtamotionfor
apreliminaryinjunctionagainsttheHARMONICACE®+7Shears,andinOctober2014,theDistrictCourtgranted
Covidien’smotionforapreliminaryinjunction.EESappealedandtheCourtofAppealsfortheFederalCircuitgrantedEES
aninterimstayoftheinjunction.TheclaimsassertedbyCovidieninthiscasearethesameclaimsthatweredeclared
invalidinDecember2014bytheCourtofAppealsintheTycocasediscussedabove.
InNovember2007,RocheDiagnosticsOperations,Inc.,etal.(Roche)filedapatentinfringementlawsuitagainstLifeScan,
Inc.(LifeScan)intheUnitedStatesDistrictCourtfortheDistrictofDelaware,allegingLifeScan’sOneTouch®Lineof
BloodGlucoseMonitoringSystemsinfringetwopatentsrelatedtotheuseofmicroelectrodesensors.Rocheisseeking
monetarydamagesandinjunctiverelief.InSeptember2009,LifeScanobtainedafavorablerulingonclaimconstruction
thatprecludedafindingofinfringement.TheCourtenteredjudgmentagainstRocheinJuly2010andRocheappealed.
TheCourtofAppealsreversedtheDistrictCourt’srulingonclaimconstructionandremandedthecasetotheDistrict
Courtfornewfindingsontheissue.InDecember2014,theDistrictCourtruledinLifeScan’sfavorandreinstatedthe
originalclaimconstruction.InFebruary2015,Rocheappealedtheruling.
InJune2009,RembrandtVisionTechnologies,L.P.(Rembrandt)filedapatentinfringementlawsuitagainstJohnson&
JohnsonVisionCare,Inc.(JJVC)intheUnitedStatesDistrictCourtfortheEasternDistrictofTexasallegingthatJJVC’s
manufactureandsaleofitsACUVUE®ADVANCE®andACUVUE®OASYS®HydrogelContactLensesinfringetheirU.S.
PatentNo.5,712,327(theChangpatent).Rembrandtisseekingmonetaryrelief.ThecasewastransferredtotheUnited
StatesDistrictCourtfortheMiddleDistrictofFlorida.InMay2012,thejuryreturnedaverdictholdingthatneitherofthe
accusedlensesinfringesthe’327patent.Rembrandtappealed,andinAugust2013,theUnitedStatesCourtofAppeals
fortheFederalCircuitaffirmedtheDistrictCourt’sjudgment.RembrandtaskedtheDistrictCourttograntitanewtrial
basedonallegednewevidence,andinJuly2014,theDistrictCourtdeniedRembrandt’smotion.Rembrandthasappealed
theDistrictCourt’sdenialofitsmotionforanewtrial.
InDecember2009,theStateofIsraelfiledalawsuitintheDistrictCourtinTelAvivJaffaagainstOmrix
Biopharmaceuticals,Inc.andvariousaffiliates(Omrix).Inthelawsuit,theStateclaimsthatanemployeeofagovernment-
ownedhospitalwastheinventoronseveralpatentsrelatedtofibringluetechnologythattheemployeedevelopedwhilehe
wasagovernmentemployee.TheStateclaimsthathehadnorighttotransferanyintellectualpropertytoOmrixbecauseit
belongstotheState.TheStateisseekingdamagesplusroyaltiesonQUIXIL™andEVICEL®products,oralternatively,
transferofthepatentstotheState.Thecaseremainsactive,butnotrialdatehasbeenset.
InSeptember2011,LifeScan,Inc.(LifeScan)filedalawsuitagainstShastaTechnologies,InstacareCorpandConductive
Technologies(collectively,Shasta)intheUnitedStatesDistrictCourtfortheNorthernDistrictofCaliforniaforpatent
infringementforthemakingandmarketingofastripforuseinLifeScan’sOneTouch®BloodGlucoseMeters.Shastahas
allegedthatthethreeLifeScanpatents-in-suitareinvalid.Shastaalsochallengedthevalidityoftheassertedpatentsinthe
UnitedStatesPatentandTrademarkOffice(USPTO)andthepatentinfringementcasehasbeenstayedpendingthe
outcomeoftheUSPTOproceedings.ThevalidityoftwoofthepatentswasconfirmedbytheUSPTOandinAugust2014,
Johnson&Johnson2014AnnualReport • 55theUSPTOdeterminedthatthethirdpatent,U.S.PatentNo.7,250,105(the‘105patent),isinvalid.LifeScanisappealing
thatdecision.Thepatentcasehasresumedonthetwootherpatents.InApril2013,Shastabroughtcounterclaimsfor
allegedantitrustviolationsandfalseadvertisingandthoseclaimshavebeenstayedpendingresolutionofthepatent
infringementcase.InMay2014,LifeScanfiledapatentinfringementlawsuitagainstUniStripTechnologies,LLC(UniStrip)
intheUnitedStatesDistrictCourtfortheDistrictofNorthCarolinaallegingthatthemakingandmarketingofUnistrip’s
stripsinfringethesamepatentsassertedagainstShastaabove.Thatcasehasbeenstayedpendingtheoutcomeofthe
appealoftheUSPTO’sdecisiononthevalidityofthe‘105patent.InJuly2014,UniStripbroughtalawsuitagainst
LifeScanintheUnitedStatesDistrictCourtfortheEasternDistrictofPennsylvania,allegingantitrustviolationsrelatingto
marketingpracticesforLifeScan’sstrips.
InNovember2011,HowmedicaOsteonicsCorp.(Howmedica)andStrykerIrelandLtd.(Stryker)filedapatent
infringementlawsuitagainstDePuyOrthopaedics,Inc.(DePuy)intheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyalleginginfringementbyDePuy’sPINNACLE®AcetabularCupSystemandDURALOC®AcetabularCupSystemof
apatentrelatingtoadual-lockingmechanismfeatureinanacetabularcupsystem.HowmedicaandStrykersought
monetarydamagesandinjunctiverelief.DePuyfiledacounterclaiminFebruary2012assertingthatStryker’sTrident
AcetabularHipSysteminfringesDePuy’sU.S.PatentNo.6,610,097.DePuysoughtdamagesandinjunctiverelief.InJune
2014,thecasewassettledanddismissed.
InMay2012,MedtronicMiniMed,Inc.,MedtronicPuertoRicoOperationsCo.andMiniMedDistributionCorp.
(collectively,MedtronicMiniMed)filedapatentinfringementlawsuitagainstAnimasCorporation(Animas)intheUnited
StatesDistrictCourtfortheCentralDistrictofCaliforniaallegingthatAnimas’sOneTouch®Ping®GlucoseManagement
SystemandtheIR1250,IR2020andIR2000insulinpumpsinfringenineoftheirpatents.MedtronicMiniMedsince
withdrewtwoofthepatentsfromthelawsuitandisseekingmonetarydamagesandinjunctivereliefwithrespecttothe
remainingpatents.InJuly2014,Animasenteredintoasettlementofthislawsuit.
InSeptember2012,BonuttiSkeletalInnovationsLLC(Bonutti),anon-practicingentity,filedapatentinfringementlawsuit
againstDePuyMitek,LLC,TheDePuyInstitute,LLC(nowDePuySynthesInstitute,LLC),DePuy,Inc.(nowDePuy
Synthes,Inc.)andDePuyOrthopaedics,Inc.(collectively,DePuy)intheUnitedStatesDistrictCourtfortheDistrictof
Massachusetts,allegingthatDePuy’smanufacture,saleand/ormethodofusingtheSIGMA®FamilyofPartialandTotal
KneeSystemsandtheLCS®COMPLETE™KneeSystemwillfullyinfringethreeofBonutti’spatents.Bonuttialsoalleges
thatthemethodofusingcertainofDePuy’ssutureanchorswillfullyinfringefourofBonutti’sotherpatents.InAugust2014,
thepartiesenteredintoasettlementoftheportionofthelawsuitrelatingtosutureanchors.
InMarch2013,MedinolLtd.(Medinol)filedapatentinfringementlawsuitagainstCordisCorporation(Cordis)and
Johnson&JohnsonintheUnitedStatesDistrictCourtfortheSouthernDistrictofNewYorkallegingthatallofCordis’s
salesoftheCYPHER®andCYPHERSELECT™StentsmadeintheUnitedStatessince2005willfullyinfringedfourof
Medinol’spatentsdirectedtothegeometryofarticulatedstents.Medinolisseekingdamagesandattorney’sfees.After
trialinJanuary2014,theDistrictCourtdismissedthecase,findingMedinolunreasonablydelayedbringingitsclaims,and
Medinoldidnotappealthedecision.InSeptember2014,theDistrictCourtdeniedamotionbyMedinoltovacatethe
judgmentandgrantitanewtrial.Medinolisappealingthisdecision.
InJanuary2014,BaxterInternationalInc.,BaxterHealthcareCorporation,andBaxterHealthcareS.A.(collectively,Baxter)
filedalawsuitagainstJohnson&Johnson,Ethicon,Inc.(Ethicon),FerrosanMedicalDevicesA/SandPackaging
CoordinatorsInc.intheUnitedStatesDistrictCourtfortheNorthernDistrictofIllinois,allegingthatthemanufacture,
importation,saleand/oruseofEthicon’sSURGIFLO®HemostaticMatrixfamilyofproductsinfringessixofBaxter’s
patents.Baxterisseekingmonetarydamagesandinjunctiverelief.InFebruary2014,Baxteralsofiledacomplaintbefore
theUnitedStatesInternationalTradeCommission(ITC)againstthesamedefendantsallegingthattheimportationintothe
UnitedStatesofEthicon’sSURGIFLO®HemostaticMatrixFamilyofProductsviolatesSection337oftheTariffActof
1930duetotheallegedinfringementoffourofitsproducts,andisseekinganexclusionordertoenjointheimportation
intotheUnitedStatesofsuchproducts.TheDistrictCourtcasehasbeenstayedpendingtheoutcomeoftheITCcase.
AllthepatentsexpireinAugust2016.TheITCcasewastriedinJanuary2015andthepartiesareawaitingadecision.
InJune2014,MyHealth,Inc.(MyHealth)filedapatentinfringementlawsuitagainstLifeScan,Inc.(LifeScan)intheUnited
StatesDistrictCourtfortheEasternDistrictofTexas,allegingLifeScan’sOneTouch®Verio®IQBloodGlucose
MonitoringSysteminfringesMyHealth’spatentrelatedtoamethodformonitoringandtreatingpatients.MyHealthis
seekingmonetarydamagesandinjunctiverelief.InAugust2014,LifeScanfiledamotiontodismissthelawsuit.InOctober
2014,LifescanfiledanInterPartesreviewproceedingintheUnitedStatesPatentandTrademarkOfficeseekingto
invalidateMyHealth’spatent.InDecember2014,LifeScanmovedtostaythelawsuitpendingadecisionintheInter
Partesreviewproceeding.
56 • Johnson&Johnson2014AnnualReportInDecember2014,BonuttiSkeletalInnovationsLLC(Bonutti)suedDePuySynthesSales,Inc.andDePuySynthes
Products,Inc.intheUnitedStatesDistrictCourtfortheDistrictofMassachusetts,allegingthatDePuySynthes’sproduct
lineofspineimplantsinfringessixpatentsownedbyBonutti,generallycoveringwedgeimplantsandtheirmethodsof
implantation.
Pharmaceutical
InMay2009,AbbottBiotechnologyLtd.(Abbott)filedapatentinfringementlawsuitagainstCentocor,Inc.(Centocor)
(nowJanssenBiotech,Inc.(JBI))intheUnitedStatesDistrictCourtfortheDistrictofMassachusettsallegingthat
SIMPONI®infringesAbbott’sU.S.PatentNos.7,223,394and7,541,031(theSalfeldpatents).Abbottwasseeking
monetarydamagesandinjunctiverelief.Thepartieshavesettledthecase.
InAugust2009,AbbottGmbH&Co.(AbbottGmbH)andAbbottBioresearchCenter(collectivelynowreferredtoas,
AbbVie)filedapatentinfringementlawsuitagainstCentocor(nowJBI)intheUnitedStatesDistrictCourtfortheDistrictof
MassachusettsallegingthatSTELARA®infringestwoUnitedStatespatentsassignedtoAbbottGmbH.Trialwasheldin
September2012andajuryreturnedaverdictinfavorofJBI,invalidatingAbbVie’spatentclaims.AbbVieappealed,andin
July2014,theCourtofAppealsfortheFederalCircuitaffirmedthelowercourt’sruling.AlsoinAugust2009,Abbott
GmbHandAbbottLaboratoriesLimited(collectivelynowreferredtoas,AbbVie)broughtapatentinfringementlawsuitin
TheFederalCourtofCanadaallegingthatSTELARA®infringesAbbottGmbH’sCanadianpatent.Atrialwasheldin
December2013intheCanadiancaseandtheCourtruledinfavorofAbbVie,findingthattheassertedclaimswerevalid
andinfringedbySTELARA®.JBIappealedthatdecision.InMay2014,AbbVie’smotionforaninjunctionwasgrantedin
part,andJBIalsoappealedthatdecision.InOctober2014,theappellatecourtoverturnedthefindingofliability,remanded
thecasetothetrialcourtforre-trial,andliftedtheinjunction.InadditiontotheU.S.andCanadianlitigations,inAugust
2012,AbbViefiledpatentinfringementlawsuitsrelatedtoSTELARA®intheNetherlands,SwitzerlandandGermany.The
partieshavesettledallofthecasesdiscussedaboverelatedtoSTELARA®.
In2012and2013,Noramco,Inc.(Noramco),asubsidiaryofJohnson&Johnson,movedtointerveneinseveralpatent
infringementlawsuitsfiledintheUnitedStatesDistrictCourtfortheSouthernDistrictofNewYorkbyPurduePharmaL.P.
andothers(Purdue)againstNoramcooxycodonecustomers,ImpaxLaboratories,Inc.(Impax),TevaPharmaceuticalsUSA,
Inc.(Teva)andAmnealPharmaceuticals,LLC(Amneal),WatsonLaboratories,Inc.-Florida(Watson)andAndrxLabs,LLC
(Andrx).Thelawsuitsareinresponsetothedefendants’respectiveAbbreviatedNewDrugApplicationsseekingapproval
tomarketgenericextendedreleaseoxycodoneproductsbeforetheexpirationofcertainPurduepatents.Threeofthe
assertedpatentsrelatetooxycodoneandprocessesformakingoxycodone,andNoramcohasagreedtodefendthe
lawsuitsonbehalfofImpax,Teva,Amneal,Watson,andAndrx.InApril2013,WatsonandAndrxenteredintoasettlement
withPurdue.ThetrialagainstImpaxandTeva(aswellastwopartiesnotdefendedbyNoramco)tookplaceinSeptember
2013,andNoramcodefendedTevaandImpax.InNovember2013,ImpaxenteredintoasettlementwithPurdue.In
January2014,theCourtissuedadecisioninvalidatingtherelevantPurduepatentsandsubsequentlydismissedthe
lawsuitagainstAmneal(andotherpartiesnotdefendedbyNoramco).PurduehasappealedtheCourt’sdecision.In
December2014,TevaenteredintoaconfidentialsettlementwithPurdue,andTevasubsequentlymovedtohavethe
appealdismissedasmootinviewofthesettlement.PurduehasopposedTeva’smotion.
InAugust2012,Dr.JamesM.SwansonfiledalawsuitagainstALZACorporation(ALZA)intheNorthernDistrictof
CaliforniaseekingtobeaddedasaninventoronthreeALZA-ownedpatentsrelatingtoCONCERTA®.Alternatively,
Dr.Swansonhasallegedthatthepatents-in-suitareinvalidasaresultofALZA’sallegedomissionofDr.Swansonasa
namedinventor.Thelawsuitalsoincludesclaimsoffraud,breachoffiduciarydutyandunfaircompetition.Dr.Swansonis
seekingdamagesandanawardofunjustenrichment.ALZAfiledamotiontodismissDr.Swanson’sclaims,aswellas
counterclaimsforbreachofcontractandnegligentmisrepresentation.TheCourtgrantedthemotioninpart,anddeniedit
inpart.ALZAfiledamotionforsummaryjudgmentontheissueofinventorshipandahearingwasheldinFebruary2015.
Thepartiesareawaitingadecision.
Johnson&JohnsonacquiredtheprostatecancerbusinessofAragonPharmaceuticals,Inc.(Aragon),includingARN-509,
acompoundbeingtestedfortreatmentofprostatecancer,inSeptember2013.Priortotheacquisition,inMay2011,
Medivation,Inc.(Medivation)hadsuedAragonandtheUniversityofCaliforniaseekingrightstoARN-509.InDecember
2012,theStateCourtgrantedsummaryjudgmenttoAragononMedivation’sclaims,awardingtherightsoftheARN-509
compoundtoAragon,andinJanuary2013,theCourtdismissedthecaseagainstAragon.Medivationhasappealed.
REMICADE®RelatedCases
InMarch2013,HospiraHealthcareCorporation(Hospira)filedanimpeachmentproceedingagainstTheKennedyInstitute
ofRheumatology(Kennedy)challengingthevalidityofaCanadianpatentrelatedtoREMICADE®(aFeldmanpatent),
Johnson&Johnson2014AnnualReport • 57whichisexclusivelylicensedtoJanssenBiotech,Inc.(JBI).InOctober2013,Kennedy,alongwithJBI,JanssenInc.and
CilagGmbHInternational(bothaffiliatesofJBI),filedacounterclaimforinfringementagainstCelltrionHealthcareCo.,Ltd.,
CelltrionInc.(together,Celltrion)andHospira.ThecounterclaimallegesthattheproductsdescribedinCelltrion’sand
Hospira’smarketingapplicationstoHealthCanadafortheirsubsequententrybiologics(SEB)toREMICADE®would
infringetheFeldmanpatentsownedbyKennedy.Discoveryinthepatentactionisongoing.Trialhasbeenscheduledfor
September2016.
InJanuary2014,HealthCanadaapprovedCelltrion’sSEBtoREMICADE®,allowingCelltriontomarketitsbiosimilar
versionofREMICADE®inCanada,regardlessofthependingpatentaction.InJune2014,Hospirareceivedapprovalfor
itsSEBtoREMICADE®.InJuly2014,JanssenInc.(Janssen)filedalawsuittocompeltheCanadianMinisterofHealthto
withdrawtheNoticeofComplianceforHospira’sSEBbecauseHospiradidnotserveaNoticeofAllegationonJanssento
addressthepatentlistedbyJanssenonthePatentRegister.IftheNoticeofComplianceiswithdrawn,Hospirawouldhave
toserveaNoticeofAllegationandJanssencouldcommenceanapplicationtoprohibitissuanceoftheNoticeof
Complianceuntilexpiryoftherelevantpatent.AhearinghasbeenscheduledforMarch2015.
InSeptember2013,JBIandNYULangoneMedicalCenter(NYUMedicalCenter)receivedanOfficeActionfromthe
UnitedStatesPatentandTrademarkOffice(USPTO)rejectingtheclaimsinU.S.PatentNo.6,284,471relatingto
REMICADE®(the’471patent)inareexaminationproceedinginstitutedbyathirdparty.The’471patentisco-ownedby
JBIandNYUMedicalCenter,andNYUMedicalCentergrantedJBIanexclusivelicensetoNYUMedicalCenter’srights
underthepatent.Currently,the’471patentintheUnitedStatesexpiresinSeptember2018.JBIrespondedtothat
rejectioninDecember2013andinAugust2014,JBIandNYUMedicalCenterreceivedafurtherrejection.JBIresponded
totherejectionbyfilingafurtheramendmentandinNovember2014,JBI’spetitiontoentertheamendmentwasgranted.
TheapplicationwasreturnedtotheexaminerforissuanceofanewOfficeAction,whichoccurredinFebruary2015further
rejectingthepatent.JBIhassixtydaystorespondtotherejection.JBIbelievesthe’471patentisvalid,willrespondtothe
latestOfficeActiontodefendthepatentand,ifnecessary,JBIwillpursueallavailableappeals.
InMarch2014,CelltrionfiledadeclaratoryjudgmentlawsuitagainstJBIintheUnitedStatesDistrictCourtfortheDistrict
ofMassachusettsseekingtoinvalidatethe’471patentandtwootherU.S.patentsthatrelatetoREMICADE®andareco-
ownedbyJBIandNYUMedicalCenter,andexclusivelylicensedtoJBI(collectively,theLepatents).JBImovedtodismiss
thecaseforlackofjurisdictionandCelltrionvoluntarilydismisseditslawsuit.AlsoinMarch2014,Celltrionfiledalawsuit
intheUnitedStatesDistrictCourtfortheSouthernDistrictofNewYorkagainstKennedyseekingtoinvalidatethree
patentsownedbyKennedy(theFeldmanpatents).TheFeldmanpatentsarelicensedtoJBIandalsorelateto
REMICADE®.Kennedymovedtodismissthecaseforlackofjurisdiction,includingfailuretocomplywiththeprocedural
requirementsoftheBiologicsPriceCompetitionandInnovationAct(theBPCIA).InDecember2014,theCourtgranted
themotion.
InAugust2014,Hospira,Inc.(Hospira)filedalawsuitintheUnitedStatesDistrictCourtfortheSouthernDistrictofNew
YorkagainstJBI,NewYorkUniversity(NYU),NYUMedicalCenterandKennedyseekingtoinvalidatetheFeldman
patents.HospiraallegesthatithasexclusiverightstomarketCelltrion’sbiosimilarversionofREMICADE®intheUnited
StatesifitisapprovedbytheFDA.InOctober2014,JBI,NYUandNYUMedicalCentermovedtodismissthiscasefor
lackofjurisdiction,includingfailuretocomplywiththeproceduralrequirementsoftheBPCIA.InDecember2014,the
Courtgrantedthemotion.
InAugust2014,CelltrionfiledforFDAapprovaltomakeandsellitsownbiosimilarversionofREMICADE®.InFebruary
2015,JBIreceivedaNoticeofCommercialMarketingfromCelltrioninaccordancewiththeBPCIAnotifyingJBIthat
Celltrionand/orHospiraintendtobegincommercialmarketingofabiosimilarproductasearlyas180daysfromthedate
ofthenotice.ThepartiesareproceedingwiththepatentresolutionproceduressetforthintheBPCIA.JBIbelievesthe
patentsarevalidandwillenforcetherelevantpatents.
IfanyoftheLeorFeldmanpatentsisfoundtobeinvalid,anysuchpatentcouldnotbereliedupontopreventthe
introductionofbiosimilarversionsofREMICADE®.Thetimingofthepossibleintroductionofabiosimilarversionof
REMICADE®intheUnitedStateswouldbesubjecttoapprovalbytheFDA.Lossofexclusivitywilllikelyresultina
reductioninsalesasbiosimilarversionsofREMICADE®areintroducedtothemarket.
LitigationAgainstFilersofAbbreviatedNewDrugApplications(ANDAs)
ThefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledAbbreviatedNewDrugApplications
(ANDAs)withtheFDA,orundertakensimilarregulatoryprocessesoutsideoftheUnitedStates,seekingtomarketgeneric
formsofproductssoldbyvarioussubsidiariesofJohnson&Johnsonpriortoexpirationoftheapplicablepatentscovering
thoseproducts.TheseANDAstypicallyincludeallegationsofnon-infringement,invalidityandunenforceabilityofthe
58 • Johnson&Johnson2014AnnualReportapplicablepatents.Intheeventthesubsidiariesarenotsuccessfulintheseactions,orthestatutory30-monthstaysofthe
ANDAsexpirebeforetheUnitedStatesDistrictCourtrulingsareobtained,thethird-partycompaniesinvolvedwillhavethe
ability,uponapprovaloftheFDA,tointroducegenericversionsoftheproductsatissuetothemarket,resultinginthe
potentialforsubstantialmarketshareandrevenuelossesforthoseproducts,andwhichmayresultinanon-cash
impairmentchargeinanyassociatedintangibleasset.
PREZISTA®
AnumberofgenericcompanieshavefiledANDAsseekingapprovaltomarketgenericversionsofPREZISTA®.In
November2010,Tibotec,Inc.(nowTibotec,LLC)andTibotecPharmaceuticals(nowJanssenR&DIreland)(collectively,
Tibotec)filedapatentinfringementlawsuitagainstLupin,Ltd.,LupinPharmaceuticals,Inc.(collectively,Lupin),Mylan,Inc.
andMylanPharmaceuticals,Inc.(collectively,Mylan)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyin
responsetoLupin’sandMylan’srespectiveANDAsseekingapprovaltomarketgenericversionsofTibotec’sPREZISTA®
productbeforetheexpirationofTibotec’spatentrelatingtoPREZISTA®.LupinandMylaneachfiledcounterclaims
allegingnon-infringementandinvalidity.InJuly2011,TibotecfiledanotherpatentinfringementlawsuitagainstLupininthe
UnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponsetoLupin’ssupplementtoitsANDAtoaddnew
dosagestrengthsforitsproposedproduct.InAugust2011,TibotecandG.D.Searle&Company(G.D.Searle)fileda
patentinfringementlawsuitagainstLupinandMylaninresponsetotheirnoticelettersadvisingthattheirANDAsare
seekingapprovaltomarketgenericversionsofTibotec’sPREZISTA®productbeforetheexpirationoftwoadditional
patentsrelatingtoPREZISTA®thatTibotecexclusivelylicensesfromG.D.Searle.InSeptember2011,theCourt
consolidatedtheabovelawsuits(referredtohereastheFirstConsolidatedAction).
TheapprovedNewDrugApplicationforPREZISTA®wastransferredfromTibotec,Inc.toJanssenProducts,LPin
December2011.In2012and2013,JanssenProducts,LPandJanssenR&DIreland(collectively,Janssen)addedseveral
patentsthattheyownorexclusivelylicensefromG.D.SearletotheFirstConsolidatedActionagainstMylanandLupin.In
June2013,JanssenandG.D.SearledismissedtheirclaimsrelatingtothepatentsownedbyG.D.SearleagainstLupin
andMylan,basedonthoseparties’agreementnottoseekFDAapprovaloftheirrespectiveANDAsuntiltheNovember
2017expirationoftheG.D.Searlepatents.AfteratrialregardingtheremainingpatentsintheFirstConsolidatedAction,
theCourtissuedadecisioninAugust2014infavorofJanssen,holdingthattheassertedpatentsarevalidandwouldbe
infringedbyLupin’sandMylan’smarketingoftheirproposedproducts.Lupinfiledanappeal.
InMay2013,LupinnotifiedJanssenthatitfiledanANDAseekingapprovaltomarketanewdosagestrengthofitsgeneric
versionofPREZISTA®.Inresponse,JanssenfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtforthe
DistrictofNewJersey,allegingthatLupin’snewdosagestrengthwouldinfringethesamepatentsthatJanssenisasserting
againstLupinintheoriginalaction.InMarch2014,JanssenfiledapatentinfringementlawsuitagainstLupinintheUnited
StatesDistrictCourtfortheDistrictofNewJersey,alleginginfringementofUnitedStatesPatentNo8,518,987.InJanuary
2015,theCourtconsolidatedtheselawsuits(referredtohereastheSecondConsolidatedAction),andstayedthem
pendingLupin’sappealoftheCourt’sdecisionintheFirstConsolidatedAction.
JanssenfiledapatentinfringementlawsuitagainstHeteroDrugs,Ltd.UnitIIIandHeteroUSAInc.inMarch2013inthe
UnitedStatesDistrictCourtfortheDistrictofNewJersey,alleginginfringementofUnitedStatesPatentNos.7,126,015
and7,595,408.DiscoveryinthiscaseisongoingandatrialdateissetforOctober2015.
JanssenandG.D.SearlealsofiledpatentinfringementlawsuitsagainstTevaPharmaceuticalsUSA,Inc.andTeva
Pharmaceuticals,Ltd.(collectively,Teva)intheUnitedStatesDistrictCourtfortheDistrictofNewJerseyinresponseto
Teva’sANDAseekingapprovaltomarketagenericversionofPREZISTA®beforetheexpirationofcertainpatentsrelating
toPREZISTA®thatJansseneitherownsorexclusivelylicensesfromG.D.Searle.InMarch2014,thepartiesenteredintoa
settlementagreementandthelawsuitsagainstTevaweredismissed.
InJuly2014,JanssenfiledapatentinfringementlawsuitagainstMylanintheUnitedStatesDistrictCourtfortheDistrictof
NewJersey,alleginginfringementofUnitedStatesPatentNo.8,153,829.Discoveryinthecaseinongoing.
InAugust2014,JanssenfiledpatentinfringementlawsuitsagainstCiplaLtd.andCiplaUSA,Inc.(collectively,Cipla)inthe
UnitedStatesDistrictCourtsfortheDistrictsofNewJerseyandDelawareinresponsetoCipla’sANDAseekingapproval
tomarketagenericversionofJanssen’sPREZISTA®productbeforetheexpirationofcertainofJanssen’spatentsrelating
toPREZISTA®.Ciplafiledcounterclaimsseekingdeclarationsofnoninfringementandinvalidityofthepatents-in-suit.
Discoveryisongoing.
InresponsetoitsNoticeofAllegationseekingapprovaltomarketagenericversionofPREZISTA®inCanadabeforethe
expirationofCanadianPatentNo.2,485,834,JanssenInc.andJanssenR&DIrelandfiledaNoticeofApplicationagainst
MylanPharmaceuticalsULCinJuly2014.InDecember2014,JanssenR&DIrelandtransferreditsPREZISTA®patentsto
Johnson&Johnson2014AnnualReport • 59JanssenSciencesIrelandUC,andJanssenSciencesIrelandUCwassubstitutedforJanssenR&DIrelandasplaintiffinthe
above-referencedactions.InJanuary2015,JanssenInc.andJanssenSciencesIrelandUCfiledaNoticeofApplication
againstTevaCanadaLimitedinresponsetoitsNoticeofAllegationseekingapprovaltomarketagenericversionof
PREZISTA®beforetheexpirationofCanadianPatentNo.2,485,834.
Ineachoftheabovelawsuits,JanssensoughtorisseekinganOrderenjoiningthedefendantsfrommarketingtheirgeneric
versionsofPREZISTA®beforetheexpirationoftherelevantpatents.
CONCERTA®
InJune2013,ALZACorporation(ALZA)andJanssenPharmaceuticals,Inc.(JPI)filedpatentinfringementlawsuitsinthe
UnitedStatesDistrictCourtfortheDistrictofDelawareagainstParPharmaceuticals,Inc.(Par),OsmoticaKereskedelmies
SzolgaltatoKft(Osmotica),andNorwichPharmaceuticals,Inc.(Norwich)inresponsetothoseparties’ANDAsseeking
approvaltomarketagenericversionofCONCERTA®beforetheexpirationofUnitedStatesPatentNo.8,163,798(the
’798patent).Inaddition,inSeptember2013,ParandOsmoticafiledcounterclaimsagainstALZAandJPIseeking
declarationsofinvalidityandnoninfringementofthepatent-in-suit,andNorwichfiledamotiontodismiss.Norwichwas
dismissedfromthecaseinOctober2013basedonitsagreementtobeboundbytheoutcomeofthecasewith
Osmotica.InMarch2014,ALZAandJPIamendeditscomplaintagainstParandOsmoticatoassertinfringementofnewly
issuedUnitedStatesPatentNo.8,629,179(the’179patent).InJune2014,ALZA,JPIandOsmoticaenteredintoa
settlementoftheaction,andinSeptember2014,ALZA,JPIandParenteredintoasettlement.
InMay2014,ALZAandJPIfiledapatentinfringementlawsuitintheUnitedStatesDistrictCourtfortheDistrictofWest
VirginiaagainstMylan,Inc.andMylanPharmaceuticals,Inc.(Mylan)inresponsetoitsANDAseekingapprovaltomarketa
genericversionofCONCERTA®beforetheexpirationofthe’798patent.Mylanfiledcounterclaimsseekingdeclarations
ofinvalidityandnoninfringementofthepatents-in-suit.
InJune2014,ALZAandJPIfiledapatentinfringementlawsuitintheDistrictofDelawareagainstSandoz,Inc.inresponse
toitsANDAseekingapprovaltomarketagenericversionofCONCERTA®beforetheexpirationofthe’798and’179
patents.Sandozfiledcounterclaimsseekingdeclarationsofinvalidity,unenforceability,andnoninfringementofthepatents-
in-suit.InDecember2014,thepartiesenteredintoasettlementagreementandthelawsuitwasdismissed.
InDecember2014,JanssenInc.andALZAfiledaNoticeofApplicationagainstActavisPharmaCompany(Actavis)in
responsetoitsNoticeofAllegationseekingapprovaltomarketagenericversionofCONCERTA®beforetheexpirationof
CanadianPatentNo.2,264,852.
Ineachoftheabovelawsuits,ALZAand/orJPIareseekinganOrderenjoiningthedefendantsfrommarketingtheirgeneric
versionsofCONCERTA®beforetheexpirationofthe’798and/or’179patents.
NUCYNTA®ANDNUCYNTA®ER
InJuly2013,JanssenPharmaceuticals,Inc.(JPI)filedpatentinfringementlawsuitsintheUnitedStatesDistrictCourtfor
theDistrictofNewJerseyagainstActavisElizabethLLC,ActavisInc.andActavisLLC(collectively,Actavis),aswellas
AlkemLaboratoriesLimitedandAscendLaboratories,LLC(collectively,Alkem).Thepatentinfringementclaimsagainst
ActavisandAlkemrelatetotheirrespectiveANDAsseekingapprovaltomarketagenericversionofNUCYNTA®ER
beforetheexpirationofUnitedStatesReissuePatentNo.39,593(the’593patent),UnitedStatesPatentNo.7,994,364
(the’364patent)and,astoActavisonly,UnitedStatesPatentNo.8,309,060(the‘060patent).Thelawsuitalsoincludes
apatentinfringementclaimagainstAlkeminresponsetoitsANDAseekingapprovaltomarketagenericversionof
NUCYNTA®beforetheexpirationofthe’593and’364patents.InDecember2013,JPIfiledanadditionalcomplaintinthe
DistrictCourtofNewJerseyagainstAlkemassertingUnitedStatesPatentNo.8,536,130relatedtoitsANDAseeking
approvaltomarketagenericversionofNUCYNTA®ER.InAugust2014,JPIamendedthecomplaintagainstAlkemtoadd
additionaldosagestrengths.
InOctober2013,JPIreceivedaParagraphIVNoticefromSandoz,Inc.(Sandoz)withrespecttoNUCYNTA®relatedto
the’364patent,andaParagraphIVNoticefromRoxaneLaboratories,Inc.(Roxane)withrespecttoNUCYNTA®relatedto
the’364and’593patents.Inresponsetothosenotices,JPIfiledanadditionalcomplaintintheUnitedStatesDistrict
CourtfortheDistrictofNewJerseyagainstRoxaneandSandozassertingthe’364patentagainstSandozandthe’364
and’593patentsagainstRoxane.InApril2014,JPIandSandozenteredintoajointstipulationofdismissalofthecase
againstSandoz,basedonSandoz’sagreementnottoenterthemarketpriortotheexpirationoftheassertedpatents.In
June2014,inresponsetoaParagraphIVNoticefromRoxanewithrespecttoNUCYNTA®ER,JPIfiledacomplaint
assertingthe’364and’593patentsagainstRoxane.
60 • Johnson&Johnson2014AnnualReportInJuly2014,inresponsetoaParagraphIVNoticefromWatsonLaboratories,Inc.(Watson)withrespecttothe
NUCYNTA®oralsolutionproductandthe’364and’593patents,JPIfiledalawsuitintheUnitedStatesDistrictCourtfor
theDistrictofNewJerseyassertingthe’364and’593patentsagainstWatson.
Ineachoftheabovelawsuits,JPIisseekinganOrderenjoiningthedefendantsfrommarketingtheirgenericversionsof
NUCYNTA®ERandNUCYNTA®beforetheexpirationoftheassertedpatents.
GOVERNMENTPROCEEDINGS
Likeothercompaniesinthepharmaceuticalandmedicaldevicesindustries,Johnson&Johnsonandcertainofits
subsidiariesaresubjecttoextensiveregulationbynational,stateandlocalgovernmentagenciesintheUnitedStatesand
othercountriesinwhichtheyoperate.Asaresult,interactionwithgovernmentagenciesisongoing.Themostsignificant
litigationbroughtby,andinvestigationsconductedby,governmentagenciesarelistedbelow.Itispossiblethatcriminal
chargesandsubstantialfinesand/orcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation.
AverageWholesalePrice(AWP)Litigation
Johnson&Johnsonandseveralofitspharmaceuticalsubsidiaries(theJ&JAWPDefendants),alongwithnumerousother
pharmaceuticalcompanies,aredefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolvingallegationsthatthe
pricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwiseactionableconduct
because,amongotherthings,thecompaniesallegedlyreportedaninflatedAverageWholesalePrice(AWP)forthedrugs
atissue.PayorsallegedthattheyusedthoseAWPsincalculatingproviderreimbursementlevels.Manyofthesecases,
bothfederalactionsandstateactionsremovedtofederalcourt,wereconsolidatedforpre-trialpurposesinaMulti-District
Litigation(MDL)intheUnitedStatesDistrictCourtfortheDistrictofMassachusetts.
Theplaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchase
ofthedrugsatissuebasedonAWP,andstategovernmententitiesthatmadeMedicaidpaymentsforthedrugsatissue
basedonAWP.InJune2007,afteratrialonthemerits,theMDLCourtdismissedtheclaimsoftwooftheplaintiffclasses
againsttheJ&JAWPDefendants.InMarch2011,theCourtdismissedtheclaimsofthethirdclassagainsttheJ&JAWP
Defendantswithoutprejudice.
AWPcasesbroughtbyvariousAttorneysGeneralhaveproceededtotrialagainstothermanufacturers.Severalstate
casesagainstcertainsubsidiariesofJohnson&Johnsonhavebeensettled,includingthecaseinAlaska,whichsettledin
April2014,andcasesarestillpendinginIllinois,NewJersey,Wisconsin,UtahandPennsylvania.ThecasesinIllinois,New
JerseyandWisconsinhavenotyetproceededtotrial.InUtah,theclaimsbroughtbytheAttorneyGeneralweredismissed
bytheCourtin2013,buttheStatemayappealthedismissalaftertheconclusionofsimilarpendingmattersagainstother
defendants.TheAWPcaseagainsttheJ&JAWPDefendantsbroughtbytheAttorneyGeneraloftheCommonwealthof
PennsylvaniawastriedinCommonwealthCourtin2010.TheCourtfoundintheCommonwealth’sfavorwithregardto
certainofitsclaimsunderthePennsylvaniaUnfairTradePracticesandConsumerProtectionLaw(“UTPL”),enteredan
injunction,andawarded$45millioninrestitutionand$6.5millionincivilpenalties.TheCourtfoundintheJ&JAWP
Defendants’favorontheCommonwealth’sclaimsofunjustenrichment,misrepresentation/fraud,civilconspiracy,andon
certainoftheCommonwealth’sclaimsundertheUTPL.TheJ&JAWPDefendantsappealedtheCommonwealthCourt’s
UTPLruling,andinJune2014,thePennsylvaniaSupremeCourtvacatedthejudgmententeredbytheCommonwealth
Courtandremandedthecaseforfurtherproceedings.Onremand,inJanuary2015,theCommonwealthCourtdismissed
themonetaryawardsagainsttheJ&JAWPDefendants,whichmaybeappealed.
RISPERDAL®
InNovember2013,Johnson&Johnsonanditssubsidiary,JanssenPharmaceuticals,Inc.(JPI),finalizedpreviously
disclosedsettlementagreementswiththeUnitedStatesDepartmentofJusticeandforty-fivestatesresolvingfederal
investigationsandstateMedicaidclaimsrelatedtopastpromotionalpracticesofRISPERDAL®from1999through2005,
andothermatters.JPIhadalsosettledallegedconsumerfraudclaimsinconnectionwiththesaleandmarketingof
RISPERDAL®withthirty-sixstatesandtheDistrictofColumbiainSeptember2012.Inadditiontotheseactions,the
AttorneysGeneralofseveralstatesbroughtactionsagainstJPI,relatedtothesaleandmarketingofRISPERDAL®,
seekingoneormoreofthefollowingremedies:reimbursementofMedicaidorotherpublicfundsforRISPERDAL®
prescriptionswrittenforoff-labeluse,compensationfortreatingtheircitizensforallegedadversereactionsto
RISPERDAL®,civilfinesorpenaltiesforviolationsofstatefalseclaimsactsorconsumerfraudstatutes,punitivedamages,
orotherreliefrelatingtoallegedunfairbusinesspractices.Certainoftheseactionsalsosoughtinjunctivereliefrelatingto
thepromotionofRISPERDAL®.ManyoftheactionsandclaimsbroughtbythestateAttorneysGeneralhavebeensettled,
eitherindividuallyoraspartofthesettlementsdescribedabove.
Johnson&Johnson2014AnnualReport • 61FourstateshaveremainingclaimsinlitigationrelatedtoRISPERDAL®:oneclaimisonremandinArkansas;thecasein
SouthCarolinaisonappeal;inKentucky,atrialhasbeensetforApril2016;andinMississippi,thecasehasnot
progressedtotrial.TheCompanyhasnotaccruedanamountequaltothejudgmentobtainedinSouthCarolina.Tothe
extentanystatehasanoutstandingMedicaid-relatedclaimnotresolvedbythesettlementsreferencedabove,the
Companyhasaccruedanamountapproximatelyequaltowhatthatstatewouldhavereceivedifithadparticipatedinthe
relevantfederalsettlement.Statecasesthatwenttojudgmentaftertrialarediscussedbelow.
In2004,theAttorneyGeneralofWestVirginiacommencedalawsuitagainstJanssenPharmaceutica,Inc.(nowJPI)based
onclaimsofallegedconsumerfraudastoDURAGESIC®,aswellasRISPERDAL®.JPIwasfoundliableanddamages
wereassessedat$4.5million.JPIfiledanappeal,andinNovember2010,theWestVirginiaSupremeCourtofAppeals
reversedthetrialcourt’sdecision.InDecember2010,theAttorneyGeneralofWestVirginiadismissedthecaseasit
relatedtoRISPERDAL®withoutanypayment.Thereafter,JPIsettledthecaseinsofarasitrelatedtoDURAGESIC®.
In2004,theAttorneyGeneralofLouisianafiledamulti-countComplaintagainstJanssenPharmaceutica,Inc.(nowJPI).
Johnson&Johnsonwaslateraddedasadefendant.ThecasewastriedinOctober2010.Theissuetriedtothejurywas
whetherJohnson&JohnsonorJPIhadviolatedtheState’sMedicalAssistanceProgramIntegrityLaw(theAct)through
misrepresentationsallegedlymadeinthemailingofaNovember2003DearHealthCareProfessionalletterregarding
RISPERDAL®.ThejuryreturnedaverdictthatJPIandJohnson&JohnsonhadviolatedtheActandawarded$257.7
millionindamages.ThetrialjudgesubsequentlyawardedtheAttorneyGeneralcounselfeesandexpensesintheamount
of$73million.InJanuary2014,theLouisianaSupremeCourtreversedtheDistrictCourt’sjudgmentinfavorofthe
AttorneyGeneral,andrenderedjudgmentinfavorofJohnson&JohnsonandJPI.InApril2014,theLouisianaSupreme
CourtdeniedtheAttorneyGeneral’spetitionseekingarehearingoftheappellatearguments,resultinginfinaldismissalof
thecase.
In2007,theOfficeofGeneralCounseloftheCommonwealthofPennsylvaniafiledalawsuitagainstJanssen
Pharmaceutica,Inc.(nowJPI)onamulti-CountComplaintrelatedtoJanssenPharmaceutica’ssaleofRISPERDAL®tothe
Commonwealth’sMedicaidprogram.ThetrialoccurredinJune2010.Thetrialjudgedismissedthecaseafterthecloseof
theplaintiff’sevidence.TheCommonwealthfiledanappealandinJuly2012,thePennsylvaniaAppealsCourtupheldthe
dismissaloftheCommonwealth’scase.
In2007,theAttorneyGeneralofSouthCarolinafiledalawsuitagainstJohnson&JohnsonandJanssenPharmaceutica,
Inc.(nowJPI)onseveralcounts.InMarch2011,thematterwastriedtoajuryonliabilityonly,atwhichtimethelawsuit
waslimitedtoclaimsofviolationoftheSouthCarolinaUnfairTradePracticesAct,including,amongothers,questionsof
whetherJohnson&JohnsonorJPIengagedinunfairordeceptiveactsorpracticesintheconductofanytradeor
commercebydistributingtheNovember2003DearHealthCareProfessionalletterregardingRISPERDAL®orintheiruse
oftheproduct’sFDA-approvedlabel.ThejuryfoundinfavorofJohnson&JohnsonandagainstJPI.InJune2011,the
Courtawardedcivilpenaltiesofapproximately$327.1millionagainstJPI.JPIhasappealedthisjudgmentandthe
Companybelievesithasstrongargumentssupportingtheappeal.Oralargumentontheappealtookplacebeforethe
SouthCarolinaSupremeCourtinMarch2013,andthepartiesareawaitingadecision.
InApril2012,inthelawsuitbroughtbytheAttorneyGeneralofArkansas,thejuryfoundagainstbothJPIandJohnson&
Johnson,andtheCourtimposedpenaltiesintheamountofapproximately$1.2billion.InJanuary2013,thetrialcourt
awardedattorneyfeesofapproximately$181million.JPIandJohnson&JohnsonappealedbothawardstotheArkansas
SupremeCourt,andinMarch2014,theArkansasSupremeCourtdismissedtheState’sclaimundertheArkansas
MedicaidFraudFalseClaimsAct,aswellastheapproximately$1.2billioninpenalties,andreversedandremandeda
claimundertheArkansasDeceptiveTradePracticesAct.InApril2014,theArkansasSupremeCourtrejectedapetition
bytheStateforrehearingonthecase.TrialontheremandofthecaseisscheduledforJune2015.
McNeilConsumerHealthcare
StartinginJune2010,McNeilConsumerHealthcareDivisionofMcNEIL-PPC,Inc.(McNeilConsumerHealthcare)and
certainaffiliates,includingJohnson&Johnson(theCompanies),receivedgrandjurysubpoenasfromtheUnitedStates
Attorney’sOfficefortheEasternDistrictofPennsylvaniarequestingdocumentsbroadlyrelatingtorecallsofvarious
productsofMcNeilConsumerHealthcare,andtheFDAinspectionsoftheFortWashington,PennsylvaniaandLancaster,
Pennsylvaniamanufacturingfacilities,aswellascertaindocumentsrelatingtorecallsofasmallnumberofproductsof
othersubsidiaries.Inaddition,inFebruary2011,thegovernmentservedMcNEIL-PPC,Inc.(McNEIL-PPC)withaCivil
InvestigativeDemandseekingrecordsrelevanttoitsinvestigationtodetermineiftherewasaviolationoftheFederalFalse
ClaimsAct.ThegrandjuryandFalseClaimsinvestigationsarecontinuing.TheCompaniesarecooperatingwiththe
UnitedStatesAttorney’sOfficeinrespondingtotheseinvestigations.
62 • Johnson&Johnson2014AnnualReportTheCompanieshavealsoreceivedCivilInvestigativeDemandsfrommultipleStateAttorneysGeneralOfficesbroadly
relatingtotheMcNeilrecallissues.TheCompaniescontinuetocooperatewiththeseinquiries,whicharebeing
coordinatedthroughamulti-statecoalition.Ifaresolutioncannotbereachedwiththismulti-statecoalition,itispossible
thatindividualStateAttorneysGeneralOfficesmayfilecivilmonetaryclaimsagainsttheCompanies.InJanuary2011,the
OregonAttorneyGeneralfiledacivilcomplaintagainstJohnson&Johnson,McNEIL-PPCandMcNeilHealthcareLLCin
statecourtallegingcivilviolationsoftheOregonUnlawfulTradePracticesActrelatingtoanearlierrecallofaMcNeilOTC
product.InNovember2012,thestatecourtgrantedamotionbytheCompaniestodismissOregon’scomplaintinits
entirety,withprejudice.InDecember2012,OregonfiledaNoticeofAppealintheCourtofAppealsoftheStateof
Oregon.OralargumenttookplaceinJuly2014andthepartiesareawaitingadecision.
OpioidsLitigation
Alongwithotherpharmaceuticalcompanies,JanssenPharmaceuticals,Inc.(JPI)hasbeennamedinanumberoflawsuits
allegingclaimsrelatedtoopioidmarketingpractices.InMay2014,SantaClaraandOrangeCountiesinCalifornia(the
Counties)filedacomplaintinstatecourtinOrangeCounty,Californiaagainstnumerouspharmaceuticalmanufacturers,
includingJPI,allegingclaimsrelatedtoopioidmarketingpractices,includingfalseadvertising,unfaircompetition,and
publicnuisance.InJune2014,theCityofChicagofiledacomplaintinCookCountyCircuitCourtagainstseveral
pharmaceuticalmanufacturers,includingJPI,alleginganumberofclaimsrelatedtoopioidmarketingpractices,including
consumerfraudviolationsandfalseclaims.ThecasewaslaterremovedtotheUnitedStatesDistrictCourtforthe
NorthernDistrictofIllinois,andinDecember2014,defendantsfiledamotiontodismisstheCityofChicago’sFirst
AmendedComplaintforfailuretostateaclaim.InSeptember2014,theTennesseeAttorneyGeneralDivisionof
ConsumerAffairsissuedaRequestforInformationtoJPIrelatedtoopioidsmarketingpractices.
Other
InSeptember2011,Synthes,Inc.(Synthes)receivedaCivilInvestigativeDemandissuedpursuanttotheFalseClaimsAct
fromtheUnitedStatesAttorney’sOfficefortheEasternDistrictofPennsylvania.TheDemandsoughtinformation
regardingallegationsthatfellowshipshadbeenofferedtohospitalsinexchangeforagreementstopurchaseproducts.
SyntheshasproduceddocumentsandinformationinresponsetotheDemandandiscooperatingwiththeinquiry.
InMay2012,Acclarent,Inc.(Acclarent)receivedasubpoenafromtheUnitedStatesAttorney’sOfficefortheDistrictof
Massachusettsrequestingdocumentsbroadlyrelatingtothesales,marketingandallegedoff-labelpromotionbyAcclarent
ofRELIEVASTRATUS®MicroFlowSpacerproducts.TheinvestigationiscontinuingandAcclarentiscooperatingwiththe
UnitedStatesAttorney’sOfficeinrespondingtothesubpoena.
InAugust2012,DePuyOrthopaedics,Inc.,DePuy,Inc.(nowDePuySynthes,Inc.),andJohnson&JohnsonServices,Inc.
(theCompanies)receivedaninformalrequestfromtheUnitedStatesAttorney’sOfficefortheDistrictofMassachusetts
andtheCivilDivisionoftheUnitedStatesDepartmentofJustice(theUnitedStates)fortheproductionofmaterialsrelating
totheASR™XLHipdevice.InJuly2014,theUnitedStatesnotifiedtheUnitedStatesDistrictCourtfortheDistrictof
MassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttotheFalseClaimsActagainstthe
Companies.TheDistrictCourtissuedanorderinAugust2014thatpubliclyunsealedtheUnitedStates’declination
notice;however,thecomplaintinthematterremainsunderseal.Inaddition,inOctober2013,agroupofstateAttorneys
GeneralissuedCivilInvestigativeDemandsrelatingtothedevelopment,salesandmarketingofseveralofDePuy
Orthopaedics,Inc.’shipproducts.InJuly2014,theOregonDepartmentofJustice,whichwasinvestigatingthesematters
independentlyoftheotherstates,announcedasettlementofitsASR™XLHipdeviceinvestigationforatotalpaymentof
$4milliontotheStateofOregon.
InOctober2012,Johnson&JohnsonwascontactedbytheCaliforniaAttorneyGeneral’sofficeregardingamulti-state
AttorneyGeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby
Johnson&Johnson’ssubsidiary,Ethicon,Inc.(Ethicon).Johnson&JohnsonandEthiconhavesinceenteredintoaseries
oftollingagreementswiththe45statesandtheDistrictofColumbiaparticipatinginthemulti-stateinvestigationandhave
respondedtoCivilInvestigativeDemandsservedbycertainoftheparticipatingstates.
InDecember2012,Therakos,Inc.(Therakos),formerlyasubsidiaryofJohnson&JohnsonandpartoftheOrtho-Clinical
Diagnostics,Inc.(OCD)franchise,receivedaletterfromthecivildivisionoftheUnitedStatesAttorney’sOfficeforthe
EasternDistrictofPennsylvaniainformingTherakosthattheUnitedStatesAttorney’sOfficewasinvestigatingthesales
andmarketingofUvadex®(methoxsalen)andtheUvarXts®Systemduringtheperiod2000tothepresent.TheUnited
StatesAttorney’sOfficerequestedthatOCDandJohnson&Johnsonpreservedocumentsthatcouldrelatetothe
investigation.TherakoswassubsequentlyacquiredbyanaffiliateofGoresCapitalPartnersIII,L.P.inJanuary2013.OCD
andJohnson&Johnsonretaincertainliabilitiesthatmayresultfromtheinvestigationforactivitythatoccurredpriortothe
Johnson&Johnson2014AnnualReport • 63saleofTherakos.InMarch2014,theUnitedStatesAttorney’sOfficerequestedthatJohnson&Johnsonproducecertain
documents,andJohnson&Johnsoniscooperatingwiththerequest.FollowingthedivestitureofOCD,Johnson&Johnson
retainsOCD’sportionofanyliabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleof
Therakos.
InMay2013,JanssenPharmaceuticals,Inc.(JPI)receivedasubpoenafromtheAtlantaRegionalOfficeoftheDepartment
ofHealthandHumanServices,OfficeofInspectorGeneral,seekingproductionofdocumentsandinformationregarding:
(1)thesales,marketingandpromotionalpractices,includingtheremunerationofhealthcareproviders,relatedto
NUCYNTA®IRandNUCYNTA®ER;and(2)anystudies,reportsand/orcomplaintsregardingthesafetyand/oractualor
potentialsideeffectsofNUCYNTA®IRandNUCYNTA®ER.InOctober2014,theUnitedStatesDepartmentofJustice
(DOJ)informedJPIthatthegovernment’sinvestigationstemmedfromthefilingofaquitamcomplaint,thattheDOJhad
formallydeclinedtointerveneinthequitamaction,andthattheDOJwasclosingitsinvestigationrelatedtoNUCYNTA®
IRandNUCYNTA®ER.TheplaintiffinthequitamcomplaintfiledanoticeofdismissalandtheCourtdismissedthequi
tamactioninDecember2014.
Inrecentyears,Johnson&JohnsonhasreceivednumerousrequestsfromavarietyofUnitedStatesCongressional
Committeestoproduceinformationrelevanttoongoingcongressionalinquiries.ItisthepolicyofJohnson&Johnsonto
cooperatewiththeseinquiriesbyproducingtherequestedinformation.
GENERALLITIGATION
InSeptember2006,Johnson&JohnsonfiledalawsuitagainstGuidantCorporation(Guidant)intheUnitedStatesDistrict
CourtfortheSouthernDistrictofNewYork,allegingthatGuidantbreachedprovisionsofamergeragreementbetween
Johnson&JohnsonandGuidant.InJune2011,GuidantfiledamotionforsummaryjudgmentandinJuly2014,thejudge
deniedGuidant’smotion.ThetrialconcludedinJanuary2015andinFebruary2015,beforeadecisionwasissuedbythe
Court,Johnson&JohnsonandGuidantenteredintoasettlementagreement,pursuanttowhichGuidantagreedtopay
Johnson&Johnson$600millionandagreedthatitwillnotsueJohnson&Johnsonoritsaffiliatesforpatentinfringement
regardingcertainstentproducts.Johnson&JohnsonwilldismissitsactionagainstGuidantwithprejudice.TheCompany
willrecordthistransactioninfiscalyear2015.
InJune2009,followingthepublicannouncementthatOrtho-ClinicalDiagnostics,Inc.(OCD)hadreceivedagrandjury
subpoenafromtheUnitedStatesDepartmentofJustice,AntitrustDivision,inconnectionwithaninvestigationthathas
sincebeenclosed,multipleclassactioncomplaintswerefiledagainstOCDbydirectpurchasersseekingdamagesfor
allegedpricefixing.Thesecaseswereconsolidatedforpre-trialpurposesintheUnitedStatesDistrictCourtforthe
EasternDistrictofPennsylvaniaasInreBloodReagentAntitrustLitigation.InAugust2012,theDistrictCourtgranteda
motionfiledbyPlaintiffsforclasscertification.InOctober2012,theUnitedStatesCourtofAppealsfortheThirdCircuit
grantedOCD’spetitionforinterlocutoryreviewoftheclasscertificationruling.Oralargumentontheappealwasheldin
February2014andthepartiesareawaitingadecision.FollowingthedivestitureofOCD,Johnson&Johnsonretainsany
liabilitythatmayresultfromthesecases.
InSeptember2010,ashareholder,RonaldMonk,filedalawsuitintheUnitedStatesDistrictCourtfortheDistrictofNew
JerseyseekingclasscertificationandallegingthatJohnson&Johnsonandcertainindividuals,includingexecutiveofficers
andemployeesofJohnson&Johnson,failedtodisclosethatanumberofmanufacturingfacilitiesfailedtomaintaincurrent
goodmanufacturingpractices,andthatasaresult,thepriceoftheCompany’sstockdeclinedsignificantly.Plaintiffsought
topursueremediesundertheSecuritiesExchangeActof1934torecoverhisallegedeconomiclosses.InDecember
2011,amotionbyJohnson&Johnsontodismisswasgrantedinpartanddeniedinpart.InSeptember2012,Plaintifffiled
aSecondAmendedComplaintandJohnson&JohnsonandtheindividualdefendantsmovedtodismissPlaintiff’sSecond
AmendedComplaintinpart.Followingmediation,thepartiesreachedanagreementinprincipletosettlethecase,andin
July2013,filedforpreliminaryapprovaloftheproposedsettlement.InNovember2013,theCourtapprovedthe
settlement.ThreepartiesthathadobjectedtothesettlementappealedtheCourt’sapprovalorders.Priortothemediation
fortheappeal,thepartiesagreedtodismisstheappealwithprejudiceandwithoutcostsagainstanyparty.TheUnited
StatesCourtofAppealsfortheThirdCircuitdismissedthecaseinApril2014.
InApril2011,OMJPharmaceuticals,Inc.(OMJPR)filedalawsuitagainsttheUnitedStatesinUnitedStatesDistrictCourt
fortheDistrictofPuertoRicoallegingoverpaymentoffederalincometaxesforthetaxyearsendedNovember30,1999
andNovember30,2000.OMJPRallegedthattheInternalRevenueServiceerroneouslycalculatedOMJPR’staxcredits
underSection936oftheTaxCode.OMJPRfiledamotionforsummaryjudgment,andtheUnitedStatesfiledacross
motionforsummaryjudgment.InOctober2012,theCourtgrantedamotionbytheUnitedStatesforsummaryjudgment
anddeniedamotionbyOMJPRforsummaryjudgment.OMJPRappealedthisdecision.InJune2014,theappellatecourt
reversedthetrialcourt’sdecisionandinstructedthetrialcourttoentersummaryjudgmentinfavorofOMJPR.
64 • Johnson&Johnson2014AnnualReportInSeptember2011,Johnson&Johnson,Johnson&JohnsonInc.andMcNeilConsumerHealthcareDivisionofJohnson&
JohnsonInc.receivedaNoticeofCivilClaimfiledbyNickFieldintheSupremeCourtofBritishColumbia,Canada(the
BCCivilClaim).TheBCCivilClaimisaputativeclassactionbroughtonbehalfofpersonswhoresideinBritishColumbia
andwhopurchasedduringtheperiodbetweenSeptember20,2001andinoraboutDecember2010oneormorevarious
McNeilinfants’orchildren’sover-the-countermedicinesthatweremanufacturedattheFortWashingtonfacility.TheBC
CivilClaimallegesthatthedefendantsviolatedtheBCBusinessPracticesandConsumerProtectionAct,andother
Canadianstatutesandcommonlaws,bysellingmedicinesthatwereallegedlynotsafeand/oreffectiveordidnotcomply
withCanadianGoodManufacturingPractices.TheclasscertificationhearingisscheduledforOctober2015.
InAugust2014,UnitedStatesCustomsandBorderProtectionissuedaPenaltyNoticeagainstJanssenOrthoLLC
(JanssenOrtho),assessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolate(PREZISTA®)in
connectionwithitsimportationintotheUnitedStates.InOctober2014,JanssenOrthosubmittedaPetitionforReliefin
responsetothePenaltyNotice.
Johnson&JohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtundertheComprehensive
EnvironmentalResponse,Compensation,andLiabilityAct,commonlyknownasSuperfund,andcomparablestate,localor
foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastand/orfutureremediation.
ShareholderDerivativeAction
InSeptember2011,twoshareholderderivativelawsuitswerefiledintheUnitedStatesDistrictCourtfortheDistrictof
NewJerseybyDonovanSpamerandTheGeorgeLeonFamilyTrustnamingcurrentandformerdirectorsofJohnson&
JohnsonasdefendantsandJohnson&Johnsonasthenominaldefendant.Theselawsuitsallegethatthedefendants
breachedtheirfiduciarydutiesintheirdecisionswithrespecttothecompensationoftheChiefExecutiveOfficerduring
theperiodfrom2008through2011,andthatthedefendantsmademisleadingstatementsintheCompany’sannualproxy
statements.Bothoftheselawsuitswerevoluntarilydismissedwithoutprejudice,butasimilarlawsuit,TheGeorgeLeon
FamilyTrustv.Coleman,wasrefiledinJuly2012.Thatlawsuitsoughtavarietyofrelief,includingmonetarydamages,
injunctiverelief,andcorporategovernancereforms.InJune2013,theBoardofDirectorsofJohnson&Johnson(the
Board)receivedareportpreparedbyspecial,independentcounseltotheBoard,whichinvestigatedtheallegations
containedinthederivativeactionsfiledbyDonovanSpamerandbyTheGeorgeLeonFamilyTrust,andinseveral
shareholderdemandlettersthattheBoardreceivedin2011and2012raisingsimilarissues.Thereportrecommended
thatJohnson&Johnsonrejecttheshareholderdemandsandtakewhateverstepsarenecessaryorappropriatetosecure
dismissalofthederivativelitigation.TheBoardunanimouslyadoptedthereport’srecommendations.
InSeptember2013,Johnson&Johnsonmovedtodismissor,inthealternative,forsummaryjudgmentinTheGeorge
LeonFamilyTrustv.Coleman,basedupontheBoard’sdetermination.InOctober2013,theplaintiffintheLeonlitigation
filedanamendedcomplaintandJohnson&Johnsonmovedtodismisstheamendedcomplaintor,inthealternative,for
summaryjudgment,basedupontheBoard’sdetermination.InJune2014,theCourtgrantedsummaryjudgmentinfavorof
Johnson&Johnson.
Johnson&Johnson2014AnnualReport • 65Report of Independent Registered Public
Accounting Firm
TotheShareholdersandBoardofDirectorsofJohnson&Johnson:
Inouropinion,theaccompanyingconsolidatedbalancesheetsandtherelatedconsolidatedstatementsofearnings,
statementsofcomprehensiveincome,statementsofequity,andstatementsofcashflowspresentfairly,inallmaterial
respects,thefinancialpositionofJohnson&JohnsonanditssubsidiariesatDecember28,2014andDecember29,2013,
andtheresultsoftheiroperationsandtheircashflowsforeachofthethreeyearsintheperiodendedDecember28,2014
inconformitywithaccountingprinciplesgenerallyacceptedintheUnitedStatesofAmerica.Alsoinouropinion,the
Companymaintained,inallmaterialrespects,effectiveinternalcontroloverfinancialreportingasofDecember28,2014,
basedoncriteriaestablishedinInternalControl–IntegratedFramework(2013)issuedbytheCommitteeofSponsoring
OrganizationsoftheTreadwayCommission(COSO).TheCompany’smanagementisresponsibleforthesefinancial
statements,formaintainingeffectiveinternalcontroloverfinancialreportingandforitsassessmentoftheeffectivenessof
internalcontroloverfinancialreporting,includedintheaccompanying“Management’sReportonInternalControlover
FinancialReporting.”OurresponsibilityistoexpressopinionsonthesefinancialstatementsandontheCompany’sinternal
controloverfinancialreportingbasedonourintegratedaudits.Weconductedourauditsinaccordancewiththestandards
ofthePublicCompanyAccountingOversightBoard(UnitedStates).Thosestandardsrequirethatweplanandperform
theauditstoobtainreasonableassuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatementand
whethereffectiveinternalcontroloverfinancialreportingwasmaintainedinallmaterialrespects.Ourauditsofthefinancial
statementsincludedexamining,onatestbasis,evidencesupportingtheamountsanddisclosuresinthefinancial
statements,assessingtheaccountingprinciplesusedandsignificantestimatesmadebymanagement,andevaluatingthe
overallfinancialstatementpresentation.Ourauditofinternalcontroloverfinancialreportingincludedobtainingan
understandingofinternalcontroloverfinancialreporting,assessingtheriskthatamaterialweaknessexists,andtesting
andevaluatingthedesignandoperatingeffectivenessofinternalcontrolbasedontheassessedrisk.Ourauditsalso
includedperformingsuchotherproceduresasweconsiderednecessaryinthecircumstances.Webelievethatouraudits
provideareasonablebasisforouropinions.
Acompany’sinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe
reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith
generallyacceptedaccountingprinciples.Acompany’sinternalcontroloverfinancialreportingincludesthosepoliciesand
proceduresthat(i)pertaintothemaintenanceofrecordsthat,inreasonabledetail,accuratelyandfairlyreflectthe
transactionsanddispositionsoftheassetsofthecompany;(ii)providereasonableassurancethattransactionsare
recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting
principles,andthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof
managementanddirectorsofthecompany;and(iii)providereasonableassuranceregardingpreventionortimelydetection
ofunauthorizedacquisition,use,ordispositionofthecompany’sassetsthatcouldhaveamaterialeffectonthefinancial
statements.
Becauseofitsinherentlimitations,internalcontroloverfinancialreportingmaynotpreventordetectmisstatements.Also,
projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate
becauseofchangesinconditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
PricewaterhouseCoopersLLP
FlorhamPark,NewJersey
February23,2015
66 • Johnson&Johnson2014AnnualReportManagement’s Report on Internal Control
Over Financial Reporting
UnderSection404oftheSarbanes-OxleyActof2002,managementisrequiredtoassesstheeffectivenessofthe
Company’sinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreport,basedonthatassessment,
whethertheCompany’sinternalcontroloverfinancialreportingiseffective.
ManagementoftheCompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial
reporting.TheCompany’sinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe
reliabilityoftheCompany’sfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith
generallyacceptedaccountingprinciples.
Internalcontrolsoverfinancialreporting,nomatterhowwelldesigned,haveinherentlimitations.Therefore,internalcontrol
overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial
statementpreparationandmaynotpreventordetectallmisstatements.Moreover,projectionsofanyevaluationof
effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin
conditions,orthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate.
TheCompany’smanagementhasassessedtheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingas
ofDecember28,2014.Inmakingthisassessment,theCompanyusedthecriteriaestablishedbytheCommitteeof
SponsoringOrganizationsoftheTreadwayCommission(COSO)in“InternalControl-IntegratedFramework(2013).”
Thesecriteriaareintheareasofcontrolenvironment,riskassessment,controlactivities,informationandcommunication,
andmonitoring.TheCompany’sassessmentincludedextensivedocumenting,evaluatingandtestingthedesignand
operatingeffectivenessofitsinternalcontrolsoverfinancialreporting.
BasedontheCompany’sprocessesandassessment,asdescribedabove,managementhasconcludedthat,asof
December28,2014,theCompany’sinternalcontroloverfinancialreportingwaseffective.
TheeffectivenessoftheCompany’sinternalcontroloverfinancialreportingasofDecember28,2014hasbeenauditedby
PricewaterhouseCoopersLLP,anindependentregisteredpublicaccountingfirm,asstatedintheirreport,whichappears
herein.
AlexGorsky DominicJ.Caruso
Chairman,BoardofDirectors VicePresident,Finance
ChiefExecutiveOfficer ChiefFinancialOfficer
Johnson&Johnson2014AnnualReport • 67Summary of Operations and Statistical Data
2004-2014
(DollarsinMillionsExceptPerShare
Amounts) 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004
Salestocustomers–U.S. $34,782 31,910 29,830 28,908 29,450 30,889 32,309 32,444 29,775 28,377 27,770
Salestocustomers–International 39,549 39,402 37,394 36,122 32,137 31,008 31,438 28,651 23,549 22,137 19,578
Totalsales 74,331 71,312 67,224 65,030 61,587 61,897 63,747 61,095 53,324 50,514 47,348
Costofproductssold 22,746 22,342 21,658 20,360 18,792 18,447 18,511 17,751 15,057 14,010 13,474
Selling,marketingandadministrativeexpenses 21,954 21,830 20,869 20,969 19,424 19,801 21,490 20,451 17,433 17,211 16,174
Researchanddevelopmentexpense 8,494 8,183 7,665 7,548 6,844 6,986 7,577 7,680 7,125 6,462 5,344
In-processresearchanddevelopment 178 580 1,163 – – – 181 807 559 362 18
Interestincome (67) (74) (64) (91) (107) (90) (361) (452) (829) (487) (195)
Interestexpense,netofportioncapitalized 533 482 532 571 455 451 435 296 63 54 187
Other(income)expense,net (70) 2,498 1,626 2,743 (768) (526) (1,015) 534 (671) (214) 15
Restructuring – – – 569 – 1,073 – 745 – – –
53,768 55,841 53,449 52,669 44,640 46,142 46,818 47,812 38,737 37,398 35,017
Earningsbeforeprovisionfortaxesonincome $20,563 15,471 13,775 12,361 16,947 15,755 16,929 13,283 14,587 13,116 12,331
Provisionfortaxesonincome 4,240 1,640 3,261 2,689 3,613 3,489 3,980 2,707 3,534 3,056 4,151
Netearnings 16,323 13,831 10,514 9,672 13,334 12,266 12,949 10,576 11,053 10,060 8,180
Add:Netlossattributabletononcontrolling
interest – – 339 – – – – – – – –
NetearningsattributabletoJohnson&
Johnson 16,323 13,831 10,853 9,672 13,334 12,266 12,949 10,576 11,053 10,060 8,180
Percentofsalestocustomers 22.0% 19.4 16.1 14.9 21.7 19.8 20.3 17.3 20.7 19.9 17.3
Dilutednetearningspershareofcommon
stock(1) $5.70 4.81 3.86 3.49 4.78 4.40 4.57 3.63 3.73 3.35 2.74
Percentreturnonaverageshareholders’equity 22.7% 19.9 17.8 17.0 24.9 26.4 30.2 25.6 28.3 28.2 27.3
Percentincrease(decrease)overprevious
year:
Salestocustomers 4.2% 6.1 3.4 5.6 (0.5) (2.9) 4.3 14.6 5.6 6.7 13.1
Dilutednetearningspershare 18.5% 24.6 10.6 (27.0) 8.6 (3.7) 25.9 (2.7) 11.3 22.3 19.7
Supplementarybalancesheetdata:
Property,plantandequipment,net 16,126 16,710 16,097 14,739 14,553 14,759 14,365 14,185 13,044 10,830 10,436
Additionstoproperty,plantandequipment 3,714 3,595 2,934 2,893 2,384 2,365 3,066 2,942 2,666 2,632 2,175
Totalassets 131,119 132,683 121,347 113,644 102,908 94,682 84,912 80,954 70,556 58,864 54,039
Long-termdebt 15,122 13,328 11,489 12,969 9,156 8,223 8,120 7,074 2,014 2,017 2,565
Operatingcashflow 18,471 17,414 15,396 14,298 16,385 16,571 14,972 15,022 14,248 11,799 11,089
Commonstockinformation
Dividendspaidpershare $2.76 2.59 2.40 2.25 2.11 1.93 1.795 1.62 1.455 1.275 1.095
Shareholders’equitypershare 25.06 26.25 23.33 20.95 20.66 18.37 15.35 15.25 13.59 13.01 10.95
Marketpricepershare(year-endclose) $105.06 92.35 69.48 65.58 61.85 64.41 58.56 67.38 66.02 60.10 63.42
Averagesharesoutstanding(millions)
–basic 2,815.2 2,809.2 2,753.3 2,736.0 2,751.4 2,759.5 2,802.5 2,882.9 2,936.4 2,973.9 2,968.4
–diluted 2,863.9 2,877.0 2,812.6 2,775.3 2,788.8 2,789.1 2,835.6 2,910.7 2,961.0 3,002.8 2,992.7
Employees(thousands) 126.5 128.1 127.6 117.9 114.0 115.5 118.7 119.2 122.2 115.6 109.9
(1) AttributabletoJohnson&Johnson.
68 • Johnson&Johnson2014AnnualReportShareholder Return Performance Graphs
SetforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnontheCompany’sCommonStockfor
periodsoffiveyearsandtenyearsendingDecember31,2014,againstthecumulativetotalreturnoftheStandard&
Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexandtheStandard&Poor’sHealthCareEquipment
Index.Thegraphsandtablesassumethat$100wasinvestedonDecember31,2009andDecember31,2004ineachof
theCompany’sCommonStock,theStandard&Poor’s500StockIndex,theStandard&Poor’sPharmaceuticalIndexand
theStandard&Poor’sHealthCareEquipmentIndexandthatalldividendswerereinvested.
5 Year Shareholder Return
Performance J&J vs. Indices
$240
Johnson & Johnson
$210
S&P 500 Index
S&P Pharmaceu(cid:2)cal Index $180
S&P Healthcare Equipment
Index $150
5-Year CAGR
$120
J&J 13.8%
S&P 500 15.4%
S&P Pharm 17.5%
$90
S&P H/C Equip 12.8% 2009 2010 2011 2012 2013 2014
2009 2010 2011 2012 2013 2014
Johnson&Johnson $100.00 $99.42 $109.25 $121.05 $162.95 $191.20
S&P500Index $100.00 $115.06 $117.49 $136.29 $180.42 $205.10
S&PPharmaceuticalIndex $100.00 $100.77 $118.67 $135.79 $183.63 $224.43
S&PHealthcareEquipmentIndex $100.00 $97.29 $96.51 $113.18 $144.52 $182.49
10 Year Shareholder Return
Performance J&J vs. Indices
$260
Johnson & Johnson
$230
S&P 500 Index
$200
S&P Pharmaceu(cid:2)cal Index
$170
S&P Healthcare Equipment
Index
$140
10-Year CAGR
J&J 8.3% $110
S&P 500 7.7%
S&P Pharm 9.8%
$80
S&P H/C Equip 6.4% 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Johnson&Johnson $100.00 $96.64 $108.68 $112.61 $103.92 $115.64 $114.97 $126.34 $139.98 $188.34 $220.99
S&P500Index $100.00 $104.91 $121.48 $128.15 $80.74 $102.11 $117.48 $119.97 $139.16 $184.22 $209.42
S&PPharmaceuticalIndex $100.00 $96.64 $111.96 $117.17 $95.85 $113.69 $114.57 $134.91 $154.38 $208.76 $255.14
S&PHealthcareEquipmentIndex $100.00 $100.05 $104.18 $109.52 $79.25 $102.06 $99.29 $98.50 $115.51 $147.49 $186.25
Johnson&Johnson2014AnnualReport • 69ReconciliationofNon-GAAPFinancialMeasures
Thetablesthatfollowareprovidedtoreconcilecertainfinancialdisclosuresinthe2014Chairman’sLetterandBusiness
Highlights.
%Change
(DollarsinMillionsExceptPerShareData) 2014 2013 2012 '14vs.'13 '13vs.'12
Earningsbeforeprovisionfortaxesonincome–asreported $20,563 15,471 13,775 32.9% 12.3
Ortho-ClinicalDiagnosticsdivestiturenetgain (1,899) – –
Litigationexpenses 1,253 2,282 1,229
Synthesintegration/transactioncostsandcurrencyrelated 754 683 1,028
AdditionalyearofBrandedPrescriptionDrugFee 220 – –
In-processresearchanddevelopment 178 580 1,163
DePuyASR™Hipprogram 126 251 110
Intangibleassetwrite-downs – – 939
Other – (98) (30)
Earningsbeforeprovisionfortaxesonincome–asadjusted $21,195 19,169 18,214 10.6% 5.2
NetEarningsattributabletoJohnson&Johnson–asreported $16,323 13,831 10,853 18.0% 27.4
Ortho-ClinicalDiagnosticsdivestiturenetgain (1,062) – –
Litigationexpenses 1,225(1) 1,646 1,052
Synthesintegration/transactioncostsandcurrencyrelated 555 483 899
AdditionalyearofBrandedPrescriptionDrugFee 220 – –
In-processresearchanddevelopment 131 462 743(2)
DePuyASR™Hipprogram 111 240 97
TaxbenefitassociatedwithConorMedsystems (398) – –
Sciostaxbenefit – (707) –
Intangibleassetwrite-downs – – 717
Other – (79) (16)
NetEarningsattributabletoJohnson&Johnson–asadjusted $17,105 15,876 14,345 7.7% 10.7
DilutedNetEarningspershareattributabletoJohnson&Johnson–asreported $5.70 4.81 3.86 18.5% 24.6
Ortho-ClinicalDiagnosticsdivestiturenetgain (0.37) – –
Litigationexpenses 0.43 0.57 0.37
Synthesintegration/transactioncostsandcurrencyrelated 0.19 0.17 0.32
AdditionalyearofBrandedPrescriptionDrugFee 0.08 – –
In-processresearchanddevelopment 0.04 0.16 0.27
DePuyASR™Hipprogram 0.04 0.08 0.03
TaxbenefitassociatedwithConorMedsystems (0.14) – –
SciosTaxBenefit – (0.25) –
Intangibleassetwrite-downs – – 0.26
Other – (0.02) (0.01)
DilutedNetEarningspershareattributabletoJohnson&Johnson–asadjusted $5.97 5.52 5.10 8.2% 8.2
(1) Includesadjustmenttodeferredtaxassetrelatedtodeductibilitybytaxjurisdiction
(2) Amountincludesin-processresearchanddevelopmentchargeof$679millionrelatedtobapineuzumabIVoffsetby$339millionreportedasnetloss
attributabletononcontrollinginterest.
TheCompanyprovidesearningsbeforeprovisionfortaxesonincome,netearningsattributabletoJohnson&Johnsonandnet
earningspershareattributabletoJohnson&Johnson(diluted)onanadjustedbasisbecausemanagementbelievesthatthese
measuresprovideusefulinformationtoinvestors.Amongotherthings,thesemeasuresmayassistinvestorsinevaluatingthe
Company'sresultsofoperationsperiodoverperiod.Invariousperiods,thesemeasuresmayexcludesuchitemsassignificant
costsassociatedwithacquisitions,restructuring,litigation,andchangesinapplicablelawsandregulations(includingsignificant
accountingortaxmatters).Thesespecialitemsmaybehighlyvariable,difficulttopredict,andofasizethatsometimeshas
substantialimpactontheCompany'sreportedresultsofoperationsforaperiod.Managementusesthesemeasuresinternally
forplanning,forecastingandevaluatingtheperformancesoftheCompany'sbusinesses,includingallocatingresourcesand
evaluatingresultsrelativetoemployeeperformancecompensationtargets.Unlikeearningsbeforeprovisionfortaxesonincome,
netearningsattributabletoJohnson&JohnsonandnetearningspershareattributabletoJohnson&Johnson(diluted)prepared
inaccordancewithGAAP,adjustedearningsbeforeprovisionfortaxesonincome,adjustednetearningsattributableto
Johnson&JohnsonandadjustednetearningspershareattributabletoJohnson&Johnson(diluted)maynotbecomparable
withthecalculationofsimilarmeasuresforothercompanies.Thelimitationsofusingthesenon-GAAPfinancialmeasuresas
performancemeasuresarethattheyprovideaviewoftheCompany'sresultsofoperationswithoutincludingalleventsduringa
period,suchastheeffectsofanacquisition,theOrtho-ClinicalDiagnosticsdivestiture,restructuring,litigation,andchangesin
applicablelawsandregulations(includingsignificantaccountingortaxmatters)anddonotprovideacomparableviewofthe
Company'sperformancetoothercompaniesinthehealthcareindustry.Investorsshouldconsidernon-GAAPfinancial
measuresinadditionto,andnotasreplacementsfor,orsuperiorto,measuresoffinancialperformancepreparedinaccordance
withGAAP.
70 • Johnson&Johnson2014AnnualReportOperational Sales Growth by Segment Excluding Acquisitions
and Divestitures
2014 vs. 2013
Consumer Pharmaceutical MedicalDevices Total
Operational%(1)
WWAsReported: 1.0% 16.5% (1.6)% 6.1%
Women'sHealth
SanitaryProtection 1.4 0.3
Women'sHealth
K-Y® 0.3 0.1
Diagnostics
Ortho-ClinicalDiagnostics 3.2 1.4
AllOtherAcquisitionsandDivestitures 0.1 0.1 0.1
WWOpsexcludingAcquisitionsandDivestitures 2.8% 16.6% 1.6% 8.0%
(1) Operationalgrowthexcludestheimpactofcurrencytranslation
“Operationalsalesgrowthexcludingthenetimpactofacquisitionsanddivestitures”isanon-GAAPfinancialmeasure.
Investorsshouldconsidernon-GAAPfinancialmeasuresinadditionto,andnotasreplacementsfor,orsuperiorto,
measuresoffinancialperformancepreparedinaccordancewithGAAP.Duetothevariablenatureofacquisitionsand
divestituresandtheimpacttheymayhaveontheanalysisofunderlyingbusinessperformanceandtrends,management
believesthatprovidingthismeasureenhancesaninvestor’sunderstandingoftheCompany’sperformanceandmayassist
intheevaluationofongoingbusinessoperationsperiodoverperiod.Thisnon-GAAPfinancialmeasureispresentedto
permitinvestorstomorefullyunderstandhowmanagementassessestheperformanceoftheCompany,includingfor
internalevaluationoftheperformanceoftheCompany’sbusinessesandplanningandforecastingforfutureperiods.The
useofthisnon-GAAPfinancialmeasureasaperformancemeasureislimitedinthatitprovidesaviewoftheCompany’s
resultsofoperationswithoutincludingalleventsduringaperiodandmaynotprovideacomparableviewoftheCompany’s
performancetothatofothercompaniesinthehealthcareindustry.
Johnson&Johnson2014AnnualReport • 71Board of Directors Senior Management
ALEXGORSKY ALEXGORSKY
Chairman,BoardofDirectors ChiefExecutiveOfficer
Chairman,ExecutiveCommittee
MARYSUECOLEMAN
PresidentEmerita,UniversityofMichigan DOMINICJ.CARUSO
VicePresident,Finance
JAMESG.CULLEN ChiefFinancialOfficer
RetiredPresidentandChiefOperatingOfficer, Member,ExecutiveCommittee
BellAtlanticCorporation
DOUGLASK.CHIA
D.SCOTTDAVIS CorporateSecretary
ChairmanandFormerChiefExecutiveOfficer, AssistantGeneralCounsel
UnitedParcelService,Inc.
STEPHENJ.COSGROVE
IANE.L.DAVIS CorporateController
Chairman,Rolls-RoyceHoldingsplc;FormerChairman ChiefAccountingOfficer
andWorldwideManagingDirector,
McKinsey&Company JOAQUINDUATO
WorldwideChairman,Pharmaceuticals
SUSANL.LINDQUIST
MemberandFormerDirector,WhiteheadInstitutefor PETERM.FASOLO
BiomedicalResearch;ProfessorofBiology, VicePresident,GlobalHumanResources
MassachusettsInstituteofTechnology Member,ExecutiveCommittee
MARKB.McCLELLAN JORGEMESQUITA
SeniorFellowinEconomicStudiesand WorldwideChairman,Consumer
DirectoroftheInitiativeonValueand
MICHELORSINGER
InnovationinHealthCare,BrookingsInstitution
WorldwideChairman,GlobalOrthopaedics
ANNEM.MULCAHY
JOHNA.PAPA
FormerChairmanandChiefExecutiveOfficer,
Treasurer
XeroxCorporation
SANDRAE.PETERSON
LEOF.MULLIN
GroupWorldwideChairman
RetiredChairmanandChiefExecutiveOfficer,
Member,ExecutiveCommittee
DeltaAirLines,Inc.
GARYJ.PRUDEN
WILLIAMD.PEREZ
WorldwideChairman,GlobalSurgery
RetiredPresidentandChiefExecutiveOfficer,
Wm.WrigleyJr.Company MICHAELE.SNEED
VicePresident,GlobalCorporateAffairs
CHARLESPRINCE
RetiredChairmanandChiefExecutiveOfficer, PAULUSSTOFFELS
CitigroupInc. ChiefScientificOfficer
WorldwideChairman,Pharmaceuticals
A.EUGENEWASHINGTON
Member,ExecutiveCommittee
ViceChancellorofHealthSciences,DeanoftheDavid
GeffenSchoolofMedicineattheUniversityofCalifornia, MICHAELH.ULLMANN
LosAngeles(UCLA);ChiefExecutiveOfficerofthe VicePresident,GeneralCounsel
UCLAHealthSystem Member,ExecutiveCommittee
RONALDA.WILLIAMS KATHRYNE.WENGEL
FormerChairmanandChiefExecutiveOfficer, VicePresident,Johnson&JohnsonSupplyChain
AetnaInc.
JESSEJ.WU
Chairman,Johnson&JohnsonChina
Johnson&Johnson2014AnnualReportPRINCIPALOFFICE COMMONSTOCK JOHNSON&JOHNSONONLINE
OneJohnson&JohnsonPlaza ListedonNewYorkStockExchange
www.jnj.com
NewBrunswick,NewJersey08933 StockSymbol:JNJ
(732)524-0400
SHAREHOLDERRELATIONSCONTACT www.jnj.com/our-news-center
ANNUALMEETING DouglasK.Chia
The2015AnnualMeetingofShareholders CorporateSecretary
(732)524-2455 www.blogjnj.com/
willtakeplaceonThursday,April23,2015,at
theStateTheatre,15LivingstonAvenue,New
INVESTORRELATIONSCONTACT
Brunswick,NewJersey.Themeetingwill
LouiseMehrotra www.facebook.com/jnj
conveneat10:30a.m.(Eastern).All
VicePresident,InvestorRelations
shareholdersasoftherecorddateof (800)950-5089 www.twitter.com/JNJCares
February24,2015arecordiallyinvitedto www.twitter.com/JNJNews
(732)524-6492
attend.AformalNoticeofAnnualMeeting,
www.youtube.com/jnj
ProxyStatementandProxyhavebeenmade TRANSFERAGENTANDREGISTRAR
availabletoshareholders. Questionsregardingstockholdings,certificatereplace- www.linkedin.com/company/
ment/transfer,dividendsandaddresschangesshould johnson-&-johnson
CORPORATEGOVERNANCE
bedirectedto:
Copiesofour2014AnnualReporton Computershare
Form10-KfiledwiththeSecuritiesand P.O.Box30170 Toviewtheonline2014Johnson&Johnson
ExchangeCommission,2015Proxy CollegeStation,TX77842-3170 YearInReview,pleasegoto
Statement,andthisAnnualReportare Overnightcorrespondenceshouldbesentto: www.2014YearInReview.jnj.comorscanthis
availableonlineatwww.investor.jnj.com,or Computershare QRcode.
toshareholderswithoutcharge,upon 211QualityCircle,Suite210
writtenrequesttotheOfficeofthe CollegeStation,TX77845
CorporateSecretaryatourprincipal Shareholderwebsite
address,orbycalling(800)950-5089. www.computershare.com/investor
Shareholderonlineinquiries
OntheCorporateGovernancesectionofour
https://www-us.computershare.com/investor/
website,www.investor.jnj.com,shareholders
contact
canviewourfilingswiththeSecuritiesand
ExchangeCommission,includingQuarterly DIVIDENDREINVESTMENTPLAN
ReportsonForm10-QandCurrentReports OurDividendReinvestmentPlanallowsforfullor
onForm8-K;RestatedCertificateof partialdividendreinvestmentandadditionalweekly
Incorporation;By-Laws;Principlesof cashinvestmentsupto$50,000peryearin
CorporateGovernance;ChartersoftheAudit Johnson&JohnsonCommonStockwithoutpershare
Committee,Compensation&Benefits orservicechargesonstockpurchases.Ifyouare
interestedinparticipatinginthePlanandneedan
Committee,Nominating&Corporate
enrollmentformand/ormoreinformation,pleasecall
GovernanceCommittee,Regulatory,
thePlanadministrator,ComputershareTrust
Compliance&GovernmentAffairs
Company,N.A.at(800)328-9033(or(781)575-2718
Committee,andScience,Technology& outsidetheU.S.)orgotowww.computershare.com/
SustainabilityCommittee;PolicyonBusiness investor.
Conduct(foremployees);CodeofBusiness
Conduct&EthicsforMembersoftheBoard HEARINGIMPAIRED
ofDirectorsandExecutiveOfficers;andother Shareholderswhohaveinquiriesregardingstock-
corporategovernancematerials.Copiesof relatedmatterscancommunicatedirectlywith
thesedocumentsareavailabletoshareholders ComputershareTrustCompany,N.A.viaa
telecommunicationsdevice(TDD).Thetelephone
withoutchargeuponwrittenrequesttothe
numberforthisserviceis(800)952-9245(or
CorporateSecretaryatourprincipaladdress.
(781)575-2692outsidetheU.S.).
UnderSection302oftheSarbanes-OxleyAct,
ELECTRONICDELIVERYNOTIFICATION
wearerequiredtofilecertificationssignedby
Our2015ProxyStatementandthisAnnualReportare
theChiefExecutiveOfficerandtheChief
availableonourwebsiteatwww.investor.jnj.com/
FinancialOfficerasexhibitstoourForm10-K
annual-reports.cfm.Shareholderswhoarestill
orForm10-Qforeachfiscalyearorquarter. receivingpapercopiesofourproxystatementsand
Inaddition,wearerequiredtosubmita annualreportsbymailcanelecttoreceiveinsteadan
certificationsignedbytheChiefExecutive e-mailthatwillprovidealinktothosedocumentson
OfficertotheNewYorkStockExchange theInternet.Shareholderswhoholdtheirsharesin
within30daysfollowingtheAnnualMeeting theirownnamemayenrollintheelectronicproxyand
ofShareholders.Copiesofthecertifications annualreportaccessserviceforfutureannualmeetings
filedforpreviousyearsarepostedonthe
onlineatwww.computershare-na.com/green.
CorporateGovernancesectionofourwebsite, TheJohnson&Johnson2014AnnualReport
Shareholderswhoholdtheirsharesbeneficiallyin
andfuturecertificationswillbeposted containsmanyofthevaluabletrademarksand
“streetname”(thatis,inthenameofabank,brokeror
promptlyuponfiling. otherholderofrecord)andwishtoenrollforelectronic tradenamesownedandusedbytheJohnson&
accessmayregisteratenroll.icsdelivery.com/jnj. JohnsonFamilyofCompaniesintheUnited
Statesandinternationallytodistinguish
productsandservicesofoutstandingquality.
©Johnson&Johnson2015
SHAREHOLDER INFORMATIONCaring for the world, one person at a time…
inspires and unites the people of
Scan this QR code to view a digital version of the 2014 Johnson & Johnson Annual Report